Methods of treating non-muscle invasive bladder cancer (NMIBC) with antibody drug conjugates (ADCs) that bind to 191P4D12 protein

By administering antibody drug conjugates that bind 191P4D12 protein to the bladder, the treatment problem of BCG non-responsive NMIBC is solved, and a safe and effective treatment plan is provided, suitable for patients who are not suitable for radical cystectomy, and the treatment is improved safety and tolerance.

CN118949064APending Publication Date: 2024-11-15AGENSYS INC +1
View PDF 34 Cites 0 Cited by

Patent Information

Application Number
CN202411104630.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-07
Filing Date
2022-08-12
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The prior art is difficult to effectively treat BCG non-responsive non-muscular invasive bladder cancer (NMIBC), especially in patients who are not suitable or refuse to undergo radical cystectomy, and there is a lack of safe and effective intravesical treatment methods.

Method used

In the treatment of non-muscular invasive bladder cancer by administering an antibody drug conjugate (ADC) that binds the 191P4D12 protein, which contains an antibody or antigen-binding fragment thereof, is used to treat non-muscularly infiltrating bladder cancer. Especially for patients with BCG non-responsive diseases and high-risk risks.

Benefits of technology

Provides a safe and effective treatment plan that can target BCG-nonreactive NMIBC, especially papillary disease and carcinoma in situ, reduces the risk of disease recurrence and progression, is suitable for patients who are not suitable for radical cystectomy, and improves treatment Safety and tolerance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118949064A_ABST
    Figure CN118949064A_ABST
Patent Text Reader

Abstract

Provided herein are methods of intravesical treatment of bladder cancer and methods of treating non-muscle invasive bladder cancer with antibody drug conjugates (ADCs) that bind to 191P4D12 protein (connexin-4).
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application is a divisional application of Chinese Patent Application No. 202280068824.5, filed on August 12, 2022, entitled "Method for treating non-muscle invasive bladder cancer (NMIBC) with an antibody-drug conjugate (ADC) bound to the 191P4D12 protein".

[0003] This application claims the benefits of U.S. Application No. 63 / 233,048, filed August 13, 2021; U.S. Application No. 63 / 242,380, filed September 9, 2021; and U.S. Application No. 63 / 328,441, filed April 7, 2022, the disclosures of each of which are incorporated herein by reference in their entirety. References to the sequence list filed electronically.

[0004] This application contains a computer-readable sequence list, which has been submitted with this application in XML file format, the entire contents of which are incorporated herein by reference. The sequence list XML file submitted with this application is named "14369-281-228_SEQ_LISTING.xml", was created on August 2, 2022, and has a size of 34,743 bytes. 1. Technical Field

[0005] Provided herein are methods for treating non-muscle invasive bladder cancer (NMIBC) with an antibody drug conjugate (ADC) that binds to the 191P4D12 protein (connexin-4). 2. Background Technology

[0006] Bladder cancer is the most common form of urothelial carcinoma (UC) and the sixth most common cancer in the United States (US), estimated to kill nearly 200,000 people annually worldwide, including more than 65,000 in Europe and nearly 18,000 in the United States (Bray 2018; Ferlay 2018; Siegel 2019). In 2018, an estimated 549,000 new cases of bladder cancer were diagnosed globally each year. In 2020, an estimated 81,400 new cases of bladder cancer were diagnosed in the United States; this estimate rose to over 83,000 in 2021 (American Cancer Society (ACS) 2021; National Cancer Institute (NCI) 2021). The incidence and mortality rates of bladder cancer increase dramatically with age and will become an increasingly serious problem as the population ages.

[0007] Approximately 70% to 80% of bladder cancer diagnoses present as non-muscle-invasive disease (Chang 2016; Woldu 2017; Kates 2020; Li 2020). Non-muscle-invasive bladder cancer (NMIBC) represents a heterogeneous group of cancers, including those that are essentially papillary and confined to the mucosa (Ta), high-grade and flat and confined to the epithelium (Tis or carcinoma in situ [CIS]), and those that infiltrate into the submucosa or lamina propria (T1) (Pasin 2008). In NMIBC patients, papillary disease is the most common, affecting approximately 70% of patients, while T1 disease and CIS affect approximately 20% and 10% of patients, respectively (Kirkali 2005; Anastasiadis 2012).

[0008] Standard care for NMIBC involves surgical removal of the bladder tumor via transurethral resection of bladder tumor (TURBT), followed by intravesical administration of a therapeutic agent to further obtain antitumor activity (Kawai 2013; Chang 2016; Woldu 2017; Jamil 2019; Kates 2020). Intravesical Bacillus Calmette-Guerin (BCG) is considered the preferred agent for triggering a local immune response, which appears to be associated with antitumor activity in patients with NMIBC, particularly those with high-risk disease characteristics (Kassouf 2015; Chang 2016).

[0009] BCG-unresponsive disease represents a subgroup of patients with NMIBC who have not responded to adequate BCG treatment and remain at high risk for disease recurrence and progression to subsequent UC stages. For these patients, additional BCG treatment is not an option, and radical cystectomy remains the best available option. Intravesical chemotherapeutic agents such as gemcitabine, mitomycin, and valrubicin have shown some efficacy; however, current guidelines state that treatments other than radical cystectomy are inferior for BCG-unresponsive disease (Navai 2016; Taylor 2020) (EAU. Guidelines for Non-muscleinvasive Bladder Cancer. 2020. https: / / uroweb.org / guideline / non-muscle-invasive-bladdercancer / accessed February 16, 2021). Although systemic pembrolizumab was recently approved for the treatment of patients with BCG-unresponsive disease and carcinoma in situ (CIS), more than half of patients treated with pembrolizumab do not achieve a complete response to therapy; therefore, there remains a need for safe and effective intravesical therapies in this patient population.

[0010] 191P4D12 (also known as connexin-4) is a 66 kDa type I transmembrane protein that belongs to the connexin family of adhesion molecules. It consists of an extracellular domain (ECD) containing three immunoglobulin (Ig)-like domains, a transmembrane helix, and an intracellular region (Takai et al., Annu Rev Cell Dev Biol (2008); 24: 309-42). Connexins are believed to mediate Ca binding via both homophilic and heterophilic trans-interactions at adherens junctions. 2 + independent cell-cell adhesion, where it recruits cadherins and regulates cytoskeletal rearrangements at adherens junctions (Rikitake et al., Cell Mol Life Sci (2008); 65(2): 253-63.). Connexin-4 shares low sequence identity with other connexin family members, and in the ECD, the sequence identity ranges from 25% to 30% (Reymond et al., Biol Chem (2001); 276(46): 43205-15).

[0011] Connexin-4 has been found to be expressed in a variety of cancers, particularly urothelial, breast, lung, pancreatic, and ovarian cancers, with higher expression being associated with disease progression and / or poor prognosis (Fabre-Lafay et al., BMC Cancer (2007); 7:73).

[0012] There remains an unmet need for safe and effective intravesical treatments for patients with BCG-unresponsive NMIBC who are ineligible or unsuitable for radical cystectomy, or for those who make an informed decision not to undergo radical cystectomy. 3. Summary of the Invention

[0013] This article provides a method for treating bladder cancer in human subjects via intravesical administration of an antibody-drug conjugate (ADC) binding to 191P4D12.

[0014] Embodiment 1. A method for treating bladder cancer in a human subject, the method comprising administering to the subject intravesically an effective amount of an antibody drug conjugate (ADC), wherein the ADC comprises an antibody or antigen-binding fragment thereof that binds to 191P4D12, which is conjugated to one or more units of monomethyl auristatin E (MMAE).

[0015] Embodiment 2. The method of embodiment 1, wherein the bladder cancer is non-muscle invasive bladder cancer (NMIBC).

[0016] Embodiment 3. The method of embodiment 2, wherein the NMIBC has been histologically confirmed and is carcinoma in situ (CIS).

[0017] Embodiment 4. The method of embodiment 3, wherein the subject has a papillary disease.

[0018] Implementation Scheme 5. The method as described in Implementation Scheme 3, wherein the subject does not suffer from papillary disease.

[0019] Embodiment 6. The method of any one of embodiments 2 to 5, wherein the NMIBC has been confirmed histologically and wherein the major histological component (>50%) is urothelial (transitional cell) carcinoma.

[0020] Implementation Scheme 7. The method of any one of Implementation Schemes 1 to 6, wherein the subject has a high-risk BCG non-responsive disease.

[0021] Embodiment 8. The method of any one of embodiments 1 to 7, wherein the subject is not suitable for or refuses radical cystectomy.

[0022] Embodiment 9. The method of any one of Embodiments 1 to 8, wherein all visible papillary Ta / T1 tumors of the subject have been completely resected within 60 days prior to the treatment.

[0023] Embodiment 10. The method of embodiment 9, wherein the subject has residual pure CIS.

[0024] Embodiment 11. The method of embodiment 9, wherein the subject does not have residual pure CIS.

[0025] Embodiment 12. The method of any one of embodiments 1 to 11, wherein the subject has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0.

[0026] Embodiment 13. The method of any one of embodiments 1 to 11, wherein the subject has an Eastern Cooperative Oncology Group (ECOG) performance status score of 1.

[0027] Embodiment 14. The method of any one of embodiments 1 to 11, wherein the subject has an Eastern Cooperative Oncology Group (ECOG) performance status score of 2.

[0028] Implementation Scheme 15. The method as described in Implementation Scheme 14, wherein the subject has a glomerular filtration rate (GFR) of not less than 50 mL / min and the subject does not have New York Heart Association (NYHA) Class III heart failure.

[0029] Embodiment 16. The method of any one of embodiments 1 to 15, wherein the subject has one or more conditions selected from the group consisting of:

[0030] a. Absolute neutrophil count (ANC) ≥1500 / μL;

[0031] b. Hemoglobin (Hgb) ≥ 10 g / dL;

[0032] c. Platelet count ≥100,000 / μL;

[0033] d. Serum bilirubin ≤1.5× upper limit of normal (ULN) or ≤3×ULN for subjects with Gilbert's disease;

[0034] e. Calculate creatinine clearance (CrCl) ≥ 30 mL / min (GFR can also be used as an alternative to creatinine or CrCl). CrCl should be calculated using the Cockcroft-Gault method or the Modification of Diet in Renal Disease (MDRD) equation. Subjects with an ECOG performance status of 2 must have a GFR ≥ 50 mL / min;

[0035] f. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN; or

[0036] g. International Normalized Ratio (INR) or Prothrombin Time (PT), Activated Partial Prothrombin Kinase Time (aPTT) or Partial Prothrombin Kinase Time (PTT) ≤1.5 ULN, unless the subject is receiving anticoagulant therapy, provided that PT or aPTT is within the therapeutic range of the intended use of the anticoagulant.

[0037] Embodiment 17. The method of embodiment 16, wherein the subject has all of conditions (a) to (g) of embodiment 16.

[0038] Implementation Scheme 18. The method of any one of Implementation Schemes 1 to 17, wherein the estimated life expectancy of the subject exceeds 2 years.

[0039] Implementation Scheme 19. The method of any one of Implementation Schemes 1 to 18, wherein the antibody or its antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence containing a complementarity-determining region (CDR) of the heavy chain variable region shown in SEQ ID NO: 22; and a light chain variable region comprising an amino acid sequence containing a CDR of the light chain variable region shown in SEQ ID NO: 23.

[0040] Embodiment 20. The method of any one of embodiments 1 to 19,

[0041] The antibody or its antigen-binding fragment comprises: CDR-H1 containing the amino acid sequence SEQ ID NO: 9, CDR-H2 containing the amino acid sequence SEQ ID NO: 10, CDR-H3 containing the amino acid sequence SEQ ID NO: 11; CDR-L1 containing the amino acid sequence SEQ ID NO: 12, CDR-L2 containing the amino acid sequence SEQ ID NO: 13, and CDR-L3 containing the amino acid sequence SEQ ID NO: 14, or

[0042] The antibody or its antigen-binding fragment comprises: CDR-H1 containing the amino acid sequence SEQ ID NO: 16, CDR-H2 containing the amino acid sequence SEQ ID NO: 17, CDR-H3 containing the amino acid sequence SEQ ID NO: 18; CDR-L1 containing the amino acid sequence SEQ ID NO: 19, CDR-L2 containing the amino acid sequence SEQ ID NO: 20, and CDR-L3 containing the amino acid sequence SEQ ID NO: 21.

[0043] Implementation Scheme 21. The method as described in any one of Implementation Schemes 1 to 19,

[0044] The antibody or its antigen-binding fragment comprises: CDR-H1 consisting of the amino acid sequence SEQ ID NO: 9, CDR-H2 consisting of the amino acid sequence SEQ ID NO: 10, and CDR-H3 consisting of the amino acid sequence SEQ ID NO: 11; CDR-L1 consisting of the amino acid sequence SEQ ID NO: 12, CDR-L2 consisting of the amino acid sequence SEQ ID NO: 13, and CDR-L3 consisting of the amino acid sequence SEQ ID NO: 14, or

[0045] The antibody or its antigen-binding fragment comprises: CDR-H1 consisting of the amino acid sequence SEQ ID NO: 16, CDR-H2 consisting of the amino acid sequence SEQ ID NO: 17, CDR-H3 consisting of the amino acid sequence SEQ ID NO: 18; CDR-L1 consisting of the amino acid sequence SEQ ID NO: 19, CDR-L2 consisting of the amino acid sequence SEQ ID NO: 20, and CDR-L3 consisting of the amino acid sequence SEQ ID NO: 21.

[0046] Implementation Scheme 22. The method of any one of Implementation Schemes 1 to 21, wherein the antibody or its antigen-binding fragment comprises a heavy chain variable region containing the amino acid sequence SEQ ID NO: 22 and a light chain variable region containing the amino acid sequence SEQ ID NO: 23.

[0047] Implementation Scheme 23. The method of any one of Implementation Schemes 1 to 22, wherein the antibody comprises a heavy chain comprising an amino acid sequence in the range of amino acid 20 (glutamic acid) to amino acid 466 (lysine) of SEQ ID NO: 7; and a light chain comprising an amino acid sequence in the range of amino acid 23 (aspartic acid) to amino acid 236 (cysteine) of SEQ ID NO: 8.

[0048] Embodiment 24. The method of any one of embodiments 1 to 23, wherein the antigen binding fragment is a Fab, F(ab')2, Fv, or scFv.

[0049] Embodiment 25. The method of any one of Embodiments 1 to 24, wherein the antibody is a fully human antibody.

[0050] Embodiment 26. The method of any one of Embodiments 1 to 25, wherein the antibody is IgG1 and the light chain is a kappa light chain.

[0051] Embodiment 27. The method of any one of Embodiments 1 to 26, wherein the antibody or antigen-binding fragment thereof is recombinantly produced.

[0052] Embodiment 28. The method of any one of embodiments 1 to 27, wherein the antibody or antigen-binding fragment is coupled to each unit of MMAE via a linker.

[0053] Embodiment 29. The method of embodiment 28, wherein the linker is an enzyme-cleavable linker, and wherein the linker forms a bond with a sulfur atom of the antibody or antigen-binding fragment thereof.

[0054] Embodiment 30. A method as described in embodiment 28 or 29, wherein the linker has the formula: -Aa-Ww-Yy-; wherein -A- is a Stretcher unit, a is 0 or 1; -W- is an Amino Acid unit, w is an integer in the range of 0 to 12; and -Y- is a Spacer unit, y is 0, 1 or 2.

[0055] Embodiment 31. The method of embodiment 30, wherein the stretcher unit has the structure of formula (1); the amino acid unit is valine-citrulline; and the spacer unit is a PAB group comprising the structure of formula (2):

[0056]

[0057] Embodiment 32. The method of embodiment 30 or 31, wherein the Stretcher unit forms a bond with a sulfur atom of the antibody or antigen-binding fragment thereof; and wherein the Spacer unit is linked to MMAE via a carbamate group.

[0058] Embodiment 33. The method of any one of Embodiments 1 to 32, wherein the ADC comprises 1 to 20 MMAE units per antibody or antigen-binding fragment thereof.

[0059] Embodiment 34. The method of any one of Embodiments 1 to 33, wherein the ADC comprises 1 to 10 MMAE units per antibody or antigen-binding fragment thereof.

[0060] Implementation Scheme 35. The method of any one of Implementation Schemes 1 to 34, wherein the ADC comprises 2 to 8 MMAE units for each antibody or its antigen-binding fragment.

[0061] Embodiment 36. The method of any one of Embodiments 1 to 35, wherein the ADC comprises 3 to 5 MMAE units per antibody or antigen-binding fragment thereof.

[0062] Embodiment 37. The method of any one of Embodiments 1 to 36, wherein the ADC has the following structure:

[0063]

[0064] wherein L- represents the antibody or antigen-binding fragment thereof, and p is 1 to 10.

[0065] Embodiment 38. The method of embodiment 37, wherein p is 2 to 8.

[0066] Implementation scheme 39. The method as described in implementation scheme 37 or 38, wherein p is 3 to 5.

[0067] Embodiment 40. The method of any one of Embodiments 37 to 39, wherein p is 3 to 4.

[0068] Embodiment 41. The method of any one of Embodiments 37 to 40, wherein p is about 4.

[0069] Embodiment 42. The method of any one of embodiments 37 to 40, wherein the effective amount of the antibody drug conjugate has an average p-value of about 3.8.

[0070] Embodiment 43. The method of any one of embodiments 1 to 42, wherein the ADC is formulated as a pharmaceutical composition comprising L-histidine, polysorbate-20 (TWEEN-20), and trehalose dihydrate.

[0071] Embodiment 44. The method of any one of embodiments 1 to 43, wherein the ADC is formulated as a pharmaceutical composition comprising about 20 mM L-histidine, about 0.02% (w / v) TWEEN-20, about 5.5% (w / v) trehalose dihydrate, and hydrochloride, and wherein the pharmaceutical composition has a pH of about 6.0 at 25°C.

[0072] Implementation Scheme 45. The method of any one of Implementation Schemes 1 to 43, wherein the ADC is formulated into a pharmaceutical composition comprising about 9 mM histidine, about 11 mM histidine monohydrate hydrochloride, about 0.02% (w / v) TWEEN-20 and about 5.5% (w / v) trehalose dihydrate, and wherein the pharmaceutical composition has a pH of about 6.0 at 25°C.

[0073] Implementation Scheme 46. The method of any one of Implementation Schemes 1 to 45, wherein the effective amount of the ADC is between about 100 mg and about 1000 mg, between about 125 mg and about 950 mg, between about 125 mg and about 900 mg, between about 125 mg and about 850 mg, between about 125 mg and about 800 mg, or between about 125 mg and about 750 mg, wherein the infusion volume is between about 10 mL and about 100 mL.

[0074] Embodiment 47. The method of any one of Embodiments 1 to 46, wherein the effective amount of the ADC is a dose between about 125 mg to about 750 mg, with an instillation volume of about 25 mL.

[0075] Embodiment 48. The method of any one of Embodiments 1 to 47, wherein the effective amount of the ADC is a dose of about 125 mg with an instillation volume of about 25 mL.

[0076] Implementation Scheme 49. The method of any one of Implementation Schemes 1 to 47, wherein the effective amount of the ADC is a dose of about 250 mg, wherein the infusion volume is about 25 mL.

[0077] Implementation Scheme 50. The method of any one of Implementation Schemes 1 to 47, wherein the effective amount of the ADC is a dose of about 500 mg, wherein the infusion volume is about 25 mL.

[0078] Embodiment 51. The method of any one of Embodiments 1 to 47, wherein the effective amount of the ADC is a dose of about 750 mg with an instillation volume of about 25 mL.

[0079] Embodiment 52. The method of any one of embodiments 1 to 51, wherein the maximum residence time per intravesical administration is about 90 minutes.

[0080] Embodiment 53. The method of any one of embodiments 1 to 51, wherein the maximum residence time per intravesical administration is about 120 minutes.

[0081] Embodiment 54. The method of any one of embodiments 1 to 51, wherein the residence time per intravesical administration is about 30, 40, 50, 60, 70, 80, 90, or 120 minutes.

[0082] Embodiment 55. The method of any one of embodiments 1 to 54, wherein the ADC is administered intravesically in two phases, wherein the two phases are an induction phase and a maintenance phase.

[0083] Embodiment 56. The method of embodiment 55, wherein the maintenance phase begins between six and ten weeks, between six and nine weeks, or between six and eight weeks after the induction phase.

[0084] Embodiment 57. The method of embodiment 55 or 56, wherein the ADC is administered intravesically once a week for six weeks during the induction phase.

[0085] Embodiment 58. The method of any one of embodiments 55 to 57, wherein the ADC is administered intravesically once a month for nine months during the maintenance phase.

[0086] Embodiment 59. The method of any one of Embodiments 1 to 58, wherein the ADC has the following structure:

[0087]

[0088] Wherein L- represents the antibody or its antigen-binding fragment, and p is about 3 to about 4, the antibody comprises a heavy chain comprising an amino acid sequence ranging from amino acid 20 (glutamic acid) to amino acid 466 (lysine) of SEQ ID NO: 7; and a light chain comprising an amino acid sequence ranging from amino acid 23 (aspartic acid) to amino acid 236 (cysteine) of SEQ ID NO: 8, wherein the ADC is administered intravesically at a dose of about 125 mg, wherein the infusion volume is about 25 mL and the maximum residence time is 90 minutes, wherein the dose is administered intravesically once a week for six weeks during the induction phase and once a month for nine months during the maintenance phase, and wherein the maintenance phase begins between six and ten weeks after the induction phase.

[0089] Embodiment 60. The method of any one of Embodiments 1 to 58, wherein the ADC has the following structure:

[0090]

[0091] wherein L- represents the antibody or antigen-binding fragment thereof, and p is from about 3 to about 4, the antibody comprising a heavy chain comprising an amino acid sequence ranging from amino acid 20 (glutamic acid) to amino acid 466 (lysine) of SEQ ID NO:7; and a light chain comprising an amino acid sequence ranging from amino acid 23 (aspartic acid) to amino acid 236 (cysteine) of SEQ ID NO:8, wherein the ADC is administered intravesically at a dose of about 250 mg with an instillation volume of about 25 mL and a maximum residence time of 90 minutes, wherein the dose is administered intravesically once weekly for six weeks in the induction phase and once monthly for nine months in the maintenance phase, and wherein the maintenance phase begins between six and ten weeks after the induction phase.

[0092] Implementation Scheme 61. The method of any one of Implementation Schemes 1 to 58, wherein the ADC has the following structure:

[0093]

[0094] wherein L- represents the antibody or antigen-binding fragment thereof, and p is from about 3 to about 4, the antibody comprising a heavy chain comprising an amino acid sequence ranging from amino acid 20 (glutamic acid) to amino acid 466 (lysine) of SEQ ID NO:7; and a light chain comprising an amino acid sequence ranging from amino acid 23 (aspartic acid) to amino acid 236 (cysteine) of SEQ ID NO:8, wherein the ADC is administered intravesically at a dose of about 500 mg with an instillation volume of about 25 mL and a maximum residence time of 90 minutes, wherein the dose is administered intravesically once weekly for six weeks in the induction phase and once monthly for nine months in the maintenance phase, and wherein the maintenance phase begins between six and ten weeks after the induction phase.

[0095] Implementation Scheme 62. The method of any one of Implementation Schemes 1 to 58, wherein the ADC has the following structure:

[0096]

[0097] wherein L- represents the antibody or antigen-binding fragment thereof, and p is from about 3 to about 4, the antibody comprising a heavy chain comprising an amino acid sequence ranging from amino acid 20 (glutamic acid) to amino acid 466 (lysine) of SEQ ID NO:7; and a light chain comprising an amino acid sequence ranging from amino acid 23 (aspartic acid) to amino acid 236 (cysteine) of SEQ ID NO:8, wherein the ADC is administered intravesically at a dose of about 750 mg with an instillation volume of about 25 mL and a maximum residence time of 90 minutes, wherein the dose is administered intravesically once weekly for six weeks in the induction phase and once monthly for nine months in the maintenance phase, and wherein the maintenance phase begins between six and ten weeks after the induction phase. 4. Description of the Figures

[0098] Figures 1A-1E The nucleotide and amino acid sequences of the connexin-4 protein are depicted ( Figure 1A The heavy chain of Ha22-2(2.4)6.1 ( Figure 1B ) and light chains ( Figure 1C ) nucleotide and amino acid sequences, and the heavy chain of Ha22-2(2.4)6.1 ( Figure 1D ) and light chains ( Figure 1E )'s amino acid sequence.

[0099] Figure 2 The study described the use of simulated intravesical administration conditions to in vitro administer enfortumabvidotin (EV) to bladder cancer cells overexpressing connexin-4 (i.e., UMUC-3hNectin-4). + ) cytotoxic activity.

[0100] Figures 3A-3E Describes the intravesical administration of enroku vedotin (EV) in connexin-4 + Efficacy in an orthotopic bladder xenograft mouse model. Figure 3A Depicts orthotopic implantation of UMUC-3hNectin4 after chemical ablation + -Luc + The generation of SCID mice and the dosing schedule of intravesical administration of EVs to mice, followed by histological analysis of bladder tissue. Figure 3B Depicted are bioluminescent imaging results confirming tumor engraftment and EV activity. SWFI, sterile water for injection. Figure 3C Depicted are the results of anti-connexin-4 immunohistochemistry confirming EV activity. Figure 3C The bladder tissues in the five right pictures are from Figure 3BFive mice were treated with an intravesical dose of EVs. Figure 3D Depicts Figure 3B Quantitative analysis of bioluminescence imaging results. Figure 3E Immunohistochemical (IHC) staining of connexin-4 and MMAE in bladder tumor tissue was depicted, showing the colocalization of connexin-4 and MMAE.

[0101] Figures 4A-4B Depicted are free MMAE in bladder tissue of Sprague-Dawley rats treated with a single intravesical dose of EVs at various concentrations and administration volumes.

[0102] Figure 5 The whole-body exposure of intravesical EVs is described.

[0103] Figure 6 The free MMAE in the bladder tissue of Sprague-Dürer rats treated with a single intravesical dose of EV was depicted at different residence times.

[0104] Figure 7 This describes the protocol of the clinical trial described in Section 6.1, a Phase 1, open-label, multicenter, dose-escalation and dose-expansion study designed to evaluate the safety, tolerability, pharmacokinetic (PK), and antitumor activity of intravesical enrofloxacin vedocin in adults with non-MIBC. (BCG = Bacillus Calmette-Guérin; CIS = carcinoma in situ; EV = enrofloxacin vedocin; mTPI = modified toxicity probability interval; q3 = every 3; q6 = every 6; TURBT = transurethral resection of bladder tumor; wkly = weekly. The expected safety at the given dose or at a lower or intermediate dose level compared to the planned dose level.) 5. Detailed Implementation

[0105] Before further describing this disclosure, it should be understood that this disclosure is not limited to the specific embodiments set forth herein, and it should also be understood that the terminology used herein is for the purpose of describing specific embodiments only and is not intended to be restrictive.

[0106] Effective use of intracapsular therapy requires consideration of numerous factors, including at least infusion volume, residence time, dose concentration, total dose, infusion pH, urine pH, and reduction in urine production before and during treatment, in order to achieve an appropriate balance between efficacy and safety. This disclosure surprisingly identifies dose concentration and total dose as the most important factors for the effective and safe delivery of ADCs, such as the MMAEADC disclosed herein. This disclosure uses this knowledge to inform the development of various methods for treating bladder cancer (e.g., non-muscle invasive bladder cancer (NMIBC)) using intracapsular ADC administration.

[0107] 5.1 Definition

[0108] The techniques and procedures described or referred to herein include those generally well understood and / or commonly employed by those skilled in the art using conventional methods, for example, the widely used methods described in Sambrook et al., Molecular Cloning: A Laboratory Manual (3rd ed. 2001); Current Protocols in Molecular Biology (Ausubel et al., eds., 2003); Therapeutic Monoclonal Antibodies: From Bench to Clinic (An ed. 2009); Monoclonal Antibodies: Methods and Protocols (Albitar ed. 2010); and Antibody Engineering, Vols. 1 and 2 (Kontermann and Dübel eds., 2nd ed. 2010).

[0109] Unless otherwise defined herein, the technical and scientific terms used in this specification shall have the meanings commonly understood by those of ordinary skill in the art. For the purpose of interpreting this specification, the following terminology will apply and, whenever appropriate, terms used in the singular will also include the plural and vice versa. In the event of a conflict between any description of a term set forth and any document incorporated herein by reference, the terminology set forth below shall prevail.

[0110] The terms “antibody,” “immunoglobulin,” or “Ig” are used interchangeably herein and are used in the broadest sense and specifically cover, for example, monoclonal antibodies (including agonists, antagonists, neutralizing antibodies, full-length or intact monoclonal antibodies), antibody compositions having multiple or single epitope specificity, polyclonal or monovalent antibodies, multivalent antibodies, multispecific antibodies formed from at least two intact antibodies (e.g., bispecific antibodies, provided they exhibit the desired biological activity), single-chain antibodies, and fragments thereof, as described below. Antibodies can be human antibodies, humanized antibodies, chimeric antibodies, and / or affinity-matured antibodies, as well as antibodies derived from other species (e.g., mice and rabbits). The term "antibody" is intended to include B-cell polypeptide products of the immunoglobulin class that are capable of binding to a specific molecular antigen and consist of two pairs of identical polypeptide chains, each pair having a heavy chain (about 50-70 kDa) and a light chain (about 25 kDa), each amino-terminal portion of each chain including a variable region having about 100 to about 130 or more amino acids, and each carboxyl-terminal portion of each chain including a constant region. See, for example, Antibody Engineering (Borrebaeck, ed., 2nd edition, 1995); and Kuby, Immunology (3rd edition, 1997). In specific embodiments, the specific molecular antigen may be bound by antibodies (including polypeptides or epitopes) provided herein. Antibodies also include, but are not limited to, synthetic antibodies, recombinantly generated antibodies, camelified antibodies, intracellular antibodies, anti-individual genotype (anti-Id) antibodies, and functional fragments (e.g., antigen-binding fragments) of any of the above, wherein the functional fragment refers to a portion of the antibody heavy or light chain polypeptide that retains some or all of the binding activity of the antibody derived from said fragment. Non-limiting examples of functional fragments (e.g., antigen-binding fragments) include single-chain Fv (scFv) (e.g., including monospecific, bispecific, etc.), Fab fragments, F(ab′) fragments, F(ab)2 fragments, F(ab′)2 fragments, disulfide-linked Fv (dsFv), Fd fragments, Fv fragments, bifunctional antibodies, trifunctional antibodies, tetrafunctional antibodies, and microantibodies. In particular, the antibodies described herein include immunoglobulin molecules and immunoactive portions of immunoglobulin molecules, such as antigen-binding domains or molecules (e.g., one or more CDRs of an antibody) containing antigen-binding sites for binding to antigens.Such antibody fragments can be found in, for example, Harlow and Lane, Antibodies: A Laboratory Manual (1989); Mol. Biology and Biotechnology: A Comprehensive Desk Reference (Myers, ed., 1995); Huston et al., 1993, Cell Biophysics 22: 189-224; Plückthun and Skerra, 1989, Meth. Enzymol. 178: 497-515; and Day, Advanced Immunochemistry (2nd edition, 1990). The antibodies described herein may belong to any class of immunoglobulin molecules (e.g., IgG, IgE, IgM, IgD, and IgA) or any subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2). Antibodies may be agonist or antagonist antibodies.

[0111] The term "monoclonal antibody" refers to an antibody derived from a substantially homogeneous population of antibodies, meaning that the individual antibodies constituting the population are identical except for the possible presence of naturally occurring mutations. Monoclonal antibodies are highly specific against a single antigenic site. In contrast to polyclonal antibody formulations, which may include different antibodies targeting different determinants (epitopes), each monoclonal antibody targets a single determinant on the antigen.

[0112] An "antigen" is a structure that an antibody can selectively bind to. The target antigen can be a polypeptide, carbohydrate, nucleic acid, lipid, hapten, or other naturally occurring or synthetic compound. In some embodiments, the target antigen is a polypeptide. In some embodiments, the antigen is cell-related, for example, present on or within cells (e.g., cancer cells).

[0113] A "complete" antibody is an antibody that contains an antigen-binding site, as well as a CL and at least heavy chain constant regions CH1, CH2, and CH3. The constant regions may include human constant regions or amino acid sequence variants thereof. In some embodiments, a complete antibody has one or more effector functions.

[0114] The terms "antigen-binding fragment," "antigen-binding domain," "antigen-binding region," and similar terms refer to a portion of an antibody that contains the amino acid residues that interact with an antigen and impart its specificity and affinity to the binding agent for the antigen (e.g., CDRs). As used herein, "antigen-binding fragment" includes "antibody fragments," which contain a portion of an intact antibody, such as the antigen-binding region or variable region of an intact antibody. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')2, and Fv fragments; diabodies and di-diabodies (see, e.g., Holliger et al., 1993, Proc. Natl. Acad. Sci. 90:6444-48; Lu et al., 2005, J. Biol. Chem. 280:19665-72; Hudson et al., 2003, Nat. Med. 9:129-34; WO 93 / 11161; and U.S. Pat. Nos. 5,837,242 and 6,492,123); single-chain antibody molecules (see, e.g., U.S. Pat. Nos. 4,946,778; 5,260,203; 5,482,858; and 5,476,786); dual variable domain antibodies (see, e.g., U.S. Pat. No. 7,612,181); single variable domain antibodies (sdAbs) (see, e.g., Woolven et al., 1999, Immunogenetics 50:98-101; and Streltsov et al., 2004, Proc Natl Acad Sci USA. 101:12444-49); and multispecific antibodies formed from antibody fragments.

[0115] The term "binds" or "binding" refers to the interaction between molecules, including, for example, the formation of a complex. The interaction can be, for example, a non-covalent interaction, including hydrogen bonds, ionic bonds, hydrophobic interactions, and / or van der Waals interactions. A complex can also include the binding of two or more molecules held together by covalent or non-covalent bonds, interactions, or forces. The total non-covalent interaction strength between a single antigen binding site on an antibody and a single epitope of a target molecule (e.g., an antigen) is the affinity of the antibody or functional fragment for the epitope. The dissociation rate (k) of a binding molecule (e.g., an antibody) from a monovalent antigen is the rate of dissociation of the binding molecule (e.g., an antibody) from the monovalent antigen. off ) and binding rate (k on ) ratio (k off / k on K is the dissociation constant. D , which is negatively correlated with affinity. K D The lower the value, the higher the antibody affinity. D The value varies for different complexes of antibody and antigen and depends on the k on With koff Both. The dissociation constant K of the antibodies provided herein D Can use any method provided herein or any other method well-known to those skilled in the art to measure.The avidity at a binding site can not always reflect the true mutual interaction intensity between antibody and antigen.When containing multiple, complex antigens (such as multivalent antigens) of repeated antigenic determinants contact with the antibody containing multiple binding sites, the mutual interaction of antibody and antigen at one site will increase the reaction probability at a second site.The intensity of this type of multiple interactions between multivalent antibodies and antigens is called avidity.

[0116] In connection with the antibodies or antigen-binding fragments thereof described herein, terms such as "bind to," "that specifically bind to," and similar terms are also used interchangeably herein and refer to a binding molecule having an antigen-binding domain that specifically binds to an antigen (e.g., a polypeptide). An antibody or antigen-binding fragment that binds to or specifically binds to an antigen may have cross-reactivity with related antigens. In certain embodiments, an antibody or antigen-binding fragment that binds to or specifically binds to an antigen does not have cross-reactivity with other antigens. An antibody or antigen-binding fragment that binds to or specifically binds to an antigen may be detected, for example, by immunoassay, Or other techniques known to those skilled in the art may be used for identification. In some embodiments, the antibody or antigen-binding fragment binds to or specifically binds to the antigen when it binds to the antigen with a higher affinity than to any cross-reactive antigen, as determined by experimental techniques such as radioimmunoassay (RIA) and enzyme-linked immunosorbent assay (ELISA). Typically, the specific or selective reaction will be at least twice the background signal or noise and may exceed 10 times the background. For a discussion of binding specificity, see, for example, Fundamental Immunology 332-36 (Paul, ed., 2nd ed., 1989). In some embodiments, the degree to which the antibody or antigen-binding fragment binds to a “non-target” protein is less than about 10% of the binding of the binding molecule or antigen-binding domain to its specific target antigen, as determined, for example, by fluorescence-activated cell sorting (FACS) analysis or RIA. Terms such as “specific binding,” “specifically bound to,” or “specific to” mean a binding that is measurably different from a nonspecific interaction. Specific binding can be measured, for example, by comparing the binding of a molecule to that of a control molecule, which is typically a molecule with a similar structure that is not binding active. For example, specific binding can be determined by competition with a control molecule similar to the target (e.g., an excess of unlabeled target). In this case, specific binding is indicated if the binding of the labeled target to the probe is competitively inhibited by an excess of unlabeled target. Antibodies or antigen-binding fragments bound to antigens include antibodies or antigen-binding fragments capable of binding antigens with an affinity sufficient to make the binding molecule suitable as, for example, a diagnostic agent in the target antigen. In some embodiments, the antibodies or antigen-binding fragments bound to antigens have a dissociation constant (K) less than or equal to the following: D The effective concentrations are: 1000 nM, 800 nM, 500 nM, 250 nM, 100 nM, 50 nM, 10 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.9 nM, 0.8 nM, 0.7 nM, 0.6 nM, 0.5 nM, 0.4 nM, 0.3 nM, 0.2 nM, or 0.1 nM. In some embodiments, the antibody or antigen-binding fragment binds to an epitope of the antigen, which is conserved among antigens from different species (e.g., between humans and cynomolgus monkeys).

[0117] "Binding affinity" generally refers to the overall strength of non-covalent interactions between a single binding site of a molecule (e.g., a binding protein such as an antibody) and its binding partner (e.g., an antigen). Unless otherwise indicated, as used herein, "binding affinity" refers to intrinsic binding affinity that reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a binding molecule X for its binding partner Y can generally be expressed by the dissociation constant (K) D ) represents. Affinity can be measured by common methods known in the art, including those described herein. Low-affinity antibodies generally bind antigen slowly and tend to dissociate easily, while high-affinity antibodies generally bind antigen faster and tend to remain bound longer. A variety of methods for measuring binding affinity are known in the art, any of which can be used for the purposes of the present disclosure. Specific illustrative embodiments include the following. In one embodiment, "K D "or "K D The "value" can be measured by assays known in the art, such as by binding assays. KD can be measured using RIA, for example, using a Fab form of the antibody of interest and its antigen (Chen et al., 1999, J. Mol Biol 293:865-81). K D or K D The value can also be determined by using biolayer interferometry (BLI) or surface plasmon resonance (SPR). Use, for example system, or through Use e.g. or The "on-rate" or "rate of association" or "kon" can also be measured using the same biolayer interferometry (BLI) or surface plasmon resonance (SPR) techniques described above, using, for example or The system is used for measurement.

[0118] In certain embodiments, antibodies or antigen-binding fragments may comprise "chimeric" sequences in which a portion of the heavy and / or light chain is identical or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain is identical or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (see U.S. Pat. No. 4,816,567; and Morrison et al., 1984, Proc. Natl. Acad. Sci. USA 81:6851-55).

[0119] In certain embodiments, antibody or antigen-binding fragment can comprise part of the " humanized " form of non-human (such as murine) antibody, and described non-human antibody is chimeric antibody (such as acceptor antibody) comprising human immunoglobulin, wherein native CDR residue is by the residue replacement of corresponding CDR from non-human species (such as mouse, rat, rabbit or non-human primate) (such as donor antibody) with desired specificity, affinity and ability.In some cases, one or more FR region residues of human immunoglobulin are replaced by corresponding non-human residue.In addition, humanized antibody can be included in residue that is not found in acceptor antibody or donor antibody.Carry out these modifications to further optimize antibody performance.Humanized antibody heavy chain or light chain can comprise substantially all at least one or more variable regions, wherein all or substantially all CDR correspond to the CDR of non-human immunoglobulin, and all or substantially all FR are FR of human immunoglobulin sequence.In certain embodiments, humanized antibody will comprise at least a portion of immunoglobulin constant region (Fc), at least a portion of human immunoglobulin usually. For additional details, see Jones et al., 1986, Nature 321:522-25; Riechmann et al., 1988, Nature 332:323-29; Presta, 1992, Curr. Op. Struct. Biol. 2:593-96; Carter et al., 1992, Proc. Natl. Acad. Sci. USA 89:4285-89; U.S. Patent Nos. 6,800,738; 6,719,971; 6,639,055; 6,407,213; and 6,054,297.

[0120] In some embodiments, the antibody or antigen-binding fragment may comprise portions of a “fully human antibody” or “human antibody,” wherein the terms are used interchangeably herein and refer to an antibody comprising a human variable region and, for example, a human constant region. In a particular embodiment, the term refers to an antibody comprising both human-derived variable and constant regions. In some embodiments, a “fully human” antibody may also encompass an antibody that binds a polypeptide and is encoded by a nucleic acid sequence that is a naturally occurring somatic variant of a human germline immunoglobulin nucleic acid sequence. The term “fully human antibody” includes antibodies comprising variable and constant regions corresponding to human germline immunoglobulin sequences as described by Kabat et al. (see Kabat et al. (1991) Sequences of Proteins of Immunological Interest, 5th ed., Department of Health and Human Services, NIH Publication No. 91-3242). A “human antibody” is an antibody whose amino acid sequence corresponds to the amino acid sequence of an antibody produced by humans and / or has been prepared using any technique for preparing human antibodies. This definition of a human antibody specifically excludes humanized antibodies comprising non-human antigen-binding residues. Human antibodies can be produced using a variety of techniques known in the art, including phage display libraries (Hoogenboom and Winter, 1991, J.Mol.Biol. 227: 381; Marks et al., 1991, J.Mol.Biol. 222: 581) and yeast display libraries (Chao et al., 2006, Nature Protocols 1: 755-68). Methods described in Cole et al., Monoclonal Antibodies and Cancer Therapy 77 (1985); Boerner et al., 1991, J.Immunol. 147(1): 86-95; and van Dijk and van de Winkel, 2001, Curr. Opin. Pharmacol. 5: 368-74, can also be used to prepare human monoclonal antibodies. Human antibodies can be prepared by administering antigens to transgenic animals (e.g., mice) that have been modified to produce such antibodies in response to antigen stimulation, but whose endogenous loci have been deactivated (see, for example, Jakobovits, 1995, Curr. Opin. Biotechnol. 6(5): 561-66; Brüggemann and Taussing, 1997, Curr. Opin. Biotechnol. 8(4): 455-58; and U.S. Patent Nos. 6,075,181 and 6,150,584, concerning XENOMOUSE). TM(Technology). For information on human antibodies produced via human B-cell hybridoma technology, see, for example, Li et al., 2006, Proc. Natl. Acad. Sci. USA, 103: 3557-62.

[0121] In certain embodiments, the antibody or antigen-binding fragment may comprise a portion of a "recombinant human antibody," wherein the phrase includes human antibodies prepared, expressed, created, or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell; antibodies isolated from a recombinant combinatorial human antibody library; antibodies isolated from transgenic and / or transchromosomal animals (e.g., mice or cows) for human immunoglobulin genes (see, e.g., Taylor, LD et al. (1992) Nucl. Acids Res. 20: 6287-6295), or antibodies prepared, expressed, created, or isolated by any other means involving splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies may have variable and constant regions derived from human germline immunoglobulin sequences (see Kabat, EA et al. (1991) Sequences of Proteins of Immunological Interest, 5th ed., US Department of Health and Human Services, NIH Publication No. 91-3242). However, in some implementations, such recombinant human antibodies are induced by in vitro mutations (or by in vivo somatic mutations when using transgenic animals with human Ig sequences), and therefore the amino acid sequences of the VH and VL regions of the recombinant antibody are sequences that, although derived from and associated with human germline VH and VL sequences, are not naturally present in human antibody germline antibody libraries in vivo.

[0122] In some embodiments, the antibody or antigen-binding fragment may comprise a portion of a “monoclonal antibody,” wherein, as used herein, the term refers to an antibody derived from a substantially homogeneous population of antibodies (e.g., the individual antibodies comprising the population are identical except for a possible small number of naturally occurring mutations), and each monoclonal antibody will typically recognize a single epitope on an antigen. In specific embodiments, as used herein, a “monoclonal antibody” is an antibody produced by a single hybridoma or other cell. The term “monoclonal” is not limited to any particular method used to prepare the antibody. For example, monoclonal antibodies suitable for this disclosure may be prepared by a hybridoma method first described by Kohler et al., 1975, Nature 256:495, or may be prepared using a recombinant DNA method in bacterial or eukaryotic or plant cells (see, for example, U.S. Patent No. 4,816,567). Monoclonal antibodies can also be isolated from phage antibody libraries using techniques described, for example, those described in Clackson et al., 1991, Nature 352: 624-28 and Marks et al., 1991, J. Mol. Biol., 222: 581-97. Other methods for preparing clonal cell lines and monoclonal antibodies expressed therefrom are well known in the art. See, for example, Short Protocols in Molecular Biology (Ausubel et al., ed., 5th ed., 2002).

[0123] A typical 4-chain antibody unit is a heterotetraglycoprotein, consisting of two identical light (L) chains and two identical heavy (H) chains. In the case of IgG, the 4-chain unit is typically about 150,000 Daltons. Each L chain is linked to the H chain by a covalent disulfide bond, while the two H chains are linked to each other by one or more disulfide bonds, depending on the H chain isoform. Each H and L chain also has regularly spaced intrachain disulfide bridges. Each H chain has a variable domain (VH) at its N-terminus, followed by three constant domains (CH) for each α and γ chain, and four CH domains for the μ and ε isoforms. Each L chain has a variable domain (VL) at its N-terminus, followed by a constant domain (CL) at its other end. VL is aligned with VH, and CL is aligned with the first constant domain (CH1) of the heavy chain. It is believed that specific amino acid residues form an interface between the light chain variable domain and the heavy chain variable domain. VH and VL pair together to form a single antigen-binding site. For the structure and properties of different classes of antibodies, see, for example, Basic and Clinical Immunology 71 (Stites et al., eds., 8th ed. 1994); and Immunobiology (Janeway et al., eds., 5th ed. 2001).

[0124] The term "Fab" or "Fab region" refers to the region of an antibody that binds to an antigen. Conventional IgG typically comprises two Fab regions, each residing on one of the two arms of the Y-shaped IgG structure. Each Fab region is typically composed of one variable region and one constant region of each of the heavy and light chains. More specifically, the heavy chain variable region and constant region in the Fab region are the VH and CH1 regions, and the light chain variable region and constant region in the Fab region are the VL and CL regions. The VH, CH1, VL, and CL in the Fab region can be arranged in various ways to confer antigen binding ability according to the present disclosure. For example, the VH and CH1 regions can be located on one polypeptide, and the VL and CL regions can be located on separate polypeptides, similar to the Fab regions of conventional IgG. Alternatively, the VH, CH1, VL, and CL regions can all be on the same polypeptide and oriented in different orders as described in more detail in the following sections.

[0125] The terms "variable region," "variable domain," "V region," or "V domain" refer to a portion of an antibody's light or heavy chain that is typically located at the amino terminus of the light or heavy chain and is about 120 to 130 amino acids in length in the heavy chain and about 100 to 110 amino acids in length in the light chain, and is used for the binding and specificity of each particular antibody to its specific antigen. The variable region of the heavy chain may be referred to as "VH." The variable region of the light chain may be referred to as "VL." The term "variable" refers to the fact that certain segments of the variable region differ widely in sequence among antibodies. The V region mediates antigen binding and defines the specificity of a particular antibody for its specific antigen. However, variability is not evenly distributed across the 110 amino acid span of the variable region. In practice, the V region consists of a weakly variable (e.g., relatively constant) stretch of about 15-30 amino acids, called a framework region (FR), separated by shorter, more variable (e.g., extremely variable) regions, called "hypervariable regions," each about 9-12 amino acids in length. The variable regions of the heavy and light chains each comprise four FRs that largely adopt a β-pleated structure, the FRs being connected by three hypervariable regions that form loops connecting the β-pleated structure and in some cases forming a portion of the β-pleated structure. The hypervariable regions in each chain are tightly bound together by the FRs with the hypervariable regions from the other chains, promoting the formation of the antigen-binding site of the antibody (see, for example, Kabat et al., Sequences of Proteins of Immunological Interest (5th edition, 1991)). The constant region is not directly involved in the binding of the antibody to the antigen, but exhibits a variety of effector functions, such as enabling the antibody to participate in antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The variable region is widely different in sequence between different antibodies. In a specific embodiment, the variable region is a human variable region.

[0126] The term "variable region residue numbering according to Kabat" or "amino acid position numbering as in Kabat" and variations thereof refer to the numbering system used by Kabat et al. (see above) to compile antibody heavy chain variable regions or light chain variable regions. Using this numbering system, the actual linear amino acid sequence may contain shortening of the FR or CDR corresponding to the variable domain or fewer or additional amino acids inserted therein. For example, the heavy chain variable domain may include a single amino acid insertion after residue 52 (residue 52a, according to Kabat) and three inserted residues after residue 82 (e.g., residues 82a, 82b, and 82c, etc., according to Kabat). For a given antibody, the Kabat numbering of the residues can be determined by aligning the homologous region of the antibody sequence with the "standard" Kabat numbering sequence. The Kabat numbering system is typically used when referring to residues in the variable domain (approximately residues 1-107 of the light chain and residues 1-113 of the heavy chain) (e.g., Kabat et al., see above). The term "EU numbering system" or "EU index" is commonly used when referring to residues in the constant region of the immunoglobulin heavy chain (e.g., the EU index reported in the previous literature by Kabat et al.). "EU index as in Kabat" refers to the residue numbering of human IgG1 EU antibodies. Other numbering systems have been described, for example, by AbM, Chothia, Contact, IMGT, and AHon.

[0127] When used with reference to an antibody, the term "heavy chain" refers to a polypeptide chain of about 50-70 kDa, wherein the amino-terminal portion includes a variable region of about 120 to 130 or more amino acids, and the carboxyl-terminal portion includes a constant region. Based on the amino acid sequence of the heavy chain constant region, the constant region can be one of five different types (e.g., isotypes), referred to as alpha (α), delta (δ), epsilon (ε), gamma (γ), and mu (μ). The different heavy chains are of different sizes: α, δ, and γ contain approximately 450 amino acids, while μ and ε contain approximately 550 amino acids. When combined with a light chain, these different types of heavy chains give rise to the five well-known classes (e.g., isotypes) of antibodies, namely IgA, IgD, IgE, IgG, and IgM, including the four subclasses of IgG, i.e., IgG1, IgG2, IgG3, and IgG4.

[0128] When referring to antibody use, the term "light chain" refers to a polypeptide chain of approximately 25 kDa, in which the amino-terminal portion includes a variable region of approximately 100 to approximately 110 or more amino acids, and the carboxyl-terminal portion includes a constant region. The approximate length of a light chain is 211 to 217 amino acids. Based on the amino acid sequence of the constant region, two distinct types exist, referred to as kappa(K) or lambda(λ).

[0129] As used herein, the terms “hypervariant region,” “HVR,” “complementarity-determining region,” and “CDR” are used interchangeably. “CDR” refers to one of the three hypervariable regions (H1, H2, or H3) within the non-framework region of the immunoglobulin (Ig or antibody) VH β-sheet frame, or one of the three hypervariable regions (L1, L2, or L3) within the non-framework region of the antibody VL β-sheet frame. Therefore, a CDR is a variable region sequence interspersed within a framework sequence.

[0130] The CDR regions are well known to those skilled in the art and are defined by well-known numbering systems. For example, the Kabat complementarity determining regions (CDRs) are based on sequence variability and are most commonly used (see, e.g., Kabat et al., supra). Chothia actually refers to the position of the structural loops (see, e.g., Chothia and Lesk, 1987, J. Mol. Biol. 196:901-17). When numbering using the Kabat numbering convention, the terminus of the Chothia CDR-H1 loop varies between H32 and H34, depending on the length of the loop (this is because the Kabat numbering scheme places the insertion at H35A and H35B; if neither 35A nor 35B is present, the loop terminus is at 32; if only 35A is present, the loop terminus is at 33; if both 35A and 35B are present, the loop terminus is at 34). The AbM hypervariable region represents a compromise between the Kabat CDR and the Chothia structural ring, and is used by the AbM antibody modeling software from Oxford Molecular (see, for example, Antibody Engineering, Vol. 2 (edited by Kontermann and Dübel, 2nd ed., 2010)). The “contact” hypervariable region is based on the analysis of available complex crystal structures. Another universal numbering system that has been developed and widely adopted is the ImMunoGeneTics (IMGT) Information. (Lafranc et al., 2003, Dev. Comp. Immunol. 27(1): 55-77). IMGT is an integrated information system specifically for immunoglobulins (IG), T-cell receptors (TCRs), and major histocompatibility complexes (MHC) in humans and other vertebrates. In this paper, CDRs are referred to as amino acid sequences and positions within the light or heavy chains. Since the “position” of CDRs within the variable domain structure of immunoglobulins is conserved across species and exists in structures called loops, CDRs and framework residues can be easily identified by using a numbering system that compares the variable domain sequence based on structural features. This information can be used to transplant and replace CDR residues of immunoglobulins from one species into receptor frameworks typically derived from human antibodies. Honegger and Plückthun, 2001, J. Mol. Biol. 309: 657-70 have developed another numbering system (AHon). The correspondence between numbering systems (including, for example, Kabat numbering and the IMGT unique numbering system) is well known to those skilled in the art (see, for example, Kabat, supra; Chothia and Lesk, supra; Martin, supra; Lefranc et al., supra). The residues from each of these hypervariable regions or CDRs are indicated in Table 1 below.

[0131] Table 1

[0132]

[0133] The boundaries of a given CDR may vary depending on the protocol used for identification. Therefore, unless otherwise specified, the terms “CDR” and “complementarity-determining region” or regions thereof of a given antibody, such as variable regions, and individual CDRs of an antibody (e.g., CDR-H1, CDR-H2) or regions thereof, should be understood to encompass complementarity-determining regions as defined by any of the known protocols described above. In some cases, a protocol for identifying one or more specific CDRs is specified, such as CDRs defined by the Kabat, Chothia, or Contact methods. In other cases, a specific amino acid sequence of the CDR is given.

[0134] The hypervariable regions may comprise the following "extended hypervariable regions": 24-36 or 24-34 (L1), 46-56 or 50-56 (L2), and 89-97 or 89-96 (L3) in VL; and 26-35 or 26-35A (H1), 50-65 or 49-65 (H2) and 93-102, 94-102 or 95-102 (H3) in VH.

[0135] The term "constant region" or "constant domain" refers to the carboxyl-terminal portion of the light and heavy chains that is not directly involved in binding the antibody to the antigen, but exhibits various effector functions, such as interaction with Fc receptors. The term refers to the portion of the immunoglobulin molecule that contains an amino acid sequence that is more conserved relative to the rest of the immunoglobulin (the variable region, which contains the antigen-binding site). The constant region may contain the CH1, CH2, and CH3 regions of the heavy chain and the CL region of the light chain.

[0136] The term "frame" or "FR" refers to the variable domain residues flanking a CDR. FR residues are found in, for example, chimeric antibodies, humanized antibodies, human antibodies, domain antibodies, bifunctional antibodies, linear antibodies, and bispecific antibodies. FR residues are variable domain residues other than hypervariable region residues or CDR residues.

[0137] As used herein, the term "Fc region" is used to define the C-terminal region of an immunoglobulin heavy chain, including, for example, native sequence Fc regions, recombinant Fc regions, and variant Fc regions. Although the boundaries of the Fc region of an immunoglobulin heavy chain can vary, the human IgG heavy chain Fc region is typically defined as extending from the amino acid residue at position Cys226 or from Pro230 to its carboxyl terminus. The C-terminal lysine (residue 447, according to the EU numbering system) of the Fc region can be removed, for example, during the preparation or purification of the antibody, or by recombinantly engineering the nucleic acid encoding the heavy chain of the antibody. Thus, a composition of intact antibodies can include antibody populations in which all K447 residues have been removed, antibody populations in which the K447 residue has not been removed, and antibody populations comprising a mixture of antibodies with and without the K447 residue. A "functional Fc region" possesses the "effector functions" of a native sequence Fc region. Exemplary "effector functions" include C1q binding; CDC; Fc receptor binding; ADCC; phagocytosis; downregulation of cell surface receptors (e.g., B cell receptors), etc. Such effector functions generally require an Fc region in combination with a binding region or binding domain (e.g., an antibody variable region or domain), and can be assessed using various assays known to those skilled in the art. A "variant Fc region" comprises an amino acid sequence that differs from a native sequence Fc region by at least one amino acid modification (e.g., substitution, addition, or deletion). In certain embodiments, the variant Fc region has at least one amino acid substitution in the native sequence Fc region or in the Fc region of the parent polypeptide, e.g., about one to about ten amino acid substitutions or about one to about five amino acid substitutions, compared to the native sequence Fc region or compared to the Fc region of the parent polypeptide. The variant Fc region herein may have at least about 80% homology to the Fc region of the native sequence Fc region and / or the parent polypeptide, or at least about 90% homology thereto, e.g., at least about 95% homology thereto.

[0138] As used herein, "epitope" is a term in the art and refers to a localized region of an antigen that a binding molecule (e.g., an antibody) can specifically bind to. An epitope can be a linear epitope or a conformational, non-linear, or discontinuous epitope. For example, in the case of a polypeptide antigen, an epitope can be a continuous amino acid of the polypeptide ("linear" epitope), or an epitope can comprise amino acids from two or more discontinuous regions of the polypeptide ("conformational," "non-linear," or "discontinuous" epitope). Those skilled in the art will understand that, in general, a linear epitope may or may not depend on secondary, tertiary, or quaternary structures. For example, in some embodiments, the binding molecule binds to a set of amino acids, regardless of whether they are folded in the native three-dimensional protein structure. In other embodiments, the binding molecule requires the amino acid residues constituting the epitope to exhibit a specific conformation (e.g., bending, twisting, turning, or folding) to recognize and bind to the epitope.

[0139] The terms “polypeptide” and “protein” are used interchangeably herein and refer to amino acid polymers of any length. Polymers may be linear or branched, may contain modified amino acids, and may be interspersed with non-amino acids. The term also covers amino acid polymers that have been naturally modified or modified by interventions (e.g., disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification). The definition also includes, for example, polypeptides containing one or more amino acid analogs (including, but not limited to, non-natural amino acids) and other modifications known in the art. It should be understood that, because the polypeptides of this disclosure may be based on antibodies or other members of the immunoglobulin superfamily, in some embodiments, “polypeptide” may appear in single-chain form or in the form of two or more related chains.

[0140] As used in this article, the term "pharmaceutically acceptable" means approved by federal or state regulatory agencies or listed in the United States Pharmacopeia, the European Pharmacopeia, or other recognized pharmacopoeias for use in animals, and more particularly in humans.

[0141] "Excipient" means a pharmaceutically acceptable material, composition, or medium, such as a liquid or solid filler, diluent, solvent, or encapsulating material. Excipients include, for example, encapsulating materials or additives, such as absorption accelerators, antioxidants, binders, buffers, carriers, coatings, colorants, diluents, disintegrants, emulsifiers, extenders, fillers, flavorings, humectants, lubricants, fragrances, preservatives, propellants, release agents, sterilizing agents, sweeteners, solubilizers, wetting agents, and mixtures thereof. The term "excipient" may also refer to diluents, adjuvants (e.g., Freunds' adjuvant) (complete or incomplete), or mediums.

[0142] In one embodiment, each component is "pharmaceutically acceptable" in the sense that it is compatible with the other ingredients of the pharmaceutical formulation and suitable for use in contact with the tissues or organs of humans and animals without excessive toxicity, irritation, allergic response, immunogenicity, or other problems or complications commensurate with a reasonable benefit / risk ratio. See, for example, Lippincott Williams & Wilkins: Philadelphia, PA, 2005; Handbook of Pharmaceutical Excipients, 6th ed.; Rowe et al., eds.; The Pharmaceutical Press and the American Pharmaceutical Association: 2009; Handbook of Pharmaceutical Additives, 3rd ed.; Ash and Ash, eds.; Gower Publishing Company: 2007; Pharmaceutical Preformulation and Formulation, 2nd ed.; Gibson, ed.; CRC Press LLC: Boca Raton, FL, 2009. In some embodiments, a pharmaceutically acceptable excipient is nontoxic to cells or mammals to which it is exposed at the dosages and concentrations employed. In some embodiments, a pharmaceutically acceptable excipient is an aqueous pH buffered solution.

[0143] The abbreviation "MMAE" refers to monomethylolpropionate E.

[0144] Unless the context indicates otherwise, a hyphen (-) indicates the point of attachment to the side molecule.

[0145] The term "chemotherapeutic agent" refers to all compounds that are effective in inhibiting tumor growth. Non-limiting examples of chemotherapeutic agents include: alkylating agents, such as nitrogen mustards, ethyleneimine compounds, and alkyl sulfonates; antimetabolites, such as folic acid, purine or pyrimidine antagonists; mitotic inhibitors, such as anti-tubulin agents, such as vinca alkaloids, auristatins, and derivatives of podophyllotoxin; cytotoxic antibiotics; compounds that damage or interfere with DNA expression or replication, such as DNA minor groove binders; and growth factor receptor antagonists. In addition, chemotherapeutic agents include cytotoxic agents (as defined herein), antibodies, biomolecules, and small molecules.

[0146] As used herein, the term "conservative substitution" refers to the substitution of an amino acid that is known to those skilled in the art and is generally permissible without altering the biological activity of the resulting molecule. Those skilled in the art will recognize that, in general, substitution of a single amino acid in a non-essential region of a polypeptide does not substantially alter the biological activity (see, for example, Watson et al., MOLECULARBIOLOGY OF THE GENE, The Benjamin / Cummings Pub. Co., p. 224 (4th edition 1987)). Such exemplary substitutions are preferably made according to those described in Tables 2 and 3. For example, such changes include the substitution of any of isoleucine (1), valine (V), and leucine (L) for any other amino acid in these hydrophobic amino acids; the substitution of aspartic acid (D) for glutamic acid (E) and vice versa; the substitution of glutamine (Q) for asparagine (N) and vice versa; and the substitution of serine (S) for threonine (T) and vice versa. Other substitutions may also be considered conserved depending on the context of the particular amino acid and its role in the three-dimensional structure of the protein. For example, glycine (G) and alanine (A) are often interchangeable, as are alanine (A) and valine (V). The relatively hydrophobic methionine (M) is often interchangeable with leucine and isoleucine, and sometimes with valine. Lysine (K) and arginine (R) are often interchangeable in positions where the amino acid residues are characterized by their charge, and the pK difference between these two amino acid residues is not significant. In certain contexts, other variations can still be considered “conservative” (see, for example, Table 3 in this paper; “Biochemistry” 2nd edition, edited by Lubert Stryer (Stanford University), pp. 13-15; Henikoff et al., PNAS 1992, Vol. 89, pp. 10915-10919; Lei et al., J Biol Chem, May 19, 1995; 270(20): 11882-11886). Other substitutions are also permissible and can be determined empirically or based on known conservative substitutions.

[0147] Table 2. Amino acid abbreviations

[0148] Single letter Three letters Full name F Phe Phenylalanine L Leu Leucine S Ser Serine Y Tyr Tyrosine C Cys Cysteine W Trp Tryptophan P Pro Proline H His Histidine Q Gln glutamine R Arg Arginine I Ile Isoleucine M Met Methionine T Thr Threonine N Asn Asparagine K Lys Lysine V Val Valine A Ala Alanine D Asp Aspartic acid E Glu glutamate G Gly Glycine

[0149] Table 3. Amino acid substitution or similarity matrix

[0150] Adapted from the GCG software 9.0 BLOSUM62 amino acid substitution matrix (block substitution matrix). The higher the value, the greater the likelihood of finding substitutions in the relevant natural protein.

[0151]

[0152] The term "homology" or "homology" is intended to refer to the sequence similarity between two polynucleotides or two polypeptides. Similarity can be determined by comparing positions in each sequence aligned for comparative purposes. If a given position in two polypeptide sequences is not identical, the similarity or conservation of said position can be determined, for example, by assessing the similarity of amino acids at said position according to Table 3. The degree of similarity between sequences varies with the number of matching or homologous positions shared by said sequences. Aligning two sequences to determine their percentage sequence similarity can be performed using software programs known in the art, such as those described in Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, MD (1999). Preferably, alignment is performed using default parameters, examples of which are illustrated below. One alignment program known in the art is BLAST with default parameters set. Specifically, the programs BLASTN and BLASTP used the following default parameters: genetic code = standard; filter = none; strands = two; cutoff value = 60; expected value = 10; matrix = BLOSUM62; description = 50 sequences; sorting method = HIGH SCORE; database = non-redundant, GenBank+EMBL+DDBJ+PDB+GenBank CDS translation+Swissprotein+SPupdate+PIR. Details of these programs can be found at the National Center for Biotechnology Information.

[0153] The term "homology" is used to indicate that the corresponding sequence of a "homology" has a considerable degree of identity or homology with the given amino acid sequence or nucleic acid sequence.

[0154] The determination of percent identity between two sequences (e.g., amino acid sequences or nucleic acid sequences) can be accomplished using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm for comparing two sequences is the algorithm of Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. USA 87:2264-2268, as modified in Karlin and Altschul, 1993, Proc. Natl. Acad. Sci. USA 90:5873-5877. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul et al., 1990, J. Mol. Biol. 215:403. BLAST nucleotide searches can be performed using the NBLAST nucleotide program parameter set (e.g., for score=100, wordlength=12) to obtain nucleotide sequences homologous to the nucleic acid molecules described herein. BLAST protein searches can be performed using the XBLAST program parameter set, e.g., for a score of 50 and a wordlength of 3, to obtain amino acid sequences homologous to the protein molecules described herein. To perform gapped alignments for comparison purposes, Gapped BLAST can be used as described in Altschul et al., 1997, Nucleic Acids Res. 25:3389-3402. Alternatively, PSI BLAST can be used to perform an iterated search that detects distant relationships between molecules (supra). When utilizing BLAST, Gapped BLAST, and PSI Blast programs, the default parameters of the respective programs (e.g., XBLAST and NBLAST) can be used (see, e.g., the National Center for Biotechnology Information (NCBI) on the World Wide Web, ncbi.nlm.nih.gov). Another non-limiting example of a mathematical algorithm utilized for sequence comparison is the algorithm of Myers and Miller, 1988, CABIOS 4:1117. Such an algorithm is incorporated into the ALIGN program (version 2.0), which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used.

[0155] The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. When calculating percent identity, typically only exact matches are counted.

[0156] The term "cytotoxic agent" refers to a substance that inhibits or prevents cell expression activity, cell function and / or causes cell destruction. The term is intended to include radioisotopes, chemotherapeutic agents, and toxins, such as small molecule toxins or enzymatically active toxins derived from bacteria, fungi, plants or animals, including fragments and / or variants thereof. Examples of cytotoxic agents include, but are not limited to, auristatins (e.g., auristatin E, auristatin F, MMAE, and MMAF), auromycins, maytansinoids, ricin, ricin A chain, combrestatin, duocarmycins, dolastatins, doxorubicin, daunorubicin, taxols, cisplatin, cc1065, ethidium bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxyanthracin dione, actinomycin, diphtheria toxin, toxin), Pseudomonas aeruginosa exotoxin (PE) A, PE40, abrin, abrin A chain, modeccin A chain, α-sarcin, gelonin, mitogellin, retstrictocin, phenomycin, enomycin, curicin, crotin, calicheamicin, Sapaonaria officinalis inhibitors and glucocorticoids and other chemotherapeutic agents, as well as radioactive isotopes such as At 211 , I 131 , I 125 、Y 90 、Re 186 、Re 188 、Sm 153 Bi 212 Or Bi 213 、P 32 Radioactive isotopes of Lu, including Lu 177 Antibodies can also be conjugated to anticancer prodrug activating enzymes that can convert prodrugs into their active forms.

[0157] As used herein, the term "effective amount" or "therapeutically effective amount" refers to the amount of a binding molecule (eg, antibody) or pharmaceutical composition provided herein sufficient to produce a desired result.

[0158] The terms "subject" and "patient" are used interchangeably. As used herein, in certain embodiments, the subject is a mammal, such as a non-primate (e.g., a cow, pig, horse, cat, dog, rat, etc.) or a primate (e.g., a monkey and a human). In specific embodiments, the subject is a human. In one embodiment, the subject is a mammal, such as a human, diagnosed with a disease or condition. In another embodiment, the subject is a mammal, such as a human, at risk of developing a disease or condition.

[0159] "Administer" means the act of injecting or otherwise physically delivering a substance that is present outside the body into a patient's body, such as via transmucosal, intradermal, intravenous, intramuscular delivery, and / or any other physical delivery method described herein or known in the art.

[0160] As used herein, the terms "treat / treatment / treating" refer to a reduction or improvement in the progression, severity, and / or duration of a disease or condition resulting from the administration of one or more therapies. Treatment can be determined by assessing whether there has been a reduction, alleviation, and / or alleviation of one or more symptoms associated with the underlying condition, such that improvement is observed in the patient, even though the patient may still be suffering from the underlying condition. The term "treat" includes both managing and ameliorating the disease. The term "manage / managing" refers to the beneficial effects that a subject obtains from a therapy, which does not necessarily result in a cure of the disease.

[0161] The terms "prevent," "preventing," and "prevention" refer to reducing the likelihood of the onset (or recurrence) of a disease, disorder, condition, or related symptoms (eg, cancer).

[0162] The term "cancer" or "cancer cell" is used herein to refer to tissues or cells found in neoplasms that possess characteristics that distinguish them from normal tissues or tissue cells. Such characteristics include, but are not limited to, a degree of anaplasia, irregularity of shape, poorly defined cell outlines, changes in nuclear size, nuclear or cytoplasmic structure, other phenotypic changes, the presence of cellular proteins indicative of a cancerous or precancerous state, an increased number of mitoses, and the ability to metastasize. The term "cancer" includes carcinoma, sarcoma, tumor, epithelioma, leukemia, lymphoma, polyps and scirrhosis, transformation, neoplasm, and the like.

[0163] As used in this article, "locally advanced" cancer refers to cancer that has spread from its origin to nearby tissues or lymph nodes.

[0164] As used in this article, "metastatic" cancer refers to cancer that has spread from its origin to different parts of the body.

[0165] The term "intravesical administration" refers to the instillation of a therapeutic agent directly into the bladder via a catheter inserted into the urinary tract.

[0166] The term "residence time" refers to the duration for which a therapeutic substance will remain in a part or organ (e.g., the bladder) of the treated subject.

[0167] The terms "about" and "approximately" mean within 20%, within 15%, within 10%, within 9%, within 8%, within 7%, within 6%, within 5%, within 4%, within 3%, within 2%, within 1% or less of a given value or range.

[0168] Unless the context clearly specifies otherwise, as used in this disclosure and claims, the singular forms “a / an” and “the” include the plural forms.

[0169] It is to be understood that when an embodiment is described herein using the term "comprising," other similar embodiments described using the terms "consisting of" and / or "consisting essentially of" are also provided. It is also to be understood that when an embodiment is described herein using the phrase "consisting essentially of," other similar embodiments described using the term "consisting of" are also provided.

[0170] The term "and / or" as used herein in phrases such as "A and / or B" is intended to include A and B; A or B; A (alone); and B (alone). Similarly, the term "and / or" as used in phrases such as "A, B and / or C" is intended to encompass each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0171] The term "variant" refers to a molecule that exhibits differences from the described type or specification, such as in a particular described protein (e.g., Figure 1A A protein having one or more different amino acid residues in corresponding positions of the 191P4D12 protein (shown in Figure 1). Analogs are examples of variant proteins. Splice isoforms and single nucleotide polymorphisms (SNPs) are other examples of variants.

[0172] The "191P4D12 proteins" and / or "191P4D12-related proteins" of the present disclosure include those proteins specifically identified herein (see Figure 1A This includes allelic variants, conserved substitution variants, analogs, and homologs that can be isolated / produced and characterized without excessive experimentation by following methods outlined herein or readily available in the art. Fusion proteins combining portions of different 191P4D12 proteins or fragments thereof, as well as fusion proteins of 191P4D12 proteins with heterologous polypeptides, are also included. Such 191P4D12 proteins are collectively referred to as 191P4D12-related proteins, proteins of this disclosure, or 191P4D12. The term "191P4D12-related protein" refers to a protein having 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or more amino acids; or at least 30, 35, 40, 45, 50, 55, 60, 65, 70, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 225, 250, 275, 300, 325, 330, 335, 339 or more amino acids or a 191P4D12 protein sequence. The term "191P4D12" can be used interchangeably with connexin-4.

[0173] 5.2 Methods of treating non-muscle invasive bladder cancer (NMIBC) in selected patients

[0174] Provided herein are methods of treating bladder cancer in a human subject via intravesical administration of an antibody drug conjugate (ADC) that binds 191P4D12.

[0175] In one aspect, provided herein are methods for treating bladder cancer in a human subject, comprising administering to the subject intravesically an effective amount of an antibody drug conjugate (ADC), wherein the ADC comprises an antibody or antigen-binding fragment thereof that binds to 191P4D12, conjugated to one or more units of monomethyl auristatin E (MMAE).

[0176] In some embodiments, the bladder cancer is non-muscle-invasive bladder cancer (NMIBC). In some embodiments, the NMIBC has been histologically confirmed. In some embodiments, the NMIBC is carcinoma in situ (CIS). In some embodiments, the NMIBC has been histologically confirmed and is carcinoma in situ (CIS). In some embodiments, the subject has papillary disease. In some embodiments, the subject does not have papillary disease. In some embodiments, the NMIBC has been histologically confirmed and the major histological component (>50%) is urothelial (transitional cell) carcinoma.

[0177] In some embodiments, human subjects treated with the methods provided herein have high-risk BCG non-responsive disease. In some embodiments, high-risk BCG non-responsive disease is defined as persistent or recurrent CIS, alone or with recurrent Ta / T1 (non-invasive papillary disease / tumor invading subepithelial connective tissue) disease, within 12 months of completion of adequate BCG therapy. In some embodiments, adequate BCG therapy is defined as five of the six doses of the initial induction phase plus at least two of the three doses of maintenance therapy. In some embodiments, adequate BCG therapy is defined as five of the six doses of the initial induction phase plus at least two of the six doses of the second induction phase.

[0178] In some embodiments, the human subject treated with the methods provided herein is not a candidate for radical cystectomy. In some embodiments, the human subject treated with the methods provided herein refuses radical cystectomy.

[0179] In some embodiments, all visible papillary Ta / T1 tumors in the subject have been completely resected within 60 days prior to treatment. In some embodiments, the subject has residual pure CIS. In some embodiments, the subject does not have residual pure CIS.

[0180] In some embodiments, the human subjects treated with the methods provided herein have satisfactory bladder function and are able to maintain instillation of the ADC provided herein for at least 1 hour, even with premedication. In some embodiments, the human subjects are at least 18 years old. In some embodiments, the estimated life expectancy of the human subjects exceeds 2 years.

[0181] In some embodiments, the Eastern Cooperative Oncology Group (ECOG) performance status score of human subjects treated with the methods provided herein is 0. In some embodiments, the Eastern Cooperative Oncology Group (ECOG) performance status score of human subjects treated with the methods provided herein is 1. In some embodiments, the Eastern Cooperative Oncology Group (ECOG) performance status score of human subjects treated with the methods provided herein is 2. In some embodiments, the Eastern Cooperative Oncology Group (ECOG) performance status score of human subjects treated with the methods provided herein is 2, and the subject's glomerular filtration rate (GFR) is not less than 50 mL / min, and the subject does not have New York Heart Association (NYHA) Class III heart failure.

[0182] In other embodiments of the methods provided herein (including those in the preceding paragraphs), the human subjects to whom the methods provided herein may be used are human subjects with various other conditions. In some embodiments, the human subjects treated with the methods provided herein have an absolute neutrophil count (ANC) of not less than 1500 / μL. In some embodiments, the human subjects treated with the methods provided herein have a hemoglobin (Hgb) of not less than 10 g / dL. In some embodiments, the human subjects treated with the methods provided herein have a platelet count of not less than 100,000 / μL. In some embodiments, the human subjects treated with the methods provided herein have a serum bilirubin level of not more than 1.5 × the upper limit of normal (ULN) or, for subjects with Gilbert's disease, not more than 3 × ULN. In some embodiments, the human subjects treated with the methods provided herein have a creatinine clearance (CrCl) of not less than 30 mL / min. In some embodiments, CrCl is calculated using the Cockcroft-Gault method or the modified diet for kidney disease (MDRD) equation. In some embodiments, human subjects treated with the methods provided herein have a GFR of not less than 30 mL / min. In some embodiments, human subjects treated with the methods provided herein have an ECOG performance status of 2 and a GFR of not less than 50 mL / min. In some embodiments, human subjects treated with the methods provided herein have alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels not greater than 3 × ULN. In some embodiments, human subjects treated with the methods provided herein have an international normalized ratio (INR) or prothrombin time (PT), activated partial thromboplastin time (aPTT), or partial thromboplastin time (PTT) not greater than 1.5 ULN, unless the human subject is receiving anticoagulant therapy, provided that PT or aPTT is within the therapeutic range intended for the anticoagulant's purpose. In some embodiments, human subjects treated with the methods provided herein have one or more of the conditions described in this paragraph. In some embodiments, human subjects treated with the methods provided herein have all the conditions described in this paragraph.

[0183] In other embodiments of the methods provided herein (including the methods of the aforementioned paragraphs), the human subjects to whom the methods provided herein may be used are human subjects who do not have certain conditions. In some embodiments, the human subjects treated with the methods provided herein do not currently or previously have a history of muscle-invasive urothelial carcinoma (i.e., T2, T3, or T4 disease) or metastatic disease. In some embodiments, the human subjects treated with the methods provided herein do not suffer from nodular or metastatic disease as indicated on computed tomography (CT) or magnetic resonance imaging (MRI) completed within 3 months prior to ADC treatment. In some embodiments, the human subjects treated with the methods provided herein do not suffer from upper urothelial carcinoma as indicated on CT or MRI urograms of abdominal / pelvic angiography performed within 3 months prior to ADC treatment. In some embodiments, the human subjects treated with the methods provided herein do not suffer from previous or accompanying urothelial carcinoma of the prostatic urinary tract within 6 months prior to ADC treatment. In some embodiments, the human subjects treated with the methods provided herein do not suffer from tumor-associated hydronephrosis prior to administering ADC. In some embodiments, the human subjects treated with the method provided herein have not yet received systemic anticancer therapy (e.g., chemotherapy, biotherapy, immunotherapy, targeted therapy, endocrine therapy, research agent) within 4 weeks of the first administration of the method provided herein, or have not yet received any intravesical therapy for the treatment of NMIBC within 6 weeks before starting to treat with the method provided herein. In some embodiments, the human subjects treated with the method provided herein have not yet received a single instillation of cytotoxic agents (e.g., mitomycin C, doxorubicin and gemcitabine) immediately after TURBT surgery between 14 days and 60 days before starting to treat with the method provided herein. In some embodiments, the human subjects treated with the method provided herein do not have persistent symptoms (grade 2 and higher) of the adverse events (AE) related to the previous therapy of NMIBC. In some embodiments, the human subjects treated with the method provided herein have not previously received radiation for bladder for the treatment of urothelial carcinoma. In some embodiments, the human subjects treated with the methods provided herein do not have an active infection, wherein the subject has been treated with systemic (e.g., oral or intravenous) antibiotics within 14 days prior to starting ADC treatment. In some embodiments, the human subjects treated with the methods provided herein tolerate intravesical administration or intravesical surgical procedures. In some embodiments, the human subjects treated with the methods provided herein do not have a history of malignant disease within 3 years prior to treatment with the methods provided herein, or do not have any evidence of residual disease from a previously diagnosed malignant disease.In some embodiments, the human subjects treated with the methods provided herein have a negligible risk of metastasis or death (e.g., 5-year overall survival [OS] ≥ 90%), such as adequately treated cervical CIS, non-melanoma skin cancer, breast ductal CIS, or stage I uterine cancer. In some embodiments, the human subjects treated with the methods provided herein have a history of prostate cancer (T2N0M0 or lower, Gleason score ≤ 7) treated with explicit intent (surgery or radiation therapy) at least 1 year prior to treatment with the methods provided herein, provided that the subject is considered free of prostate cancer and meets the following criteria: (1) subjects who have undergone radical prostatectomy must have undetectable prostate-specific antigen (PSA) for > 1 year prior to administration of the ADC; and (2) subjects who have received radiation must have a PSA doubling time > 1 year (based on at least 3 values ​​determined at intervals > 1 month) and a total PSA value that does not meet the Phoenix criteria for biochemical recurrence (i.e., < 2.0 ng / mL above the nadir). In some embodiments, the human subjects treated with the methods provided herein have not been previously exposed to connexin-4 targeted therapies or agents containing monomethyl auristatin E (MMAE). In some embodiments, the human subjects treated with the methods provided herein do not have autoimmune or inflammatory skin conditions. In some embodiments, the human subjects treated with the methods provided herein do not have psoriasis or atopic dermatitis. In some embodiments, the human subjects treated with the methods provided herein do not have persistent sensory or motor neuropathy of grade 2 or higher. In some embodiments, the human subjects treated with the methods provided herein do not have positive hepatitis B surface antigen and / or anti-hepatitis B core antibodies. In some embodiments, the human subjects treated with the methods provided herein have a negative polymerase chain reaction (PCR) assay for hepatitis B and have undergone appropriate antiviral prophylaxis. In some embodiments, the human subjects treated with the methods provided herein do not have active hepatitis C infection or known human immunodeficiency virus (HIV) infection. In some embodiments, the human subjects treated with the methods provided herein do not have active tuberculosis. In some embodiments, the human subjects treated with the methods provided herein do not have uncontrolled diabetes. In some embodiments, uncontrolled diabetes is defined as a subject with hemoglobin A1c (HbA1c) ≥ 8% or HbA1c 7% to < 8% and associated diabetic symptoms (polyuria or polydipsia). In some embodiments, the human subjects treated with the methods provided herein do not have a cerebrovascular event (e.g., stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms consistent with NYHA Class III-IV within 6 months prior to the first administration of the ADC.In some embodiments, human subjects treated with the methods described herein did not have a serious (≥ grade 3) hypersensitivity to enrofloxacin or any excipients contained in the pharmaceutical formulation of enrofloxacin (e.g., histidine, trehalose dihydrate, and / or polysorbate 20). In some embodiments, human subjects treated with the methods described herein did not have active keratitis or corneal ulcers. In some embodiments, human subjects treated with the methods described herein had superficial punctate keratitis.

[0184] In some implementations, the methods provided herein are used to treat subjects with non-muscle-invasive bladder cancer (NMIBC) that expresses 191P4D12 RNA, 191P4D12 protein, or both 191P4D12 RNA and 191P4D12 protein.

[0185] In some embodiments, 191P4D12 RNA expression in cancer is determined by multinucleotide hybridization, sequencing (to assess the relative abundance of sequences), and / or PCR (including RT-PCR). In some embodiments, 191P4D12 protein expression in cancer is determined by IHC, fluorescence activated cell sorting (FACS) analysis, and / or Western blotting. In some embodiments, 191P4D12 protein expression in cancer is determined by more than one method. In some embodiments, expression is determined by two IHC methods.

[0186] In some embodiments, non-muscle invasive bladder cancer (NMIBC) is confirmed histologically, cytologically, or both histologically and cytologically.

[0187] On the other hand, this document provides a method for treating NMIBC in human subjects, the method comprising administering to the subject an effective amount of an antibody-drug conjugate, wherein the antibody-drug conjugate comprises an antibody or antigen-binding fragment thereof bound to 191P4D12, which is conjugated to one or more units of monomethylolpropionate E (MMAE), wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence containing a complementarity-determining region (CDR) of the heavy chain variable region as shown in SEQ ID NO: 22; and a light chain variable region comprising an amino acid sequence containing a CDR of the light chain variable region as shown in SEQ ID NO: 23; and wherein the subject has any of the suitability characteristics provided in Section 6.

[0188] In another aspect, provided herein is a method for preventing or treating cancer in a human subject, the method comprising administering to the subject an effective amount of an antibody drug conjugate, wherein the antibody drug conjugate comprises an antibody or antigen-binding fragment thereof that binds to 191P4D12, coupled to one or more units of monomethyl auristatin E (MMAE), wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising a complementarity determining region (CDR) comprising the amino acid sequence of the heavy chain variable region set forth in SEQ ID NO: 22; and a light chain variable region comprising a CDR comprising the amino acid sequence of the light chain variable region CDR set forth in SEQ ID NO: 23; and wherein the cancer has any one of the suitable markers and / or characteristics provided in Section 6.

[0189] In another aspect, provided herein is a method for preventing or treating cancer in a human subject, comprising administering to the subject an effective amount of an antibody drug conjugate, wherein the antibody drug conjugate comprises an antibody or antigen-binding fragment thereof that binds to 191P4D12, conjugated to one or more units of monomethyl auristatin E (MMAE), and wherein the subject has any one of the suitable characteristics provided in Section 6. In another aspect, provided herein is a method for preventing or treating cancer in a human subject, comprising administering to the subject an effective amount of an antibody drug conjugate, wherein the antibody drug conjugate comprises a conjugate of an antibody or antigen-binding fragment thereof that binds to 191P4D12 and one or more units of monomethyl auristatin E (MMAE), and wherein the cancer has any one of the suitable markers and / or characteristics provided in Section 6.

[0190] In all methods provided herein and those methods specifically described in the preceding paragraphs: ADCs that can be used are described in Sections 3, 5.2, 5.3, 5.4, 5.5, 5.6, and 6, selecting patients for treatment is described herein and exemplified in this section (Section 5.2) and Sections 3 and 6, dosing regimens and pharmaceutical compositions for administering therapeutic agents are described in Sections 5.4, 5.6, and 6 below, biomarkers that can be used to identify therapeutic agents, select patients, determine the outcomes of these methods, and / or serve in any way as criteria for these methods are described herein and exemplified in this section and Section 6, biomarkers can be determined as described in Section 5.7 or as known in the art, the therapeutic outcomes of the methods provided herein are described in this section (Section 5.2) and Sections 3 and 6, other therapeutic outcomes of the methods provided herein can be improvements of the biomarkers described herein, such as those described and exemplified in this section (Section 5.2) and Sections 3 and 6, and combination therapies comprising ADCs and other therapeutic agents are described in this section and Section 5.5. Thus, one skilled in the art will understand that the methods provided herein encompass all permutations and combinations of patients, therapeutic agents, dosing regimens, biomarkers, and treatment outcomes as described above and below.

[0191] 5.3 The antibody-drug conjugate used in the method described above

[0192] In various embodiments of the methods provided herein (including the methods provided in Section 5.2), the ADC used in the method comprises or is an anti-191P4D12 ADC described herein and / or in U.S. Patent No. 8,637,642, which is incorporated herein by reference in its entirety. In some embodiments, the anti-191P4D12 antibody drug conjugate provided herein for the methods comprises an antibody or antigen-binding fragment thereof that binds to 191P4D12 as provided herein (including Sections 3, 5.3.1, and 6) and a conjugate of one or more units (drug units, or D) of a cytotoxic agent as provided herein (including Sections 3 and 6, and this Section (Section 5.3)), with further details disclosed in Sections 5.3.2 and 5.3.4. In certain embodiments, the cytotoxic agent (drug unit, or D) may be covalently linked directly or via a linker unit (LU) as provided herein (including Sections 3 and 6, and this Section (Section 5.3)), with further details disclosed in Section 5.3.3.

[0193] In some embodiments, the antibody drug conjugate compound has the formula:

[0194] L-(LU-D) p (I)

[0195] or a pharmaceutically acceptable salt or solvate thereof, wherein:

[0196] L is an antibody unit, e.g., an anti-Connexin-4 antibody or antigen-binding fragment thereof, e.g., as provided in Sections 3, 5.3.1, and 6, and

[0197] (LU-D) is a Linker Unit-Drug Unit moiety, wherein:

[0198] LU- is a linker unit, such as provided in Sections 3 and 6 and this section (Section 5.3), and otherwise disclosed in Section 5.3.3, and

[0199] D is a Drug unit having cytostatic or cytotoxic activity against target cells, such as provided in Sections 3 and 6 and this section (Section 5.3), and further disclosed in Sections 5.3.2 and 5.3.4; and

[0200] p is an integer from 1 to 20, further examples are provided in Sections 3 and 6 and in this section (Section 5.3).

[0201] In some embodiments, p ranges from 1 to 20, 1 to 19, 1 to 18, 1 to 17, 1 to 16, 1 to 15, 1 to 14, 1 to 13, 1 to 12, 1 to 11, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 to 2. In some embodiments, p ranges from 2 to 20, 2 to 19, 2 to 18, 2 to 17, 2 to 16, 2 to 15, 2 to 14, 2 to 13, 2 to 12, 2 to 11, 2 to 10, 2 to 9, 2 to 8, 2 to 7, 2 to 6, 2 to 5, 2 to 4, or 2 to 3. In some embodiments, p ranges from 3 to 20, 3 to 19, 3 to 18, 3 to 17, 3 to 16, 3 to 15, 3 to 14, 3 to 13, 3 to 12, 3 to 11, 3 to 10, 3 to 9, 3 to 8, 3 to 7, 3 to 6, 3 to 5, or 3 to 4. In some embodiments, p is about 1. In some embodiments, p is about 2. In some embodiments, p is about 3. In some embodiments, p is about 4. In some embodiments, p is about 3.8. In some embodiments, p is about 5. In some embodiments, p is about 6. In some embodiments, p is about 7. In some embodiments, p is about 8. In some embodiments, p is about 9. In some embodiments, p is about 10. In some embodiments, p is about 11. In some embodiments, p is about 12. In some embodiments, p is about 13. In some embodiments, p is about 14. In some embodiments, p is about 15. In some embodiments, p is about 16. In some embodiments, p is about 17. In some embodiments, p is about 18. In some embodiments, p is about 19. In some embodiments, p is about 20.

[0202] In some embodiments, the antibody drug conjugate compound has the formula:

[0203] L-(A a -W w -Y y -D) p (II)

[0204] or a pharmaceutically acceptable salt or solvate thereof, wherein:

[0205] L is an antibody unit, e.g., an anti-Connexin-4 antibody or antigen-binding fragment thereof, e.g., as provided in Sections 3, 5.3.1, and 6; and

[0206] -A a -W w -Y y - is a joint unit (LU), wherein:

[0207] -A- is the extension subunit,

[0208] a is 0 or 1,

[0209] Each -W- is independently an amino acid unit,

[0210] w is an integer ranging from 0 to 12,

[0211] -Y- is a self-degradable spacer unit,

[0212] y is 0, 1, or 2,

[0213] Each as provided in, for example, chapters 3 and 6 and this chapter (chapter 5.3), with other content disclosed in chapter 5.3.3;

[0214] D is a Drug unit having cytostatic or cytotoxic activity against target cells, such as provided in Sections 3 and 6 and this section (Section 5.3), and further disclosed in Sections 5.3.2 and 5.3.4; and

[0215] p is an integer from 1 to 20, with other examples provided in sections 3 and 6 and this section (section 5.3).

[0216] In some embodiments, a is 0 or 1, w is 0 or 1, and y is 0, 1, or 2. In some embodiments, a is 0 or 1, w is 0 or 1, and y is 0 or 1. In some embodiments, p ranges from 1 to 20, 1 to 19, 1 to 18, 1 to 17, 1 to 16, 1 to 15, 1 to 14, 1 to 13, 1 to 12, 1 to 11, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 to 2. In some embodiments, p ranges from 2 to 20, 2 to 19, 2 to 18, 2 to 17, 2 to 16, 2 to 15, 2 to 14, 2 to 13, 2 to 12, 2 to 11, 2 to 10, 2 to 9, 2 to 8, 2 to 7, 2 to 6, 2 to 5, 2 to 4, or 2 to 3. In some embodiments, p ranges from 3 to 20, 3 to 19, 3 to 18, 3 to 17, 3 to 16, 3 to 15, 3 to 14, 3 to 13, 3 to 12, 3 to 11, 3 to 10, 3 to 9, 3 to 8, 3 to 7, 3 to 6, 3 to 5, or 3 to 4. In some embodiments, p is about 1. In some embodiments, p is about 2. In some embodiments, p is about 3. In some embodiments, p is about 4. In some embodiments, p is about 3.8. In some embodiments, p is about 5. In some embodiments, p is about 6. In some embodiments, p is about 7. In some embodiments, p is about 8. In some embodiments, p is about 9. In some embodiments, p is about 10. In some embodiments, p is about 11. In some embodiments, p is about 12. In some embodiments, p is about 13. In some embodiments, p is about 14. In some embodiments, p is about 15. In some embodiments, p is about 16. In some embodiments, p is about 17. In some embodiments, p is about 18. In some embodiments, p is about 19. In some embodiments, p is about 20. In some embodiments, when w is non-zero, y is 1 or 2. In some embodiments, when w is from 1 to 12, y is 1 or 2. In some embodiments, w is from 2 to 12 and y is 1 or 2. In some embodiments, a is 1 and w and y are 0.

[0217] In some specific embodiments of the methods provided herein, including the methods provided in Section 5.2, the cytotoxic agent that is part of any one of the ADCs provided herein for the methods comprises, consists of, or is MMAE.

[0218] For compositions comprising multiple antibodies or their antigen-binding fragments, the drug load is expressed as p (average number of drug molecules / antibody unit). The drug load can range from 1 to 20 drug (D) / antibody. The average number of drugs per antibody during the preparation of the conjugate can be characterized using conventional methods such as mass spectrometry, ELISA, and HPLC. The quantitative distribution of the antibody-drug conjugate can also be determined based on p. In some cases, the separation, purification, and characterization of homogeneous antibody-drug conjugates (where p is a specific value for antibody-drug conjugates with other drug loads) can be achieved, for example, by reversed-phase HPLC or electrophoresis. In some exemplary embodiments, p is 2 to 8.

[0219] Other embodiments of ADCs for use in the methods provided herein have been described in U.S. Pat. No. 8,637,642 and International Application No. PCT / US2019 / 056214 (Publication No. WO2020 / 117373), both of which are hereby incorporated by reference in their entireties.

[0220] In some embodiments of the methods provided herein (including Sections 3, 5.2, and 6 and this section (Section 5.3)), the ADC is enroku vedotin. In certain embodiments of the methods provided herein (including Sections 3, 5.2, and 6 and this section (Section 5.3)), the ADC is a biosimilar of enroku vedotin.

[0221] 5.3.1 Anti-191P4D12 antibody or antigen-binding fragment

[0222] In one embodiment, the antibody or antigen-binding fragment thereof that binds to a connexin-4 related protein is an antibody or antigen-binding fragment that specifically binds to a connexin-4 protein comprising the amino acid sequence of SEQ ID NO: 2 (see Figure 1A The corresponding cDNA encoding the 191P4D12 protein has the sequence SEQ ID NO: 1 (see [link to SEQ ID NO: 1]). Figure 1A ).

[0223] Antibodies that specifically bind to a connexin-4 protein comprising the amino acid sequence of SEQ ID NO: 2 include antibodies that can bind to other connexin-4-related proteins. For example, an antibody that binds to a connexin-4 protein comprising the amino acid sequence of SEQ ID NO: 2 can bind to connexin-4-related proteins, such as connexin-4 variants and homologs or analogs thereof.

[0224] In some embodiments, the anti-Connexin-4 antibodies provided herein are monoclonal antibodies.

[0225] In some embodiments, the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 4 (cDNA sequence of SEQ ID NO: 3) and / or a light chain comprising the amino acid sequence of SEQ ID NO: 6 (cDNA sequence of SEQ ID NO: 5), such as Figure 1B and Figure 1C As shown in .

[0226] In some embodiments, the anti-connector protein-4 antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising a CDR containing an amino acid sequence of the complementarity-determining region (CDR) of the heavy chain variable region as shown in SEQ ID NO: 22 (which is an amino acid sequence ranging from the 20th amino acid (glutamic acid) to the 136th amino acid (serine) of SEQ ID NO: 7); and a light chain variable region comprising a CDR containing an amino acid sequence of the CDR of the light chain variable region as shown in SEQ ID NO: 23 (which is an amino acid sequence ranging from the 23rd amino acid (aspartic acid) to the 130th amino acid (arginine) of SEQ ID NO: 8). In some embodiments, the anti-linkin-4 antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising CDR-H1, CDR-H2, and CDR-H3 containing the amino acid sequences of corresponding complementarity-determining regions 1 (CDR-H1), CDR-H2, and CDR-H3 in the heavy chain variable region sequence shown in SEQ ID NO: 22 (which is the amino acid sequence of the 20th amino acid (glutamic acid) to the 136th amino acid (serine) of SEQ ID NO: 7); and a light chain variable region comprising CDR-L1, CDR-L2, and CDR-L3 containing the amino acid sequences of corresponding CDR-L1, CDR-L2, and CDR-L3 in the light chain variable region sequence shown in SEQ ID NO: 23 (which is the amino acid sequence of the 23rd amino acid (aspartic acid) to the 130th amino acid (arginine) of SEQ ID NO: 8). In some embodiments, the anti-connector protein-4 antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising an amino acid sequence of the complementarity-determining region (CDR) of the heavy chain variable region as shown in SEQ ID NO: 22 (which is an amino acid sequence ranging from the 20th amino acid (glutamic acid) to the 136th amino acid (serine) of SEQ ID NO: 7); and a light chain variable region comprising an amino acid sequence of the CDR of the light chain variable region as shown in SEQ ID NO: 23 (which is an amino acid sequence ranging from the 23rd amino acid (aspartic acid) to the 130th amino acid (arginine) of SEQ ID NO: 8).In certain embodiments, an anti-Connexin-4 antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising CDR-H1, CDR-H2, and CDR-H3 consisting of the amino acid sequences corresponding to complementarity determining region 1 (CDR-H1), CDR-H2, and CDR-H3 of the heavy chain variable region sequence set forth in SEQ ID NO: 22 (which is an amino acid sequence ranging from amino acid 20 (glutamic acid) to amino acid 136 (serine) of SEQ ID NO: 7); and a light chain variable region comprising CDR-L1, CDR-L2, and CDR-L3 consisting of the amino acid sequences corresponding to CDR-L1, CDR-L2, and CDR-L3 of the light chain variable region sequence set forth in SEQ ID NO: 23 (which is an amino acid sequence ranging from amino acid 23 (aspartic acid) to amino acid 130 (arginine) of SEQ ID NO: 8). SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 7, and SEQ ID NO: 8 are examples. Figure 1D and Figure 1E As shown and listed below:

[0227] SEQ ID NO: 22

[0228]

[0229] SEQ ID NO: 23

[0230]

[0231] SEQ ID NO: 7

[0232]

[0233] SEQ ID NO: 8

[0234]

[0235] The CDR sequence can be determined according to well-known numbering systems. As described above, the CDR region is well-known to those skilled in the art and has been defined by well-known numbering systems. For example, the Kabat complementarity determination region (CDR) is based on sequence variability and is the most commonly used (see, for example, Kabat et al., above). Chothia actually refers to the location of the structural loop (see, for example, Chothia and Lesk, 1987, J. Mol. Biol. 196: 901-17). When numbering using the Kabat numbering convention, the end of the Chothia CDR-H1 loop varies between H32 and H34, depending on the length of the loop (this is because the Kabat numbering scheme places the insertion at H35A and H35B; if neither 35A nor 35B exists, the loop end is at 32; if only 35A exists, the loop end is at 33; if both 35A and 35B exist, the loop end is at 34). The AbM hypervariable regions represent a compromise between the Kabat CDRs and the Chothia structural loops and are used by Oxford Molecular's AbM antibody modeling software (see, e.g., Antibody Engineering Volume 2 (edited by Kontermann and Dübel, 2nd edition, 2010). The "contact" high-variance region is based on the analysis of available complex crystal structures. Another universal numbering system that has been developed and widely adopted is the ImMunoGeneTics (IMGT) Information. (Lafranc et al., 2003, Dev. Comp. Immunol. 27(1): 55-77). IMGT is an integrated information system specifically for immunoglobulins (IG), T-cell receptors (TCR), and major histocompatibility complex (MHC) in humans and other vertebrates. In this paper, CDRs are referred to in relation to amino acid sequences and positions within the light or heavy chains. Since the “position” of CDRs within the variable domain structure of immunoglobulins is conserved across species and exists in structures called loops, CDRs and framework residues can be easily identified by using a numbering system that compares the variable domain sequence based on structural features. This information can be used to transplant and substitute CDR residues from immunoglobulins of one species into receptor frameworks typically derived from human antibodies. Honegger and Plückthun, 2001, J. Mol. Biol. 309: 657-70 have developed another numbering system (AHon). The correspondence between numbering systems (including, for example, the Kabat numbering and the IMGT unique numbering system) is well known to those skilled in the art (see, for example, Kabat, above; Chothia and Lesk, above; Martin, above; Lefranc et al., above). Residues from each of these hypervariable regions or CDRs are labeled in Table 1 above.

[0236] In some embodiments, an anti-Connexin-4 antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising CDRs (CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3) comprising the amino acid sequence of the CDRs of the heavy chain variable region set forth in SEQ ID NO: 22 according to Kabat numbering; and a light chain variable region comprising CDRs comprising the amino acid sequence of the CDRs of the light chain variable region set forth in SEQ ID NO: 23 according to Kabat numbering.

[0237] In some embodiments, an anti-Connexin-4 antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising CDRs (CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3) comprising the amino acid sequence of the CDRs of the heavy chain variable region set forth in SEQ ID NO: 22 according to AbM numbering; and a light chain variable region comprising CDRs comprising the amino acid sequence of the CDRs of the light chain variable region set forth in SEQ ID NO: 23 according to AbM numbering.

[0238] In other embodiments, the anti-Connexin-4 antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising CDRs (CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3) comprising the amino acid sequence of the CDRs of the heavy chain variable region set forth in SEQ ID NO: 22 according to Chothia numbering; and a light chain variable region comprising CDRs comprising the amino acid sequence of the CDRs of the light chain variable region set forth in SEQ ID NO: 23 according to Chothia numbering.

[0239] In other embodiments, the anti-Connexin-4 antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising CDRs (CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2 and CDR-L3) comprising the amino acid sequence of the CDRs of the heavy chain variable region set forth in SEQ ID NO: 22 according to Contact numbering; and a light chain variable region comprising CDRs comprising the amino acid sequence of the CDRs of the light chain variable region set forth in SEQ ID NO: 23 according to Contact numbering.

[0240] In other embodiments, the anti-Connexin-4 antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising CDRs (CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3) comprising the amino acid sequence of the CDRs of the heavy chain variable region set forth in SEQ ID NO: 22 according to IMGT numbering; and a light chain variable region comprising CDRs comprising the amino acid sequence of the CDRs of the light chain variable region set forth in SEQ ID NO: 23 according to IMGT numbering.

[0241] In some embodiments, the anti-Connexin-4 antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising CDRs (CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3) consisting of the amino acid sequences of the CDRs of the heavy chain variable region set forth in SEQ ID NO: 22 according to Kabat numbering; and a light chain variable region comprising CDRs consisting of the amino acid sequences of the CDRs of the light chain variable region set forth in SEQ ID NO: 23 according to Kabat numbering.

[0242] In some embodiments, the anti-linkin-4 antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising a CDR (CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2 and CDR-L3) consisting of the amino acid sequence of the CDR of the heavy chain variable region as shown in SEQ ID NO: 22 according to AbM number; and a light chain variable region comprising a CDR consisting of the amino acid sequence of the CDR of the light chain variable region as shown in SEQ ID NO: 23 according to AbM number.

[0243] In other embodiments, the anti-linkin-4 antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising a CDR (CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2 and CDR-L3) consisting of the amino acid sequence of the CDR of the heavy chain variable region shown in SEQ ID NO: 22 according to Chothia number; and a light chain variable region comprising a CDR consisting of the amino acid sequence of the CDR of the light chain variable region shown in SEQ ID NO: 23 according to Chothia number.

[0244] In other embodiments, the anti-linkin-4 antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising a CDR (CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2 and CDR-L3) consisting of the amino acid sequence of the CDR of the heavy chain variable region as shown in SEQ ID NO: 22 according to Contact number; and a light chain variable region comprising a CDR consisting of the amino acid sequence of the CDR of the light chain variable region as shown in SEQ ID NO: 23 according to Contact number.

[0245] In other embodiments, the anti-linkin-4 antibody or its antigen-binding fragment comprises: a heavy chain variable region comprising a CDR (CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2 and CDR-L3) consisting of the amino acid sequence of the CDR of the heavy chain variable region as shown in SEQ ID NO: 22 according to IMGT number; and a light chain variable region comprising a CDR consisting of the amino acid sequence of the CDR of the light chain variable region as shown in SEQ ID NO: 23 according to IMGT number.

[0246] As described above, CDR sequences can be readily determined according to different numbering systems, for example using online tools such as those provided by Antigen Receptor Numbering and Receptor Classification (ANARCI). For example, the heavy chain CDR sequences in SEQ ID NO: 22 and the light chain CDR sequences in SEQ ID NO: 23, as determined by ANARCI, are listed in Table 4 below.

[0247] Table 4

[0248]

[0249] For another example, the heavy chain CDR sequence within SEQ ID NO: 22 and the light chain CDR sequence within SEQ ID NO: 23 according to IMGT numbering, as determined by ANARCI, are listed in Table 5 below.

[0250] Table 5

[0251] VH of SEQ ID NO: 22 VL of SEQ ID NO: 23 CDR1 GFTFSSYN (SEQ ID NO: 16) QGISGW (SEQ ID NO: 19) CDR2 ISSSSS TI (SEQ ID NO: 1 7) AAS (SEQ ID NO: 20) CDR3 ARAYYYGMDV (SEQ ID NO: 1 8) QQANSFPPT(SEQ ID NO: 21)

[0252] In some embodiments, the antibody or its antigen-binding fragment comprises: CDR-H1, which comprises the amino acid sequence of SEQ ID NO: 9; CDR-H2, which comprises the amino acid sequence of SEQ ID NO: 10; CDR-H3, which comprises the amino acid sequence of SEQ ID NO: 11; CDR-L1, which comprises the amino acid sequence of SEQ ID NO: 12; CDR-L2, which comprises the amino acid sequence of SEQ ID NO: 13; and CDR-L3, which comprises the amino acid sequence of SEQ ID NO: 14.

[0253] In some embodiments, the antibody or its antigen-binding fragment comprises: CDR-H1, which comprises the amino acid sequence of SEQ ID NO: 16; CDR-H2, which comprises the amino acid sequence of SEQ ID NO: 17; CDR-H3, which comprises the amino acid sequence of SEQ ID NO: 18; CDR-L1, which comprises the amino acid sequence of SEQ ID NO: 19; CDR-L2, which comprises the amino acid sequence of SEQ ID NO: 20; and CDR-L3, which comprises the amino acid sequence of SEQ ID NO: 21.

[0254] In some embodiments, the antibody or its antigen-binding fragment comprises: CDR-H1, which consists of the amino acid sequence of SEQ ID NO: 9; CDR-H2, which consists of the amino acid sequence of SEQ ID NO: 10; CDR-H3, which consists of the amino acid sequence of SEQ ID NO: 11; CDR-L1, which consists of the amino acid sequence of SEQ ID NO: 12; CDR-L2, which consists of the amino acid sequence of SEQ ID NO: 13; and CDR-L3, which consists of the amino acid sequence of SEQ ID NO: 14.

[0255] In some embodiments, the antibody or its antigen-binding fragment comprises: CDR-H1, which consists of the amino acid sequence of SEQ ID NO: 16; CDR-H2, which consists of the amino acid sequence of SEQ ID NO: 17; CDR-H3, which consists of the amino acid sequence of SEQ ID NO: 18; CDR-L1, which consists of the amino acid sequence of SEQ ID NO: 19; CDR-L2, which consists of the amino acid sequence of SEQ ID NO: 20; and CDR-L3, which consists of the amino acid sequence of SEQ ID NO: 21.

[0256] In some embodiments, the antibody or its antigen-binding fragment comprises a heavy chain variable region containing the amino acid sequence of SEQ ID NO: 22 and a light chain variable region containing the amino acid sequence of SEQ ID NO: 23.

[0257] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO:22 and a light chain variable region consisting of the amino acid sequence of SEQ ID NO:23.

[0258] In some embodiments, the antibody comprises: a heavy chain comprising an amino acid sequence ranging from amino acid 20 (glutamic acid) to amino acid 466 (lysine) of SEQ ID NO:7; and a light chain comprising an amino acid sequence ranging from amino acid 23 (aspartic acid) to amino acid 236 (cysteine) of SEQ ID NO:8.

[0259] In some embodiments, the antibody comprises: a heavy chain consisting of an amino acid sequence ranging from amino acid 20 (glutamic acid) to amino acid 466 (lysine) of SEQ ID NO:7; and a light chain consisting of an amino acid sequence ranging from amino acid 23 (aspartic acid) to amino acid 236 (cysteine) of SEQ ID NO:8.

[0260] In some embodiments, amino acid sequence modifications of the antibodies described herein are contemplated. For example, it may be desirable to optimize the binding affinity and / or other biological properties of the antibody, including but not limited to specificity, thermal stability, expression level, effector function, glycosylation, reduced immunogenicity, or solubility. Thus, in addition to the antibodies described herein, it is contemplated that antibody variants may be prepared. For example, antibody variants may be prepared by introducing appropriate nucleotide changes in the encoding DNA and / or by synthesizing the desired antibody or polypeptide. One skilled in the art who understands amino acid changes may alter the post-translational processes of the antibody, such as changing the number or position of glycosylation sites or altering membrane anchoring characteristics.

[0261] In some embodiments, the antibodies provided herein are chemically modified, for example, by covalently linking any type of molecule to the antibody. Antibody derivatives may include chemically modified antibodies, for example, by glycosylation, acetylation, pegylation, phosphorylation, amidation, by derivatization with known protecting groups / blocking groups, protein cleavage, attachment to cellular ligands or other proteins, and the like. Any of a variety of chemical modifications can be performed by known techniques, including but not limited to specific chemical cleavage, acetylation, formulation, metabolic synthesis of tunicamycin, and the like. In addition, the antibody may contain one or more non-classical amino acids.

[0262] A mutation may be a substitution, deletion, or insertion of one or more codons encoding a single domain antibody or polypeptide that results in an altered amino acid sequence compared to the original antibody or polypeptide. An amino acid substitution may be the result of replacing one amino acid with another having similar structural and / or chemical properties, such as a leucine replaced with a serine, e.g., a conservative amino acid substitution. Standard techniques known to those skilled in the art can be used to introduce mutations into the nucleotide sequences encoding the molecules provided herein, including, for example, site-directed mutagenesis and PCR-mediated mutagenesis to cause amino acid substitutions. Insertions or deletions may optionally range from about 1 to 5 amino acids. In certain embodiments, substitutions, deletions, or insertions comprise fewer than 25 amino acid substitutions, fewer than 20 amino acid substitutions, fewer than 15 amino acid substitutions, fewer than 10 amino acid substitutions, fewer than 5 amino acid substitutions, fewer than 4 amino acid substitutions, fewer than 3 amino acid substitutions, or fewer than 2 amino acid substitutions relative to the original molecule. In a specific embodiment, the substitutions are conservative amino acid substitutions at one or more predicted non-essential amino acid residues. Allowable variation can be determined by systematically creating amino acid insertions, deletions, or substitutions in the sequence and testing the resulting variants for activity exhibited by the parent antibody.

[0263] Amino acid sequence insertions include amino and / or carboxyl terminus fusions of length ranging from one residue to multiple residues in a polypeptide, as well as intra-sequence insertions of single or multiple amino acid residues. Examples of terminus insertions include antibodies with an N-terminal methionyl residue.

[0264] The antibody produced by conservative amino acid substitution is included in the present disclosure. In conservative amino acid substitution, amino acid residue is replaced by the amino acid residue comprising the side chain with similar charge. As described above, the family of amino acid residues comprising the side chain with similar charge has been defined in the art. These families include amino acids with basic side chains (such as lysine, arginine, histidine), acidic side chains (such as aspartic acid, glutamic acid), uncharged polar side chains (such as glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (such as alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), β-branched side chains (such as threonine, valine, isoleucine) and aromatic side chains (such as tyrosine, phenylalanine, tryptophan, histidine). Alternatively, sudden change can be randomly introduced along all or part of the coding sequence, such as by saturation mutagenesis, and the resulting mutant can be screened according to biological activity to identify the mutant that maintains activity. After mutation induction, the encoded protein can be expressed and its activity can be measured. Conserved substitutions (e.g., within groups of amino acids with similar properties and / or side chains) can be made to maintain or not significantly alter the properties.

[0265] Amino acids can be grouped according to the similarity of their side chain properties (see, e.g., Lehninger, Biochemistry 73-75 (2nd ed. 1975)): (1) nonpolar: Ala (A), Val (V), Leu (L), Ile (I), Pro (P), Phe (F), Trp (W), Met (M); (2) uncharged polar: Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gln (Q); (3) acidic: Asp (D), Glu (E); and (4) basic: Lys (K), Arg (R), His (H). Alternatively, naturally occurring residues can be grouped based on common side-chain properties: (1) hydrophobic: leucine, Met, Ala, Val, Leu, Ile; (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues affecting chain orientation: Gly, Pro; and (6) aromatic: Trp, Tyr, Phe.

[0266] For example, any cysteine ​​residues that are not involved in maintaining the proper conformation of the antibody can be replaced with, for example, another amino acid (such as alanine or serine) to improve the oxidative stability of the molecule and prevent abnormal cross-linking.

[0267] Mutations can be generated using methods known in the art, such as oligonucleotide-mediated (site-directed) mutagenesis, alanine scanning, and PCR mutagenesis. Site-directed mutagenesis (see, for example, Carter, 1986, Biochem J. 237: 1-7; and Zoller et al., 1982, Nucl. Acids Res. 10: 6487-500), box mutagenesis (see, for example, Wells et al., 1985, Gene 34: 315-23), or other known techniques can be used to generate anti-MSLN antibody variant DNA.

[0268] Covalent modifications of antibodies are included within the scope of the present disclosure. Covalent modifications include reacting target amino acid residues of the antibody with an organic derivatizing agent that is capable of reacting with selected side chains or the N-terminal or C-terminal residues of the antibody. Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively; hydroxylation of proline and lysine; phosphorylation of the hydroxyl groups of seryl or threonyl residues; methylation of the α-amino groups of lysine, arginine, and histidine side chains (see, e.g., Creighton, Proteins: Structure and Molecular Properties 79-86 (1983)); acetylation of the N-terminal amine; and amidation of any C-terminal carboxyl group.

[0269] Other types of covalent modifications of antibodies included within the scope of the present disclosure include altering the native glycosylation pattern of the antibody or polypeptide (see, e.g., Beck et al., 2008, Curr. Pharm. Biotechnol. 9:482-501; and Walsh, 2010, Drug Discov. Today 15:773-80), and linking the antibody to one of a variety of nonproteinaceous polymers, such as polyethylene glycol (PEG), polypropylene glycol, or polyoxyalkylenes, in a manner such as described in U.S. Pat. Nos. 4,640,835, 4,496,689, 4,301,144, 4,670,417, 4,791,192, or 4,179,337.

[0270] In certain embodiments, the antibodies or antigen-binding fragments provided herein comprise a heavy chain having a certain homology or identity to the heavy chain set forth in SEQ ID NO: 7 and a light chain having a certain homology or identity to the light chain set forth in SEQ ID NO: 8. Such embodiments of heavy / light chains having homology or identity are further provided below. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise a heavy chain having greater than 70% homology or identity to the heavy chain set forth in SEQ ID NO: 7. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise a heavy chain having greater than 75% homology or identity to the heavy chain set forth in SEQ ID NO: 7. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise a heavy chain having greater than 80% homology or identity to the heavy chain set forth in SEQ ID NO: 7. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise a heavy chain having greater than 85% homology or identity to the heavy chain set forth in SEQ ID NO: 7. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise a heavy chain having greater than 90% homology or identity to the heavy chain set forth in SEQ ID NO: 7. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise a heavy chain having greater than 95% homology or identity to the heavy chain set forth in SEQ ID NO: 7. In certain embodiments, the antibodies or antigen-binding fragments provided herein comprise a heavy chain having any of the provided homologies or identities to the heavy chain set forth in SEQ ID NO: 7, wherein the CDRs (CDR-H1, CDR-H2, and CDR-H3) are identical to the CDRs in the heavy chain set forth in SEQ ID NO: 7. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise a light chain having greater than 70% homology or identity to the light chain set forth in SEQ ID NO: 8. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise a light chain having greater than 75% homology or identity to the light chain set forth in SEQ ID NO: 8. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise a light chain that is greater than 80% homologous or identical to the light chain set forth in SEQ ID NO: 8. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise a light chain that is greater than 85% homologous or identical to the light chain set forth in SEQ ID NO: 8. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise a light chain that is greater than 90% homologous or identical to the light chain set forth in SEQ ID NO: 8. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise a light chain that is greater than 95% homologous or identical to the light chain set forth in SEQ ID NO: 8.In some embodiments, the antibody or antigen-binding fragments provided herein comprise a light chain having any of the provided homology or identity with the light chain shown in SEQ ID NO: 8, wherein the CDRs (CDR-L1, CDR-L2, and CDR-L3) are identical to the CDRs in the light chain shown in SEQ ID NO: 8. In some embodiments, the antibody or antigen-binding fragments provided herein comprise any combination or arrangement of any homologous light chain and any homologous heavy chain provided in this paragraph.

[0271] In certain embodiments, the antibodies or antigen-binding fragments provided herein comprise a heavy chain variable region that has a certain homology or identity to the heavy chain variable region set forth in SEQ ID NO: 22 and a light chain variable region that has a certain homology or identity to the light chain variable region set forth in SEQ ID NO: 23. Such embodiments of heavy chain variable regions and light chain variable regions that have a certain homology or identity are further provided below. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise a heavy chain variable region that has a greater than 70% homology or identity to the heavy chain variable region set forth in SEQ ID NO: 22. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise a heavy chain variable region that has a greater than 75% homology or identity to the heavy chain variable region set forth in SEQ ID NO: 22. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise a heavy chain variable region that has a greater than 80% homology or identity to the heavy chain variable region set forth in SEQ ID NO: 22. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise a heavy chain variable region that is greater than 85% homologous or identical to the heavy chain variable region set forth in SEQ ID NO: 22. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise a heavy chain variable region that is greater than 90% homologous or identical to the heavy chain variable region set forth in SEQ ID NO: 22. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise a heavy chain variable region that is greater than 95% homologous or identical to the heavy chain variable region set forth in SEQ ID NO: 22. In certain embodiments, the antibodies or antigen-binding fragments provided herein comprise a heavy chain variable region that has any of the provided homologies or identities to the heavy chain variable region set forth in SEQ ID NO: 22, wherein the CDRs (CDR-H1, CDR-H2, and CDR-H3) are identical to the CDRs in the heavy chain variable region set forth in SEQ ID NO: 22. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise a light chain variable region that is greater than 70% homologous or identical to the light chain variable region set forth in SEQ ID NO: 23. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise a light chain variable region that is greater than 75% homologous or identical to the light chain variable region set forth in SEQ ID NO: 23. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise a light chain variable region that is greater than 80% homologous or identical to the light chain variable region set forth in SEQ ID NO: 23. In some embodiments, the antibodies or antigen-binding fragments provided herein comprise a light chain variable region that is greater than 85% homologous or identical to the light chain variable region set forth in SEQ ID NO: 23.In some embodiments, the antibody or antigen-binding fragments provided herein comprise a light chain variable region having more than 90% homology or identity with the light chain variable region shown in SEQ ID NO: 23. In some embodiments, the antibody or antigen-binding fragments provided herein comprise a light chain variable region having more than 95% homology or identity with the light chain variable region shown in SEQ ID NO: 23. In some embodiments, the antibody or antigen-binding fragments provided herein comprise a light chain variable region having any of the provided homology or identity with the light chain variable region shown in SEQ ID NO: 23, wherein the CDRs (CDR-L1, CDR-L2, and CDR-L3) are identical to the CDRs in the light chain variable region shown in SEQ ID NO: 23. In some embodiments, the antibody or antigen-binding fragments provided herein comprise any combination or arrangement of any homologous light chain variable region and any homologous heavy chain variable region provided in this paragraph.

[0272] In some embodiments, the anti-connector protein-4 antibody provided herein comprises: heavy and light chain CDR regions of an antibody called Ha22-2(2,4)6.1 (produced from a hybridoma (accession number: PTA-11267) deposited at the American Type Culture Collection (ATCC)); or heavy and light chain CDR regions comprising amino acid sequences homologous to the amino acid sequences of the heavy and light chain CDR regions of Ha22-2(2,4)6.1, wherein said antibody retains the desired functional properties of the anti-connector protein-4 antibody called Ha22-2(2,4)6.1 (produced from a hybridoma (accession number: PTA-11267) deposited at the American Type Culture Collection (ATCC)).

[0273] In some embodiments, the anti-connector protein-4 antibody provided herein comprises: heavy and light chain CDR regions (CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3) of an antibody called Ha22-2(2,4)6.1 (produced from a hybridoma (accession number: PTA-11267) deposited at the United States Type Culture Collection (ATCC); or heavy and light chain CDR regions consisting of amino acid sequences homologous to the amino acid sequences of the heavy and light chain CDR regions of Ha22-2(2,4)6.1, wherein said antibody retains the desired functional properties of the anti-connector protein-4 antibody called Ha22-2(2,4)6.1 (produced from a hybridoma (accession number: PTA-11267) deposited at the United States Type Culture Collection (ATCC)).

[0274] In some embodiments, the antibodies or antigen-binding fragments thereof provided herein comprise a humanized heavy chain variable region and a humanized light chain variable region, wherein:

[0275] (a) the heavy chain variable region comprises CDRs (CDR-H1, CDR-H2, and CDR-H3) comprising the amino acid sequences of the heavy chain variable region CDRs set forth in the antibody produced by the hybridoma deposited with the American Type Culture Collection (ATCC) under Accession No. PTA-11267;

[0276] (b) The light chain variable region comprises CDRs (CDR-L1, CDR-L2, and CDR-L3) comprising the amino acid sequences of the light chain variable region CDRs described in the antibody produced by the hybridoma deposited with the American Type Culture Collection (ATCC) under Accession No. PTA-11267.

[0277] In some embodiments, the antibodies or antigen-binding fragments thereof provided herein comprise a humanized heavy chain variable region and a humanized light chain variable region, wherein:

[0278] (a) the heavy chain variable region comprises CDRs (CDR-H1, CDR-H2, and CDR-H3) consisting of the amino acid sequences of the heavy chain variable region CDRs set forth in the antibody produced by the hybridoma deposited with the American Type Culture Collection (ATCC) under Accession No. PTA-11267;

[0279] (b) The light chain variable region comprises CDRs (CDR-L1, CDR-L2, and CDR-L3) consisting of the amino acid sequences of the light chain variable region CDRs described in the antibody produced by the hybridoma deposited with the American Type Culture Collection (ATCC) under Accession No. PTA-11267.

[0280] In some embodiments, the anti-negotiation protein-4 antibody provided herein comprises: a heavy chain and light chain variable region of an antibody called Ha22-2(2,4)6.1 (produced by a hybridoma deposited at the United States Type Culture Collection (ATCC) accession number: PTA-11267), or a heavy chain and light chain variable region comprising an amino acid sequence homologous to the amino acid sequence of the heavy chain and light chain variable region of Ha22-2(2,4)6.1, and wherein said antibody retains the desired functional properties of the anti-negotiation protein-4 antibody provided herein. In some embodiments, the connexin-4 antibody provided herein comprises: a heavy chain and light chain variable region of an antibody called Ha22-2(2,4)6.1 (produced via a hybridoma deposited at the United States Type Culture Collection (ATCC) accession number: PTA-11267), or a heavy chain and light chain variable region consisting of an amino acid sequence homologous to the amino acid sequence of the heavy chain and light chain variable region of Ha22-2(2,4)6.1, wherein said antibody retains the desired functional properties of the anti-connexin-4 antibody provided herein. Any subclass of constant region may be selected as the constant region of the antibody disclosed herein. In one embodiment, a human IgG1 constant region may be used as the heavy chain constant region and a human Igκ constant region may be used as the light chain constant region.

[0281] In some embodiments, the anti-connexin-4 antibodies provided herein comprise the heavy and light chains of the antibody designated Ha22-2(2,4)6.1 (produced by a hybridoma deposited under the American Type Culture Collection (ATCC) Accession No.: PTA-11267), or heavy and light chains comprising an amino acid sequence homologous to the amino acid sequence of the heavy and light chains of Ha22-2(2,4)6.1, and wherein the antibodies retain the desired functional properties of the anti-connexin-4 antibodies provided herein. In some embodiments, the anti-connexin-4 antibodies provided herein comprise the heavy and light chains of the antibody designated Ha22-2(2,4)6.1 (produced by a hybridoma deposited under the American Type Culture Collection (ATCC) Accession No.: PTA-11267), or heavy and light chains consisting of an amino acid sequence homologous to the amino acid sequence of the heavy and light chains of Ha22-2(2,4)6.1, and wherein the antibodies retain the desired functional properties of the anti-connexin-4 antibodies provided herein.

[0282] In some embodiments, the antibody or antigen-binding fragment thereof provided herein comprises a heavy chain variable region and a light chain variable region, wherein:

[0283] (a) The heavy chain variable region contains an amino acid sequence that is at least 80% homologous or identical to the amino acid sequence of the heavy chain variable region of an antibody produced by a hybridoma deposited at the United States Type Culture Collection (ATCC) under accession number PTA-11267; and

[0284] (b) The light chain variable region contains an amino acid sequence that is at least 80% homologous or identical to the amino acid sequence of the light chain variable region of an antibody produced by a hybridoma deposited at the United States Type Culture Collection (ATCC) under accession number PTA-11267.

[0285] In certain embodiments, the antibodies or antigen-binding fragments provided herein comprise a heavy chain variable region having a certain homology or identity to the heavy chain variable region amino acid sequence of an antibody produced by a hybridoma deposited with the American Type Culture Collection (ATCC) under Accession No. PTA-11267, and a light chain variable region having a certain homology or identity to the light chain variable region amino acid sequence of an antibody produced by a hybridoma deposited with the American Type Culture Collection (ATCC) under Accession No. PTA-11267. Such embodiments of heavy chain variable regions and light chain variable regions having homology or identity are further provided below. In some embodiments, the heavy chain variable region comprises an amino acid sequence that is at least 85% homologous or identical to the heavy chain variable region amino acid sequence of an antibody produced by a hybridoma deposited with the American Type Culture Collection (ATCC) under Accession No. PTA-11267. In other embodiments, the heavy chain variable region comprises an amino acid sequence that is at least 90% homologous or identical to the amino acid sequence of the heavy chain variable region of the antibody produced by the hybridoma deposited with the American Type Culture Collection (ATCC) under Accession No. PTA-1 1267. In other embodiments, the heavy chain variable region comprises an amino acid sequence that is at least 95% homologous or identical to the amino acid sequence of the heavy chain variable region of the antibody produced by the hybridoma deposited with the American Type Culture Collection (ATCC) under Accession No. PTA-1 1267. In other embodiments, the heavy chain variable region may be 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% homologous or identical to the amino acid sequence of the heavy chain variable region of the antibody produced by the hybridoma deposited with the American Type Culture Collection (ATCC) under Accession No. PTA-1 1267. In some embodiments, the light chain variable region comprises an amino acid sequence that is at least 85% homologous or identical to the amino acid sequence of the light chain variable region of an antibody produced by a hybridoma deposited under the American Type Culture Collection (ATCC) Accession No.: PTA-11267. In other embodiments, the light chain variable region comprises an amino acid sequence that is at least 90% homologous or identical to the amino acid sequence of the light chain variable region of an antibody produced by a hybridoma deposited under the American Type Culture Collection (ATCC) Accession No.: PTA-1 1267. In other embodiments, the light chain variable region comprises an amino acid sequence that is at least 95% homologous or identical to the amino acid sequence of the light chain variable region of an antibody produced by a hybridoma deposited under the American Type Culture Collection (ATCC) Accession No.: PTA-1 1267.In other embodiments, the light chain variable region may be 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% homologous or identical to the amino acid sequence of the light chain variable region of an antibody produced by hybridoma deposited at the United States Type Culture Collection (ATCC) registry number: PTA-11267. In some embodiments, the antibody or antigen-binding fragments provided herein comprise any combination or arrangement of any homologous light chain variable region and any homologous heavy chain variable region provided in such paragraphs.

[0286] In other embodiments, the antibodies or antigen-binding fragments thereof provided herein comprise a heavy chain and a light chain, wherein:

[0287] (a) the heavy chain comprises an amino acid sequence that is at least 80% homologous or identical to the heavy chain amino acid sequence of the antibody produced by the hybridoma deposited with the American Type Culture Collection (ATCC) under Accession No. PTA-1 1267; and

[0288] (b) The light chain contains at least 80% homologous or identical amino acid sequences to those of antibodies produced by hybridomas deposited at the American Type Culture Collection (ATCC) under accession number PTA-1 1267.

[0289] In some embodiments, the antibody or antigen-binding fragments provided herein comprise a heavy chain having some homology or identity with the heavy chain amino acid sequence of an antibody produced by a hybridoma deposited at the U.S. Culture Collection (ATCC) under accession number PTA-1 1267, and a light chain having some homology or identity with the light chain amino acid sequence of an antibody produced by a hybridoma deposited at the U.S. Culture Collection (ATCC) under accession number PTA-1 1267. Such embodiments of homologous or identical heavy and light chains are further provided below. In some embodiments, the heavy chain comprises an amino acid sequence that is at least 85% homologous or identical with the heavy chain amino acid sequence of an antibody produced by a hybridoma deposited at the U.S. Culture Collection (ATCC) under accession number PTA-1 1267. In other embodiments, the heavy chain comprises an amino acid sequence that is at least 90% homologous or identical with the heavy chain amino acid sequence of an antibody produced by a hybridoma deposited at the U.S. Culture Collection (ATCC) under accession number PTA-1 1267. In other embodiments, the heavy chain comprises an amino acid sequence that is at least 95% homologous or identical to the heavy chain amino acid sequence of an antibody produced via hybridoma deposited at the United States Type Culture Collection (ATCC) Registry No. PTA-1 1267. In other embodiments, the heavy chain may be 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% homologous or identical to the heavy chain amino acid sequence of an antibody produced via hybridoma deposited at the United States Type Culture Collection (ATCC) Registry No. PTA-1 1267. In some embodiments, the light chain comprises an amino acid sequence that is at least 85% homologous or identical to the light chain amino acid sequence of an antibody produced via hybridoma deposited at the United States Type Culture Collection (ATCC) Registry No. PTA-1 1267. In other embodiments, the light chain comprises an amino acid sequence that is at least 90% homologous or identical to the amino acid sequence of the light chain of an antibody produced via hybridoma deposited at the U.S. Culture Collection (ATCC) under accession number PTA-11267. In other embodiments, the light chain comprises an amino acid sequence that is at least 95% homologous or identical to the amino acid sequence of the light chain of an antibody produced via hybridoma deposited at the U.S. Culture Collection (ATCC) under accession number PTA-11267. In other embodiments, the light chain may be 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% homologous or identical to the amino acid sequence of the light chain of an antibody produced via hybridoma deposited at the U.S. Culture Collection (ATCC) under accession number PTA-11267. In certain embodiments, the antibodies or antigen-binding fragments provided herein comprise any combination or permutation of any cognate light chain and any cognate heavy chain as provided in this paragraph.

[0290] In some embodiments, the antibodies or antigen-binding fragments thereof provided herein bind to a specific epitope in 191P4D12. In some embodiments, the antibodies or antigen-binding fragments thereof provided herein bind to the VC1 domain of 191P4D12. In some embodiments, the antibodies or antigen-binding fragments thereof provided herein bind to the VC1 domain of 191P4D12 but do not bind to the C1C2 domain. In some embodiments, the antibodies or antigen-binding fragments thereof provided herein bind to amino acid residues 1 to 147 of 191P4D12. In some embodiments, the antibodies or antigen-binding fragments thereof provided herein bind to an epitope located within amino acid residues 1 to 147 of 191P4D12. In some embodiments, the antibodies or antigen-binding fragments thereof provided herein bind to amino acid residues 1 to 10 of 191P4D12. In some embodiments, the antibodies or antigen-binding fragments thereof provided herein bind to amino acid residues 11 to 20 of 191P4D12. In some embodiments, the antibodies or antigen-binding fragments thereof provided herein bind to amino acid residues 21 to 30 of 191P4D12. In some embodiments, the antibodies or antigen-binding fragments thereof provided herein bind to amino acid residues 31 to 40 of 191P4D12. In some embodiments, the antibodies or antigen-binding fragments thereof provided herein bind to amino acid residues 41 to 50 of 191P4D12. In some embodiments, the antibodies or antigen-binding fragments thereof provided herein bind to amino acid residues 51 to 60 of 191P4D12. In some embodiments, the antibodies or antigen-binding fragments thereof provided herein bind to amino acid residues 61 to 70 of 191P4D12. In some embodiments, the antibodies or antigen-binding fragments thereof provided herein bind to amino acid residues 71 to 80 of 191P4D12. In some embodiments, the antibodies or antigen-binding fragments thereof provided herein bind to amino acid residues 81 to 90 of 191P4D12. In some embodiments, the antibodies or antigen-binding fragments thereof provided herein bind to amino acid residues 91 to 100 of 191P4D12. In some embodiments, the antibodies or antigen-binding fragments thereof provided herein bind to amino acid residues 101 to 110 of 191P4D12. In some embodiments, the antibodies or antigen-binding fragments thereof provided herein bind to amino acid residues 111 to 120 of 191P4D12. In some embodiments, the antibodies or antigen-binding fragments thereof provided herein bind to amino acid residues 121 to 130 of 191P4D12. In some embodiments, the antibodies or antigen-binding fragments thereof provided herein bind to amino acid residues 131 to 140 of 191P4D12.In some embodiments, the antibodies or antigen-binding fragments thereof provided herein bind to amino acid residues 141 to 147 of 191P4D12. The binding epitopes of certain embodiments of the antibodies or antigen-binding fragments thereof provided herein have been determined and described in WO 2012 / 047724, which is incorporated herein by reference in its entirety.

[0291] In some embodiments, the antibodies or antigen-binding fragments thereof provided herein bind to an epitope in 191P4D12 that is commonly observed between 191P4D12 variants in humans. In some embodiments, the antibodies or antigen-binding fragments thereof provided herein bind to an epitope in 191P4D12 that is commonly observed between 191P4D12 polymorphisms in humans. In some embodiments, the antibodies or antigen-binding fragments thereof provided herein bind to an epitope in 191P4D12 that is commonly observed between 191P4D12 polymorphisms in human cancers. In some embodiments, the antibodies or antigen-binding fragments thereof provided herein bind to an epitope in 191P4D12 that will bind to, internalize, disrupt, or modulate the biological function of 191P4D12 or a 191P4D12 variant. In some embodiments, the antibodies or antigen-binding fragments thereof provided herein bind to an epitope in 191P4D12 that will disrupt the interaction between 191P4D12 and ligands, substrates, and binding partners.

[0292] The engineered antibodies provided herein include those in which the framework residues within VH and / or VL have been modified (e.g., to improve the properties of the antibody). Typically, such framework modifications are performed to reduce the immunogenicity of the antibody. For example, one method is to "backmutate" one or more framework residues to the corresponding germline sequence. More specifically, an antibody that has undergone somatic mutation may contain framework residues that are different from the germline sequence from which the antibody was derived. Such residues can be identified by comparing the antibody framework sequence with the germline sequence from which the antibody was derived. In order to restore the framework region sequence to its germline configuration, somatic mutations can be induced by, for example, site-directed mutagenesis or PCR-mediated mutagenesis and "backmutated" to the germline sequence (e.g., leucine "backmutates" to methionine). Such "backmutated" antibodies are also intended to be encompassed within the present disclosure.

[0293] Another type of framework modification involves mutating one or more residues within the framework region or even within one or more CDR regions to remove T cell epitopes, thereby reducing the potential immunogenicity of the antibody. This approach is also known as "deimmunization" and is further described in detail in U.S. Patent Publication No. 2003 / 0153043 to Carr et al.

[0294] In addition to or alternatively, modifications made within the frame region or CDR region, the antibodies of this disclosure may be engineered to include modifications within the Fc region, typically to alter one or more functional properties of the antibody, such as serum half-life, complement binding, Fc receptor binding, and / or antigen-dependent cytotoxicity. Furthermore, the anti-191P4D12 antibodies provided herein may be chemically modified (e.g., one or more chemical moieties may be linked to the antibody) or modified to alter their glycosylation to again alter one or more functional properties of the antibody. Each of these embodiments is further described in detail below.

[0295] In one embodiment, the hinge region of CH1 is modified to alter the number of cysteine ​​residues in the hinge region, for example, by increasing or decreasing them. This method is further described in U.S. Patent No. 5,677,425 to Bodmer et al. Changing the number of cysteine ​​residues in the CH1 hinge region can, for example, promote the assembly of light and heavy chains or improve or decrease the stability of the anti-191P4D12 antibody.

[0296] In another embodiment, the Fc hinge region of the antibody is mutated to reduce the biological half-life of the anti-191P4D12 antibody. More specifically, one or more amino acid mutations are introduced into the CH2-CH3 domain interface region of the Fc hinge fragment to weaken the binding of the antibody to Staphylococcyl protein A (SpA) relative to the binding to the native Fc hinge domain SpA. This method is further described in detail in U.S. Patent No. 6,165,745 to Ward et al.

[0297] In another embodiment, the anti-191P4D12 antibody is modified to increase its biological half-life. Several methods are possible. For example, a mutation may be introduced, as described in Ward's U.S. Patent No. 6,277,375. Alternatively, to increase the biological half-life, the antibody may be modified within the CH1 or CL region to contain a rescue receptor-binding epitope of two loops in the CH2 domain derived from the Fc region of IgG, as described in Presta et al.'s U.S. Patent Nos. 5,869,046 and 6,121,022.

[0298] In other embodiments, the Fc region is altered by replacing at least one amino acid residue with a different amino acid residue to alter the effector function of the antibody. For example, one or more amino acids selected from a particular amino acid residue can be replaced with a different amino acid residue such that the antibody's affinity for an effector ligand is altered while retaining the antigen-binding ability of the parent antibody. The effector ligand with altered affinity can be, for example, an Fc receptor or the C1 component of complement. This approach is further described in detail, for example, in U.S. Patent Nos. 5,624,821 and 5,648,260 to Winter et al.

[0299] The reactivity of anti-191P4D12 antibodies with 191P4D12-related proteins can be established by a variety of well-known means, including Western blot, immunoprecipitation, ELISA, and FACS analysis, using, where appropriate, 191P4D12-related proteins, 191P4D12-expressing cells, or extracts thereof. 191P4D12 antibodies or fragments thereof can be labeled with a detectable marker or conjugated to a second molecule. Suitable detectable markers include, but are not limited to, radioisotopes, fluorescent compounds, bioluminescent compounds, chemiluminescent compounds, metal chelators, or enzymes. In addition, bispecific antibodies specific for two or more 191P4D12 epitopes can be generated using methods generally known in the art. Homodimeric antibodies can also be generated by cross-linking techniques known in the art (e.g., Wolff et al., Cancer Res. 53:2560-2565).

[0300] In another specific embodiment, the anti-191P4D12 antibody provided herein is an antibody comprising the heavy chain and light chain of the antibody designated Ha22-2(2,4)6.1. The heavy chain of Ha22-2(2,4)6.1 consists of an amino acid sequence ranging from residue 20 (E) to residue 466 (K) of SEQ ID NO: 7; and the light chain of Ha22-2(2,4)6.1 consists of an amino acid sequence ranging from residue 23 (D) to residue 236 (C) of SEQ ID NO: 8.

[0301] The hybridoma producing the antibody designated Ha22-2(2,4)6.1 was sent (via Federal Express) to the American Type Culture Collection (ATCC), PO Box 1549, Manassas, VA 20108 on August 18, 2010 and assigned accession number PTA-1 1267.

[0302] Additional embodiments of anti-Connexin-4 antibodies have been described in U.S. Patent No. 8,637,642 and International Application No. PCT / US2019 / 056214 (Publication No. WO2020 / 117373), both of which are hereby incorporated by reference in their entirety.

[0303] 5.3.2 Cytotoxic agents (drug monoclonal antibodies) Yuan)

[0304] Since the ADC used in the methods provided herein comprises an antibody or antigen-binding fragment thereof coupled to a cytotoxic agent, the present disclosure further provides various embodiments of a cytotoxic agent as part of the ADC used in the methods. In various embodiments of the methods provided herein (including the methods provided in Section 5.2), the cytotoxic agent as part of any ADC provided herein for the methods comprises, consists of, or is a tubulin disrupting agent. In one embodiment, the cytotoxic agent is a tubulin disrupting agent. In some embodiments, the tubulin disrupting agent is selected from the group consisting of: dolastatin, auristatin, hemiasterlin, vinca alkaloids, maytansinoids, eribulin, colchicine, plocabulin, phomopsin, epothilone, cryptophycin, and taxanes. In a specific embodiment, the tubulin disrupting agent is auristatin. In another specific embodiment, olistatin is monomethylolistatin E (MMAE), monomethylolistatin F (MMAF), AFP, or olistatin T. In another specific embodiment, olistatin is monomethylolistatin E (MMAE).

[0305] In various embodiments of the methods provided herein, including the methods provided in Section 5.2, the cytotoxic agent as part of any ADC provided herein for the methods comprises, consists of, or is any agent selected from the group consisting of the cytotoxic agents described in U.S. Patent No. 8,637,642 and International Application No. PCT / US2019 / 056214 (Publication No. WO2020 / 117373), both of which are hereby incorporated by reference in their entireties.

[0306] In some implementations, olistatin is a MMAE (where the wavy line indicates a covalent connection to the linker of the antibody-drug conjugate).

[0307]

[0308] In some embodiments, an exemplary embodiment comprising MMAE and a linker component (further described herein) has the following structure (where L represents an antibody (e.g., an anti-linker protein-4 antibody or its antigen-binding fragment) and p is in the range of 1 to 12):

[0309]

[0310] In some embodiments of the formula described in the preceding paragraph, p is in the range of: 1 to 20, 1 to 19, 1 to 18, 1 to 17, 1 to 16, 1 to 15, 1 to 14, 1 to 13, 1 to 12, 1 to 11, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 to 2. In some embodiments of the formula described in the preceding paragraph, p is in the range of: 2 to 20, 2 to 19, 2 to 18, 2 to 17, 2 to 16, 2 to 15, 2 to 14, 2 to 13, 2 to 12, 2 to 11, 2 to 10, 2 to 9, 2 to 8, 2 to 7, 2 to 6, 2 to 5, 2 to 4, or 2 to 3. In some embodiments of the formula described in the preceding paragraph, p is in the range of: 3 to 20, 3 to 19, 3 to 18, 3 to 17, 3 to 16, 3 to 15, 3 to 14, 3 to 13, 3 to 12, 3 to 11, 3 to 10, 3 to 9, 3 to 8, 3 to 7, 3 to 6, 3 to 5, or 3 to 4. In some embodiments of the formula described in the preceding paragraph, p is about 1. In some embodiments of the formula described in the preceding paragraph, p is about 2. In some embodiments of the formula described in the preceding paragraph, p is about 3. In some embodiments of the formula described in the preceding paragraph, p is about 4. In some embodiments of the formula described in the preceding paragraph, p is about 3.8. In some embodiments of the formula described in the preceding paragraph, p is about 5. In some embodiments of the formula described in the preceding paragraph, p is about 6. In some embodiments of the formula described in the preceding paragraph, p is about 7. In some embodiments of the formula described in the preceding paragraph, p is about 8. In some embodiments of the formula described in the preceding paragraph, p is about 9. In some embodiments of the formula described in the preceding paragraph, p is about 10. In some embodiments of the formula described in the preceding paragraph, p is about 11. In some embodiments of the formula described in the preceding paragraph, p is about 12. In some embodiments of the formula described in the preceding paragraph, p is about 13. In some embodiments of the formula described in the preceding paragraph, p is about 14. In some embodiments of the formula described in the preceding paragraph, p is about 15. In some embodiments of the formula described in the preceding paragraph, p is about 16. In some embodiments of the formula described in the preceding paragraph, p is about 17. In some embodiments of the formula described in the preceding paragraph, p is about 18. In some embodiments of the formula described in the preceding paragraph, p is about 19. In some embodiments of the formula described in the preceding paragraph, p is about 20.

[0311] Typically, peptide-based drug units can be prepared by forming a peptide bond between two or more amino acids and / or peptide fragments. Such peptide bonds can be prepared, for example, according to liquid phase synthesis methods well known in the art of peptide chemistry (see E. and K. Lübke, "The Peptides", Vol. 1, pp. 76-136, 1965, Academic Press). The auristatin / dolastatin drug unit can be prepared according to the methods of the following documents: US 5635483; US 5780588; Pettit et al. (1989) J. Am. Chem. Soc. 111: 5463-5465; Pettit et al. (1998) Anti-Cancer Drug Design 13: 243-277; Pettit, GR et al., Synthesis, 1996, 719-725; Pettit et al. (1996) J. Chem. Soc. Perkin Trans. 15: 859-863; and Doronina (2003) Nat Biotechnol 21(7): 778-784.

[0312] Additional embodiments of cytotoxic agents have been described in U.S. Patent No. 8,637,642 and International Application No. PCT / US2019 / 056214 (Publication No. WO2020 / 117373), both of which are hereby incorporated by reference in their entirety.

[0313] 5.3.3 connector

[0314] Typically, the antibody drug conjugate comprises a linker unit between a drug unit (e.g., MMAE) and an antibody unit (e.g., an anti-191P4D12 antibody or its antigen-binding fragment). In some embodiments, the linker is cleavable under intracellular conditions so that the linker is cleaved in the intracellular environment and releases the drug unit from the antibody. In other embodiments, the linker unit is non-cleavable and releases the drug, for example, by antibody degradation. In some embodiments, the linker is cleavable by a cleavage agent present in the intracellular environment (e.g., in a lysosome or endosome or caveolae). The linker can be, for example, a peptidyl linker that can be cleaved by an intracellular peptidase or protease (including but not limited to a lysosomal or endosomal protease). In some embodiments, the length of the peptidyl linker is at least two amino acids or at least three amino acids. In other embodiments, the cleavable linker is pH-sensitive, i.e., sensitive to hydrolysis at certain pH values. Typically, pH-sensitive linkers can be hydrolyzed under acidic conditions. For example, acid labile linkers (e.g., hydrazones, semicarbazones, thiosemicarbazones, cis-aconitamides, orthoesters, acetals, ketals, etc.) that are hydrolyzable in lysosomes can be used. In other embodiments, the linker is cleavable under reducing conditions (e.g., disulfide linkers). Various disulfide linkers are known in the art, including, for example, those linkers that can be formed using N-succinimidyl-S-acetylthioacetate (SATA), N-succinimidyl-3-(2-pyridyldisulfide) propionate (SPDP), N-succinimidyl-3-(2-pyridyldisulfide) butyrate (SPDB), and N-succinimidyl-oxycarbonyl-α-methyl-α-(2-pyridyldisulfide) toluene (SMPT), SPDB, and SMPT.

[0315] A "Linker Unit" (LU) is a bifunctional compound that can be used to link a Drug unit to an Antibody unit to form an Antibody Drug Conjugate. In some embodiments, the Linker Unit has the following formula:

[0316] -A a -W w -Y y --

[0317] Where: -A- represents the extended sub-unit.

[0318] a is 0 or 1,

[0319] Each -W- is independently an amino acid unit,

[0320] w is an integer in the range of 0 to 12,

[0321] -Y- is a self-immolative spacer unit, and

[0322] y is 0, 1, or 2.

[0323] In some embodiments, a is 0 or 1, w is 0 or 1, and y is 0, 1 or 2. In some embodiments, a is 0 or 1, w is 0 or 1, and y is 0 or 1. In some embodiments, when w is 1 to 12, y is 1 or 2. In some embodiments, w is 2 to 12 and y is 1 or 2. In some embodiments, a is 1 and w and y are 0. Linkers and each of the Stretcher unit, Amino Acid unit, and Spacer unit have been described in U.S. Patent No. 8,637,642 and International Application No. PCT / US2019 / 056214 (Publication No. WO2020 / 117373), both of which are hereby incorporated by reference in their entirety.

[0324] Embodiments of antibody-drug conjugates may include:

[0325]

[0326] where w and y are each 0, 1, or 2, and

[0327]

[0328] Where w and y are both 0.

[0329]

[0330] 5.3.4 Drug load

[0331] Drug loading is represented by p, and is the average number of drug units / antibody in the molecule. Drug loading can be in the range of 1 to 20 drug units (D) / antibody. The ADC provided herein includes a set of antibodies or Fabs coupled with a series of drug units (e.g., 1 to 20). When preparing ADC by coupled reaction, the average number of drug units / antibody can be characterized by conventional means such as mass spectrometry and ELISA. The quantitative distribution of ADC can also be measured according to p. In some cases, the separation, purification and characterization of homogeneous ADCs with specific p values ​​from ADCs with other drug loadings can be achieved by means such as electrophoresis.

[0332] In some embodiments, the drug loading of the ADC provided herein is in the range of 1 to 20. In some embodiments, the drug loading of the ADC provided herein is in the range of 1 to 18. In some embodiments, the drug loading of the ADC provided herein is in the range of 1 to 15. In some embodiments, the drug loading of the ADC provided herein is in the range of 1 to 12. In some embodiments, the drug loading of the ADC provided herein is in the range of 1 to 10. In some embodiments, the drug loading of the ADC provided herein is in the range of 1 to 9. In some embodiments, the drug loading of the ADC provided herein is in the range of 1 to 8. In some embodiments, the drug loading of the ADC provided herein is in the range of 1 to 7. In some embodiments, the drug loading of the ADC provided herein is in the range of 1 to 6. In some embodiments, the drug loading of the ADC provided herein is in the range of 1 to 5. In some embodiments, the drug loading of the ADC provided herein is in the range of 1 to 4. In some embodiments, the drug loading of the ADC provided herein is in the range of 1 to 3. In some embodiments, the drug loading of the ADC provided herein is in the range of 2 to 12. In some embodiments, the drug loading of the ADC provided herein is in the range of 2 to 10. In some embodiments, the drug loading of the ADC provided herein is in the range of 2 to 9. In some embodiments, the drug loading of the ADC provided herein is in the range of 2 to 8. In some embodiments, the drug loading of the ADC provided herein is in the range of 2 to 7. In some embodiments, the drug loading of the ADC provided herein is in the range of 2 to 6. In some embodiments, the drug loading of the ADC provided herein is in the range of 2 to 5. In some embodiments, the drug loading of the ADC provided herein is in the range of 2 to 4. In some embodiments, the drug loading of the ADC provided herein is in the range of 3 to 12. In some embodiments, the drug loading of the ADC provided herein is in the range of 3 to 10. In some embodiments, the drug loading of the ADC provided herein is in the range of 3 to 9. In some embodiments, the drug loading of the ADC provided herein is in the range of 3 to 8. In some embodiments, the drug loading of the ADC provided herein is in the range of 3 to 7. In some embodiments, the drug loading of the ADC provided herein is in the range of 3 to 6. In some embodiments, the drug loading of the ADC provided herein is in the range of 3 to 5. In some embodiments, the drug loading of the ADC provided herein is in the range of 3 to 4.

[0333] In certain embodiments, the drug loading of the ADCs provided herein is in the range of: 1 to about 8; about 2 to about 6; about 3 to about 5; about 3 to about 4; about 3.1 to about 3.9; about 3.2 to about 3.8; about 3.2 to about 3.7; about 3.2 to about 3.6; about 3.3 to about 3.8; or about 3.3 to about 3.7.

[0334] In certain embodiments, the drug loading of the ADCs provided herein is about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, or more. In some embodiments, the drug loading of the ADCs provided herein is about 3.1, about 3.2, about 3.3, about 3.4, about 3.5, about 3.6, about 3.7, about 3.8, or about 3.9.

[0335] In some embodiments, the drug loading of the ADC provided herein is in the range of: 2 to 20, 2 to 19, 2 to 18, 2 to 17, 2 to 16, 2 to 15, 2 to 14, or 2 to 13. In some embodiments, the drug loading of the ADC provided herein is in the range of: 3 to 20, 3 to 19, 3 to 18, 3 to 17, 3 to 16, 3 to 15, 3 to 14, or 3 to 13. In some embodiments, the drug loading of the ADC provided herein is about 1. In some embodiments, the drug loading of the ADC provided herein is about 2. In some embodiments, the drug loading of the ADC provided herein is about 3. In some embodiments, the drug loading of the ADC provided herein is about 4. In some embodiments, the drug loading of the ADC provided herein is about 3.8. In some embodiments, the drug loading of the ADC provided herein is about 5. In some embodiments, the drug loading of the ADC provided herein is about 6. In some embodiments, the drug loading of the ADC provided herein is about 7. In some embodiments, the drug loading of the ADC provided herein is about 8. In some embodiments, the drug loading of the ADC provided herein is about 9. In some embodiments, the drug loading of the ADC provided herein is about 10. In some embodiments, the drug loading of the ADC provided herein is about 11. In some embodiments, the drug loading of the ADC provided herein is about 12. In some embodiments, the drug loading of the ADC provided herein is about 13. In some embodiments, the drug loading of the ADC provided herein is about 14. In some embodiments, the drug loading of the ADC provided herein is about 15. In some embodiments, the drug loading of the ADC provided herein is about 16. In some embodiments, the drug loading of the ADC provided herein is about 17. In some embodiments, the drug loading of the ADC provided herein is about 18. In some embodiments, the drug loading of the ADC provided herein is about 19. In some embodiments, the drug loading of the ADC provided herein is about 20.

[0336] In certain embodiments, during the coupling reaction, less than the theoretical maximum number of drug units are coupled to the antibody. Antibodies may contain, for example, lysine residues that do not react with drug-linker intermediates or linker reagents. Generally speaking, antibodies do not contain many free and reactive cysteine ​​thiol groups that can be linked to drug units; in fact, most cysteine ​​thiol residues in antibodies exist in the form of disulfide bridges. In certain embodiments, antibodies can be reduced with a reducing agent such as dithiothreitol (DTT) or tricarbonylethylphosphine (TCEP) under partial or complete reducing conditions to generate reactive cysteine ​​thiol groups. In certain embodiments, antibodies are subjected to denaturing conditions to reveal reactive nucleophilic groups such as lysine or cysteine. In some embodiments, the linker unit or drug unit is coupled via a lysine residue on the antibody unit. In some embodiments, the linker unit or drug unit is coupled via a cysteine ​​residue on the antibody unit.

[0337] In some embodiments, the amino acid connected to the Linker unit or Drug unit is in the heavy chain of an antibody or its antigen-binding fragment. In some embodiments, the amino acid connected to the Linker unit or Drug unit is in the light chain of an antibody or its antigen-binding fragment. In some embodiments, the amino acid connected to the Linker unit or Drug unit is in the hinge region of an antibody or its antigen-binding fragment. In some embodiments, the amino acid connected to the Linker unit or Drug unit is in the Fc region of an antibody or its antigen-binding fragment. In other embodiments, the amino acid connected to the Linker unit or Drug unit is in the constant region (e.g., CH1, CH2 or CH3 of the heavy chain, or CH1 of the light chain) of an antibody or its antigen-binding fragment. In other embodiments, the amino acid connected to the Linker unit or Drug unit is in the VH framework region of an antibody or its antigen-binding fragment. In other embodiments, the amino acid connected to the Linker unit or Drug unit is in the VL framework region of an antibody or its antigen-binding fragment.

[0338] The loading (drug / antibody ratio) of the ADC can be controlled in various ways, for example, by: (i) limiting the molar excess of drug-linker intermediate or linker reagent relative to the antibody, (ii) limiting the conjugation reaction time or temperature, (iii) partial or limiting reducing conditions for cysteine ​​thiol modification, (iv) engineering the amino acid sequence of the antibody by recombinant techniques such that the number and position of cysteine ​​residues are modified to control the number and / or position of linker-drug attachments (e.g., thioMabs or thioFabs prepared as disclosed herein and in WO2006 / 034488, incorporated herein by reference in their entirety).

[0339] It is understood that where more than one nucleophilic group reacts with a drug-linker intermediate or linker reagent, which is then reacted with a drug unit reagent, then the resulting product is a distributed mixture of ADC compounds and one or more drug units attached to an antibody unit. The average number of drugs per antibody can be calculated from the mixture using a dual ELISA antibody assay specific for the antibody and one specific for the drug. Individual ADC molecules can be identified in the mixture by mass spectrometry and separated by HPLC (e.g., hydrophobic interaction chromatography) (see, for example, Hamblett, KJ et al., “Effect of drug loading on the pharmacochemistry, pharmacokinetics, and toxicity of an anti-CD30 antibody-drug conjugate,” Abstract 624, American Association for Cancer Research, Annual Meeting 2004, March 27-31, 2004, AACR Conference Paper, Volume 45, March 2004; Alley, SC et al., “Controlling the location of drug attachment in antibody-drug conjugates,” Abstract 627, American Association for Cancer Research, Annual Meeting 2004, March 27-31, 2004, AACR Conference Paper, Volume 45, March 2004). In some embodiments, homogeneous ADCs with a single loading value can be separated from the conjugated mixture by electrophoresis or chromatography.

[0340] Methods for preparing, screening, and characterizing antibody drug conjugates are known to those of ordinary skill in the art and are described, for example, in U.S. Patent No. 8,637,642, which is incorporated herein by reference in its entirety.

[0341] In some embodiments, the antibody drug conjugate used in the methods provided herein is AGS-22M6E, which is prepared according to the method described in U.S. Patent No. 8,637,642 and has the following formula:

[0342]

[0343] wherein L is Ha22-2(2,4)6.1, and p is 1 to 20.

[0344] In some embodiments, p is in the range of: 1 to 20, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 to 2. In some embodiments, p is in the range of: 2 to 10, 2 to 9, 2 to 8, 2 to 7, 2 to 6, 2 to 5, 2 to 4, or 2 to 3. In other embodiments, p is about 1. In other embodiments, p is about 2. In other embodiments, p is about 3. In other embodiments, p is about 4. In other embodiments, p is about 5. In other embodiments, p is about 6. In other embodiments, p is about 7. In other embodiments, p is about 8. In other embodiments, p is about 9. In other embodiments, p is about 10. In some embodiments, p is about 3.1. In some embodiments, p is about 3.2. In some embodiments, p is about 3.3. In some embodiments, p is about 3.4. In some embodiments, p is about 3.5. In other embodiments, p is about 3.6. In some embodiments, p is about 3.7. In some embodiments, p is about 3.8. In some embodiments, p is about 3.9. In some embodiments, p is about 4.0. In some embodiments, p is about 4.1. In some embodiments, p is about 4.2. In some embodiments, p is about 4.3. In some embodiments, p is about 4.4. In some embodiments, p is about 4.5. In other embodiments, p is about 4.6. In some embodiments, p is about 4.7. In some embodiments, p is about 4.8. In some embodiments, p is about 4.9. In some embodiments, p is about 5.0.

[0345] In some embodiments, the ADC used in the methods described herein is enrofloxacin vitolamine. Enrofloxacin vitolamine is a fully human immunoglobulin G1κ (IgG1) conjugated via a protease-cleavable linker and a microtubule cleavage agent (MMAE). K (Challita-Eid PM et al., Cancer Res. 2016; 76(10): 3003-13). Enroximateb vedotin induces antitumor activity by binding to the 191P4D12 protein on the cell surface, causing internalization of the ADC-191P4D12 complex, which is then transported to the lysosomal compartment and releases MMAE via proteolytic cleavage linkers in the compartment. Intracellular release of MMAE subsequently interferes with microtubule polymerization, leading to cell cycle arrest in the G2 / M phase and apoptotic cell death (Francisco JA et al., Blood. Aug 15, 2003; 102(4): 1458-65).

[0346] As described above and in U.S. Patent No. 8,637,642, AGS-22M6E is an ADC derived from a murine hybridoma cell line. Ennosumab vedotin is an equivalent of the AGS-22M6E ADC derived from the Chinese hamster ovary (CHO) cell line and is an exemplary product for human treatment. Ennosumab vedotin has the same amino acid sequence, linker, and cytotoxic drug as AGS-22M6E. The comparability between ennosumab vedotin and AGS-22M6E was determined through in-depth analytical and biocharacterization studies, such as binding affinity to 191P4D12, in vitro cytotoxicity, and in vivo anti-tumor activity.

[0347] In one embodiment, the ADC provided herein is enrofloxacin, also known as EV, PADCEV, AGS-22M6E, AGS-22C3E, and AGS-22CE. Enrofloxacin comprises an anti-191P4D12 antibody, wherein the antibody or its antigen-binding fragment comprises a heavy chain containing amino acid residues 20 to 466 of SEQ ID NO: 7 and a light chain containing amino acid residues 23 to 236 of SEQ ID NO: 8.

[0348] Ennosumab vedotin is an antibody-drug conjugate (ADC) targeting connexin-4. It consists of a fully human anti-connexin-4 IgG1κ monoclonal antibody (AGS-22C3) conjugated to the small molecule microtubule disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable maleimidocaproyl valine-citrulline (vc) linker (SGD-1006). Conjugation occurs at a cysteine ​​residue that contains an interchain disulfide bond on the antibody, resulting in a drug:antibody ratio of approximately 3.8:1. The molecular weight is approximately 152 kDa.

[0349] Ennosumab vedotin has the following structural formula:

[0350]

[0351] Approximately four molecules of MMAE are attached to each antibody molecule. Ennosumab vedotin is produced by chemically coupling the antibody and small molecule components. The antibody is produced in mammalian (Chinese hamster ovary) cells, and the small molecule components are produced by chemical synthesis.

[0352] Enroximateb Vidocin injection is provided as a sterile, preservative-free, white to off-white lyophilized powder in single-dose vials for intravenous administration. Enroximateb Vidocin is supplied in 20 mg / vial and 30 mg / vial forms and requires reconstitution with USP sterile water for injection (2.3 mL and 3.3 mL, respectively) to produce a clear to slightly milky white, colorless to slightly yellow solution with a final concentration of 10 mg / mL. After reconstitution, 2 mL (20 mg) and 3 mL (30 mg) may be drawn from each vial. Each mL of reconstituted solution contains 10 mg enroximateb Vidocin, histidine (1.4 mg), histidine hydrochloride monohydrate (2.31 mg), polysorbate 20 (0.2 mg), and trehalose dihydrate (55 mg), at pH 6.0.

[0353] 5.4 Pharmaceutical Compositions

[0354] In some embodiments of the methods provided herein, the ADC used in the methods is provided as a “pharmaceutical composition.” Such pharmaceutical compositions include the antibody-drug conjugates provided herein and one or more pharmaceutically acceptable or physiologically acceptable excipients. In some embodiments, the antibody-drug conjugate is provided in combination with or separately from one or more additional pharmaceutical agents. A composition comprising one or more such additional pharmaceutical agents and one or more pharmaceutically acceptable or physiologically acceptable excipients is also provided. In certain embodiments, the antibody-drug conjugate and the additional pharmaceutical agents are present in therapeutically acceptable amounts. The pharmaceutical compositions may be used in accordance with the methods and uses provided herein. Thus, for example, the pharmaceutical compositions may be administered to a subject ex vivo or in vivo to practice the treatment methods and uses provided herein. The pharmaceutical compositions provided herein may be formulated to be compatible with the intended method or route of administration; exemplary routes of administration are set forth herein.

[0355] In some embodiments, pharmaceutical compositions having antibody drug conjugates that modulate cancer or tumors are provided.

[0356] In certain embodiments of the methods provided herein, the pharmaceutical compositions comprising ADCs may further comprise other therapeutic agents or compounds disclosed herein or known to those skilled in the art, which may be used to treat or prevent various diseases and conditions (e.g., cancer) as described herein. As described above, the additional therapeutic agents or compounds may be present in separate pharmaceutical compositions.

[0357] The pharmaceutical composition generally comprises a therapeutically effective amount of at least one of the antibody drug conjugates provided herein and one or more pharmaceutically acceptable formulating agents. In certain embodiments, the pharmaceutical composition further comprises one or more additional agents described herein.

[0358] In one embodiment, the pharmaceutical composition comprises an antibody drug conjugate as provided herein. In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of an antibody drug conjugate as provided herein. In certain embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable excipient.

[0359] In some embodiments, the antibody drug conjugate in the pharmaceutical compositions provided herein is selected from the antibody drug conjugates described in Section 5.3 above.

[0360] In certain embodiments, the pharmaceutical composition comprises an antibody drug conjugate at a concentration of 0.1-100 mg / mL. In some embodiments, the pharmaceutical composition comprises an antibody drug conjugate at a concentration of 1 to 20 mg / mL. In other embodiments, the pharmaceutical composition comprises an antibody drug conjugate at a concentration of 5 to 15 mg / mL. In other embodiments, the pharmaceutical composition comprises an antibody drug conjugate at a concentration of 8 to 12 mg / mL. In other embodiments, the pharmaceutical composition comprises an antibody drug conjugate at a concentration of 9 to 11 mg / mL. In some embodiments, the pharmaceutical composition comprises an antibody drug conjugate at a concentration of approximately 9.5 mg / mL. In some embodiments, the pharmaceutical composition comprises an antibody drug conjugate at a concentration of approximately 9.6 mg / mL. In some embodiments, the pharmaceutical composition comprises an antibody drug conjugate at a concentration of approximately 9.7 mg / mL. In some embodiments, the pharmaceutical composition comprises an antibody drug conjugate at a concentration of approximately 9.8 mg / mL. In some embodiments, the pharmaceutical composition comprises an antibody drug conjugate at a concentration of approximately 9.9 mg / mL. In other embodiments, the pharmaceutical composition comprises an antibody drug conjugate at a concentration of about 10 mg / mL. In other embodiments, the pharmaceutical composition comprises an antibody drug conjugate at a concentration of about 10.1 mg / mL. In some embodiments, the pharmaceutical composition comprises an antibody drug conjugate at a concentration of about 10.2 mg / mL. In some embodiments, the pharmaceutical composition comprises an antibody drug conjugate at a concentration of about 10.3 mg / mL. In some embodiments, the pharmaceutical composition comprises an antibody drug conjugate at a concentration of about 10.3 mg / mL. In some embodiments, the pharmaceutical composition comprises an antibody drug conjugate at a concentration of about 10.4 mg / mL. In some embodiments, the pharmaceutical composition comprises an antibody drug conjugate at a concentration of about 10.5 mg / mL.

[0361] In some embodiments, the pharmaceutical compositions provided herein comprise L-histidine, TWEEN-20, and at least one of trehalose dihydrate or sucrose. In some embodiments, the pharmaceutical compositions provided herein further comprise hydrochloric acid (HCl) or succinic acid.

[0362] In some embodiments, the concentration of L-histidine in the pharmaceutical compositions provided herein is in the range of 5 to 50 mM. In some embodiments, the concentration of L-histidine in the pharmaceutical compositions provided herein is in the range of 10 to 40 mM. In some embodiments, the concentration of L-histidine in the pharmaceutical compositions provided herein is in the range of 15 to 35 mM.

[0363] In some embodiments, the concentration of L-histidine in the pharmaceutical composition provided herein is in the range of 15 to 30 mM. In some embodiments, the concentration of L-histidine in the pharmaceutical composition provided herein is in the range of 15 to 25 mM. In some embodiments, the concentration of L-histidine in the pharmaceutical composition provided herein is in the range of 15 to 35 mM. In some embodiments, the concentration of L-histidine in the pharmaceutical composition provided herein is about 16 mM. In some embodiments, the concentration of L-histidine in the pharmaceutical composition provided herein is about 17 mM. In some embodiments, the concentration of L-histidine in the pharmaceutical composition provided herein is about 18 mM. In some embodiments, the concentration of L-histidine in the pharmaceutical composition provided herein is about 19 mM. In some embodiments, the concentration of L-histidine in the pharmaceutical composition provided herein is about 20 mM. In some embodiments, the concentration of L-histidine in the pharmaceutical composition provided herein is about 21 mM. In some embodiments, the concentration of L-histidine in the pharmaceutical composition provided herein is about 22 mM. In some embodiments, the concentration of L-histidine in the pharmaceutical composition provided herein is about 23 mM. In some embodiments, the concentration of L-histidine in the pharmaceutical composition provided herein is about 24 mM. In some embodiments, the concentration of L-histidine in the pharmaceutical composition provided herein is about 25 mM.

[0364] In some embodiments, the concentration of TWEEN-20 suitable for use in the pharmaceutical compositions provided herein is in the range of 0.001 to 0.1% (v / v). In another embodiment, the concentration of TWEEN-20 is in the range of 0.0025 to 0.075% (v / v). In one embodiment, the concentration of TWEEN-20 is in the range of 0.005 to 0.05% (v / v). In another embodiment, the concentration of TWEEN-20 is in the range of 0.0075 to 0.025% (v / v). In another embodiment, the concentration of TWEEN-20 is in the range of 0.0075 to 0.05% (v / v). In another embodiment, the concentration of TWEEN-20 is in the range of 0.01 to 0.03% (v / v). In a specific embodiment, the concentration of TWEEN-20 is about 0.01% (v / v). In a specific embodiment, the concentration of TWEEN-20 is about 0.015% (v / v). In a specific embodiment, the concentration of TWEEN-20 is about 0.016% (v / v). In a specific embodiment, the concentration of TWEEN-20 is about 0.017% (v / v). In a specific embodiment, the concentration of TWEEN-20 is about 0.018% (v / v). In a specific embodiment, the concentration of TWEEN-20 is about 0.019% (v / v). In a specific embodiment, the concentration of TWEEN-20 is about 0.02% (v / v). In a specific embodiment, the concentration of TWEEN-20 is about 0.021% (v / v). In a specific embodiment, the concentration of TWEEN-20 is about 0.022% (v / v). In a specific embodiment, the concentration of TWEEN-20 is about 0.023% (v / v). In one particular embodiment, the concentration of TWEEN-20 is about 0.024% (v / v). In another particular embodiment, the concentration of TWEEN-20 is about 0.025% (v / v).

[0365] In one embodiment, the concentration of trehalose dihydrate in the pharmaceutical composition provided herein is in the range of 1% to 20% (w / v). In another embodiment, the concentration of trehalose dihydrate is in the range of 2% to 15% (w / v). In one embodiment, the concentration of trehalose dihydrate is in the range of 3% to 10% (w / v). In another embodiment, the concentration of trehalose dihydrate is in the range of 4% to 9% (w / v). In another embodiment, the concentration of trehalose dihydrate is in the range of 4% to 8% (w / v). In another embodiment, the concentration of trehalose dihydrate is in the range of 4% to 7% (w / v). In another embodiment, the concentration of trehalose dihydrate is in the range of 4% to 6% (w / v). In another embodiment, the concentration of trehalose dihydrate is in the range of 4.5% to 6% (w / v). In another embodiment, the concentration of trehalose dihydrate is about 4.6% (w / v). In another embodiment, the concentration of trehalose dihydrate is about 4.7% (w / v). In another embodiment, the concentration of trehalose dihydrate is about 4.8% (w / v). In another embodiment, the concentration of trehalose dihydrate is about 4.9% (w / v). In another embodiment, the concentration of trehalose dihydrate is about 5.0% (w / v). In another embodiment, the concentration of trehalose dihydrate is about 5.1% (w / v). In another embodiment, the concentration of trehalose dihydrate is about 5.2% (w / v). In another embodiment, the concentration of trehalose dihydrate is about 5.3% (w / v). In another embodiment, the concentration of trehalose dihydrate is about 5.4% (w / v). In another embodiment, the concentration of trehalose dihydrate is about 5.5% (w / v). In another embodiment, the concentration of trehalose dihydrate is about 5.6% (w / v). In another embodiment, the concentration of trehalose dihydrate is about 5.7% (w / v). In another embodiment, the concentration of trehalose dihydrate is about 5.8% (w / v). In another embodiment, the concentration of trehalose dihydrate is about 5.9% (w / v). In another embodiment, the concentration of trehalose dihydrate is about 6.0% (w / v). In another embodiment, the concentration of trehalose dihydrate is about 6.1% (w / v). In another embodiment, the concentration of trehalose dihydrate is about 6.2% (w / v). In another embodiment, the concentration of trehalose dihydrate is about 6.3% (w / v). In another embodiment, the concentration of trehalose dihydrate is about 6.4% (w / v). In another embodiment, the concentration of trehalose dihydrate is about 6.5% (w / v).

[0366] In certain embodiments, the molar concentration of trehalose dihydrate is between 50 and 300 mM. In other embodiments, the molar concentration of trehalose dihydrate is between 75 and 250 mM. In some embodiments, the molar concentration of trehalose dihydrate is between 100 and 200 mM. In other embodiments, the molar concentration of trehalose dihydrate is between 130 and 150 mM. In some embodiments, the molar concentration of trehalose dihydrate is between 135 and 150 mM. In certain embodiments, the molar concentration of trehalose dihydrate is about 135 mM. In certain embodiments, the molar concentration of trehalose dihydrate is about 136 mM. In certain embodiments, the molar concentration of trehalose dihydrate is about 137 mM. In certain embodiments, the molar concentration of trehalose dihydrate is about 138 mM. In certain embodiments, the molar concentration of trehalose dihydrate is about 139 mM. In certain embodiments, the molar concentration of trehalose dihydrate is about 140 mM. In certain embodiments, the molar concentration of trehalose dihydrate is about 141 mM. In certain embodiments, the molar concentration of trehalose dihydrate is about 142 mM. In certain embodiments, the molar concentration of trehalose dihydrate is about 143 mM. In certain embodiments, the molar concentration of trehalose dihydrate is about 144 mM. In certain embodiments, the molar concentration of trehalose dihydrate is about 145 mM. In certain embodiments, the molar concentration of trehalose dihydrate is about 146 mM. In certain embodiments, the molar concentration of trehalose dihydrate is about 150 mM. In certain embodiments, the molar concentration of trehalose dihydrate is about 151 mM. In certain embodiments, the molar concentration of trehalose dihydrate is about 151 mM. In certain embodiments, the molar concentration of trehalose dihydrate is about 152 mM. In certain embodiments, the molar concentration of trehalose dihydrate is about 153 mM. In some embodiments, the molar concentration of trehalose dihydrate is about 154 mM. In some embodiments, the molar concentration of trehalose dihydrate is about 155 mM.

[0367] In one embodiment, the concentration of sucrose suitable for use in the pharmaceutical compositions provided herein is in the range of 1% to 20% (w / v). In another embodiment, the concentration of sucrose is in the range of 2% to 15% (w / v). In one embodiment, the concentration of sucrose is in the range of 3% to 10% (w / v). In another embodiment, the concentration of sucrose is in the range of 4% to 9% (w / v). In another embodiment, the concentration of sucrose is in the range of 4% to 8% (w / v). In another embodiment, the concentration of sucrose is in the range of 4% to 7% (w / v). In another embodiment, the concentration of sucrose is in the range of 4% to 6% (w / v). In another embodiment, the concentration of sucrose is in the range of 4.5% to 6% (w / v). In another embodiment, the concentration of sucrose is about 4.6% (w / v). In another embodiment, the concentration of sucrose is about 4.7% (w / v). In another embodiment, the concentration of sucrose is about 4.8% (w / v). In another embodiment, the concentration of sucrose is about 4.9% (w / v). In another embodiment, the concentration of sucrose is about 5.0% (w / v). In another embodiment, the concentration of sucrose is about 5.1% (w / v). In another embodiment, the concentration of sucrose is about 5.2% (w / v). In another embodiment, the concentration of sucrose is about 5.3% (w / v). In another embodiment, the concentration of sucrose is about 5.4% (w / v). In another embodiment, the concentration of sucrose is about 5.5% (w / v). In another embodiment, the concentration of sucrose is about 5.6% (w / v). In another embodiment, the concentration of sucrose is about 5.7% (w / v). In another embodiment, the concentration of sucrose is about 5.8% (w / v). In another embodiment, the concentration of sucrose is about 5.9% (w / v). In another embodiment, the concentration of sucrose is about 6.0% (w / v). In another embodiment, the concentration of sucrose is about 6.1% (w / v). In another embodiment, the concentration of sucrose is about 6.2% (w / v). In another embodiment, the concentration of sucrose is about 6.3% (w / v). In another embodiment, the concentration of sucrose is about 6.4% (w / v). In another embodiment, the concentration of sucrose is about 6.5% (w / v).

[0368] In certain embodiments, the molar concentration of sucrose is 50 to 300 mM. In other embodiments, the molar concentration of sucrose is 75 to 250 mM. In some embodiments, the molar concentration of sucrose is 100 to 200 mM. In other embodiments, the molar concentration of sucrose is 130 to 150 mM. In some embodiments, the molar concentration of sucrose is 135 to 150 mM. In certain embodiments, the molar concentration of sucrose is about 135 mM. In certain embodiments, the molar concentration of sucrose is about 136 mM. In certain embodiments, the molar concentration of sucrose is about 137 mM. In certain embodiments, the molar concentration of sucrose is about 138 mM. In certain embodiments, the molar concentration of sucrose is about 139 mM. In certain embodiments, the molar concentration of sucrose is about 140 mM. In certain embodiments, the molar concentration of sucrose is about 141 mM. In certain embodiments, the molar concentration of sucrose is about 142 mM. In certain embodiments, the molar concentration of sucrose is about 143 mM. In certain embodiments, the molar concentration of sucrose is about 144 mM. In certain embodiments, the molar concentration of sucrose is about 145 mM. In certain embodiments, the molar concentration of sucrose is about 146 mM. In certain embodiments, the molar concentration of sucrose is about 150 mM. In certain embodiments, the molar concentration of sucrose is about 151 mM. In certain embodiments, the molar concentration of sucrose is about 151 mM. In certain embodiments, the molar concentration of sucrose is about 152 mM. In certain embodiments, the molar concentration of sucrose is about 153 mM. In certain embodiments, the molar concentration of sucrose is about 154 mM. In certain embodiments, the molar concentration of sucrose is about 155 mM.

[0369] In some embodiments, the pharmaceutical compositions provided herein comprise HCl. In other embodiments, the pharmaceutical compositions provided herein comprise succinic acid.

[0370] In some embodiments, the pharmaceutical compositions provided herein have a pH in the range of 5.5 to 6.5. In other embodiments, the pharmaceutical compositions provided herein have a pH in the range of 5.7 to 6.3. In some embodiments, the pharmaceutical compositions provided herein have a pH of about 5.7. In some embodiments, the pharmaceutical compositions provided herein have a pH of about 5.8. In some embodiments, the pharmaceutical compositions provided herein have a pH of about 5.9. In some embodiments, the pharmaceutical compositions provided herein have a pH of about 6.0. In some embodiments, the pharmaceutical compositions provided herein have a pH of about 6.1. In some embodiments, the pharmaceutical compositions provided herein have a pH of about 6.2. In some embodiments, the pharmaceutical compositions provided herein have a pH of about 6.3.

[0371] In some embodiments, the pH is measured at room temperature. In other embodiments, the pH is measured at 15°C to 27°C. In other embodiments, the pH is measured at 4°C. In other embodiments, the pH is measured at 25°C.

[0372] In some embodiments, the pH is adjusted by HCl. In some embodiments, the pharmaceutical composition comprises HCl, and the pharmaceutical composition has a pH in the range of 5.5 to 6.5 at room temperature. In some embodiments, the pharmaceutical composition comprises HCl, and the pharmaceutical composition has a pH in the range of 5.7 to 6.3 at room temperature. In some more specific embodiments, the pharmaceutical composition comprises HCl, and the pharmaceutical composition has a pH of about 5.7 at room temperature. In some more specific embodiments, the pharmaceutical composition comprises HCl, and the pharmaceutical composition has a pH of about 5.8 at room temperature. In some more specific embodiments, the pharmaceutical composition comprises HCl, and the pharmaceutical composition has a pH of about 5.9 at room temperature. In some more specific embodiments, the pharmaceutical composition comprises HCl, and the pharmaceutical composition has a pH of about 6.0 at room temperature. In some more specific embodiments, the pharmaceutical composition comprises HCl, and the pharmaceutical composition has a pH of about 6.1 at room temperature. In some more specific embodiments, the pharmaceutical composition comprises HCl, and the pharmaceutical composition has a pH of about 6.2 at room temperature. In some more specific embodiments, the pharmaceutical composition comprises HCl, and the pharmaceutical composition has a pH of about 6.3 at room temperature.

[0373] In some embodiments, the pharmaceutical composition comprises HCl, and at 15°C to 27°C the pharmaceutical composition has a pH in the range of 5.5 to 6.5. In some embodiments, the pharmaceutical composition comprises HCl, and at 15°C to 27°C the pharmaceutical composition has a pH in the range of 5.7 to 6.3. In some more specific embodiments, the pharmaceutical composition comprises HCl, and at 15°C to 27°C the pharmaceutical composition has a pH of about 5.7. In some more specific embodiments, the pharmaceutical composition comprises HCl, and at 15°C to 27°C the pharmaceutical composition has a pH of about 5.8. In some more specific embodiments, the pharmaceutical composition comprises HCl, and at 15°C to 27°C the pharmaceutical composition has a pH of about 5.9. In some more specific embodiments, the pharmaceutical composition comprises HCl, and at 15°C to 27°C the pharmaceutical composition has a pH of about 6.0. In some more specific embodiments, the pharmaceutical composition comprises HCl, and at 15°C to 27°C the pharmaceutical composition has a pH of about 6.1. In some more specific embodiments, the pharmaceutical composition comprises HCl, and at 15°C to 27°C the pharmaceutical composition has a pH of about 6.2. In some more specific embodiments, the pharmaceutical composition comprises HCl, and the pharmaceutical composition has a pH of about 6.3 at 15°C to 27°C.

[0374] In some embodiments, the pH is adjusted by succinic acid. In some embodiments, the pharmaceutical composition comprises succinic acid, and the pharmaceutical composition has a pH in the range of 5.5 to 6.5 at room temperature. In some embodiments, the pharmaceutical composition comprises succinic acid, and the pharmaceutical composition has a pH in the range of 5.7 to 6.3 at room temperature. In some more specific embodiments, the pharmaceutical composition comprises succinic acid, and the pharmaceutical composition has a pH of about 5.7 at room temperature. In some more specific embodiments, the pharmaceutical composition comprises succinic acid, and the pharmaceutical composition has a pH of about 5.8 at room temperature. In some more specific embodiments, the pharmaceutical composition comprises succinic acid, and the pharmaceutical composition has a pH of about 5.9 at room temperature. In some more specific embodiments, the pharmaceutical composition comprises succinic acid, and the pharmaceutical composition has a pH of about 6.0 at room temperature. In some more specific embodiments, the pharmaceutical composition comprises succinic acid, and the pharmaceutical composition has a pH of about 6.1 at room temperature. In some more specific embodiments, the pharmaceutical composition comprises succinic acid, and the pharmaceutical composition has a pH of about 6.2 at room temperature. In some more specific embodiments, the pharmaceutical composition comprises succinic acid, and the pharmaceutical composition has a pH of about 6.3 at room temperature.

[0375] In some embodiments, the pharmaceutical composition comprises succinic acid, and at 15°C to 27°C the pharmaceutical composition has a pH in the range of 5.5 to 6.5. In some embodiments, the pharmaceutical composition comprises succinic acid, and at 15°C to 27°C the pharmaceutical composition has a pH in the range of 5.7 to 6.3. In some more specific embodiments, the pharmaceutical composition comprises succinic acid, and at 15°C to 27°C the pharmaceutical composition has a pH of about 5.7. In some more specific embodiments, the pharmaceutical composition comprises succinic acid, and at 15°C to 27°C the pharmaceutical composition has a pH of about 5.8. In some more specific embodiments, the pharmaceutical composition comprises succinic acid, and at 15°C to 27°C the pharmaceutical composition has a pH of about 5.9. In some more specific embodiments, the pharmaceutical composition comprises succinic acid, and at 15°C to 27°C the pharmaceutical composition has a pH of about 6.0. In some more specific embodiments, the pharmaceutical composition comprises succinic acid, and at 15°C to 27°C the pharmaceutical composition has a pH of about 6.1. In some more specific embodiments, the pharmaceutical composition comprises succinic acid and has a pH of about 6.2 at a temperature of 15°C to 27°C. In some more specific embodiments, the pharmaceutical composition comprises succinic acid and has a pH of about 6.3 at a temperature of 15°C to 27°C.

[0376] In some specific embodiments, the pharmaceutical composition provided herein comprises at least one of about 20 mM L-histidine, about 0.02% (w / v) TWEEN-20, and about 5.5% (w / v) trehalose dihydrate or about 5% (w / v) sucrose. In some embodiments, the pharmaceutical composition provided herein also comprises HCl or succinic acid. In some embodiments, the pH is about 6.0 at room temperature. In some embodiments, the pH is about 6.0 at 25°C.

[0377] In some specific embodiments, the pharmaceutical composition provided herein comprises about 20 mM L-histidine, about 0.02% (w / v) TWEEN-20, about 5.5% (w / v) trehalose dihydrate, and HCl. In some embodiments, the pH is about 6.0 at room temperature. In some embodiments, the pH is about 6.0 at 25°C.

[0378] In some specific embodiments, the pharmaceutical composition provided herein comprises about 20 mM L-histidine, about 0.02% (w / v) TWEEN-20, about 5% (w / v) sucrose, and HCl. In some embodiments, the pH is about 6.0 at room temperature. In some embodiments, the pH is about 6.0 at 25°C.

[0379] In other specific embodiments, the pharmaceutical composition provided herein comprises about 20 mM L-histidine, about 0.02% (w / v) TWEEN-20, about 5.5% (w / v) trehalose dihydrate, and succinic acid. In some embodiments, the pH is about 6.0 at room temperature. In some embodiments, the pH is about 6.0 at 25°C.

[0380] In some specific embodiments, the pharmaceutical composition provided herein comprises about 20 mM L-histidine, about 0.02% (w / v) TWEEN-20, about 5% (w / v) sucrose, and succinic acid. In some embodiments, the pH is about 6.0 at room temperature. In some embodiments, the pH is about 6.0 at 25°C.

[0381] In a specific embodiment, provided herein are

[0382] (a) an antibody-drug conjugate comprising the following structure:

[0383]

[0384] wherein L- represents an antibody or antigen-binding fragment thereof (eg, an anti-connexin-4 antibody or antigen-binding fragment thereof) and p is 1 to 10; and

[0385] (b) A pharmaceutically acceptable excipient comprising about 20 mM L-histidine, about 0.02% (w / v) TWEEN-20, about 5.5% (w / v) trehalose dihydrate and HCl, wherein the concentration of the antibody-drug conjugate is about 10 mg / mL and wherein the pH is about 6.0 at 25°C.

[0386] In another specific embodiment, the pharmaceutical composition provided herein comprises:

[0387] (a) an antibody-drug conjugate comprising the following structure:

[0388]

[0389] wherein L- represents an antibody or antigen-binding fragment thereof (eg, an anti-connexin-4 antibody or antigen-binding fragment thereof) and p is 1 to 10; and

[0390] (b) a pharmaceutically acceptable excipient comprising about 20 mM L-histidine, about 0.02% (w / v) TWEEN-20, about 5.5% (w / v) trehalose dihydrate, and succinic acid,

[0391] The concentration of the antibody-drug conjugate is approximately 10 mg / mL, and the pH is approximately 6.0 at 25°C.

[0392] In another specific embodiment, the pharmaceutical composition provided herein comprises:

[0393] (a) an antibody-drug conjugate comprising the following structure:

[0394]

[0395] Where L- represents the antibody or its antigen-binding fragment (e.g., anti-connector protein-4 antibody or its antigen-binding fragment) and p is 1 to 10; and

[0396] (b) a pharmaceutically acceptable excipient comprising about 20 mM L-histidine, about 0.02% (w / v) TWEEN-20, about 5.0% (w / v) sucrose, and HCl,

[0397] wherein the concentration of the antibody drug conjugate is about 10 mg / mL, and wherein the pH is about 6.0 at 25°C.

[0398] Although certain figures (and their numerical ranges) are provided, it should be understood that in some implementations, values ​​within, for example, 2%, 5%, 10%, 15%, or 20% of said figures (or numerical ranges) are also covered.

[0399] The primary solvent in the medium may be aqueous or non-aqueous in nature. Furthermore, the medium may contain other pharmaceutically acceptable excipients for modifying or maintaining the pH, molar osmotic pressure, viscosity, sterility, or stability of the pharmaceutical composition. In some embodiments, the pharmaceutically acceptable medium is an aqueous buffer solution. In other embodiments, the medium comprises, for example, sodium chloride and / or sodium citrate.

[0400] The pharmaceutical compositions provided herein may also contain other pharmaceutically acceptable preparatons for modifying or maintaining the release rate of the antibody drug conjugates and / or additional agents as described herein. Such preparatons include those substances known to those skilled in the art for preparing sustained-release formulations. For other references on pharmaceutically and physiologically acceptable preparatons, see, for example, Remington's Pharmaceutical Sciences, 18th edition (1990, Mack Publishing Co., Easton, Pa. 18042) pages 1435-1712, The Merck Index, 12th edition (1996, Merck Publishing Group, Whitehouse, NJ); and Pharmaceutical Principles of Solid Dosage Forms (1993, Technonic Publishing Co., Inc., Lancaster, Pa.). Additional pharmaceutical compositions suitable for administration are known in the art and can be applied to the methods and compositions provided herein.

[0401] In some embodiments, the pharmaceutical compositions provided herein are in liquid form. In other embodiments, the pharmaceutical compositions provided herein are lyophilized.

[0402] The pharmaceutical composition can be formulated to suit its intended route of administration. Thus, the pharmaceutical composition includes excipients suitable for administration by routes including parenteral (e.g., subcutaneous (sc), intravenous, intramuscular, or intraperitoneal), intradermal, oral (e.g., ingestion), inhalation, intracavity, intracranial, and transdermal (topical). Other exemplary routes of administration are described herein.

[0403] The pharmaceutical composition may be in the form of a sterile injectable aqueous or oily suspension. Such suspensions may be formulated using suitable dispersants or wetting agents and suspending agents disclosed herein or known to those skilled in the art. Sterile injectable preparations may also be in the form of sterile injectable solutions or suspensions in a non-toxic parenterally acceptable diluent or solvent, for example, in the form of a solution in 1,3-butanediol. Acceptable diluents, solvents, and dispersion media that may be used include water, Ringer's solution, isotonic sodium chloride solution, Cremophor EL TM(BASF, Parsippany, NJ) or phosphate buffered saline (PBS), ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. In addition, sterile fixed oils are conventionally used as solvents or suspension media. For this purpose, any gentle fixed oil can be used, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid can be used to prepare injectables. Prolonged absorption of specific injectable formulations can be achieved by including agents that delay absorption (e.g., aluminum monostearate or gelatin).

[0404] In one embodiment, the pharmaceutical compositions provided herein can be administered parenterally for local or systemic administration by injection, infusion or implantation. As used herein, parenteral administration includes intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, ​​intrasternal, intracranial, intramuscular, intrasynovial, intravesical and subcutaneous administration.

[0405] In one embodiment, the pharmaceutical compositions provided herein can be formulated into any dosage form suitable for parenteral administration, including solutions, suspensions, emulsions, micelles, liposomes, microspheres, nanosystems, and solid forms suitable for liquid solutions or suspensions prior to injection. Such dosage forms can be prepared according to conventional methods known to those skilled in the art of pharmaceutical science (see, for example, Remington, The Science and Practice of Pharmacy, above).

[0406] In one embodiment, pharmaceutical compositions intended for parenteral administration may include one or more pharmaceutically acceptable excipients including, but not limited to, aqueous vehicles, water-miscible vehicles, non-aqueous vehicles, antimicrobial agents or preservatives to combat the growth of microorganisms, stabilizers, solubility enhancers, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, wetting or emulsifying agents, complexing, clotting or chelating agents, cryoprotectants, lyoprotectants, thickening agents, pH adjusters, and inert gases.

[0407] In one embodiment, suitable aqueous media include (but are not limited to) water, saline, physiological saline or phosphate-buffered saline (PBS), sodium chloride injection, Ringer's solution, isotonic dextran injection, sterile water injection, dextran and lactated Ringer's solution. Non-aqueous media include (but are not limited to) non-volatile oils of plant origin, medium-chain triglycerides of castor oil, corn oil, cottonseed oil, olive oil, peanut oil, peppermint oil, safflower oil, sesame oil, soybean oil, hydrogenated vegetable oil, hydrogenated soybean oil, and coconut oil, and palm seed oil. Water-miscible media include (but are not limited to) ethanol, 1,3-butanediol, liquid polyethylene glycol (e.g., polyethylene glycol 300 and polyethylene glycol 400), propylene glycol, glycerol, N-methyl-2-pyrrolidone, N,N-dimethylacetamide, and dimethyl sulfoxide.

[0408] In one embodiment, suitable antimicrobial agents or preservatives include (but are not limited to) phenol, cresol, mercury, benzyl alcohol, chlorobutanol, methylparaben and propylparaben, thimerosal, benzalkonium chloride (e.g., benzylparaben), methylparaben and propylparaben, and sorbic acid. Suitable isotonic agents include (but are not limited to) sodium chloride, glycerol, and dextran. Suitable buffers include (but are not limited to) phosphates and citrates. Suitable antioxidants are those described herein, including bisulfite and sodium metabisulfite. Suitable local anesthetics include (but are not limited to) procaine hydrochloride. Suitable suspending and dispersing agents are those described herein, including sodium carboxymethyl cellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Suitable emulsifiers include those described herein, including polyethylene glycol monolaurate, polyethylene glycol monooleate 80, and triethanolamine oleate. Suitable chelating or binding agents include (but are not limited to) EDTA. Suitable pH adjusters include (but are not limited to) sodium hydroxide, hydrochloric acid, citric acid, and lactic acid. Suitable complexing agents include (but are not limited to) cyclodextrins, including α-cyclodextrin, β-cyclodextrin, hydroxypropyl-β-cyclodextrin, sulfobutyl ether-β-cyclodextrin, and sulfobutyl ether 7-β-cyclodextrin. CyDex, Lenexa, KS).

[0409] In one embodiment, the pharmaceutical compositions provided herein can be formulated for single-dose or multiple-dose administration. Single-dose formulations are packaged in ampoules, vials, or syringes. Multiple-dose parenteral formulations may contain antimicrobial agents at antibacterial or antifungal concentrations. As is known and practiced in the art, all parenteral formulations must be sterile.

[0410] In one embodiment, the pharmaceutical composition is provided as a ready-to-use sterile solution. In another embodiment, the pharmaceutical composition is provided as a sterile dry soluble product to be reconstituted with a vehicle before use, including lyophilized powders and subcutaneous tablets. In another embodiment, the pharmaceutical composition is provided as a ready-to-use sterile suspension. In another embodiment, the pharmaceutical composition is provided as a sterile dry insoluble product to be reconstituted with a vehicle before use. In another embodiment, the pharmaceutical composition is provided as a ready-to-use sterile emulsion.

[0411] In one embodiment, the pharmaceutical composition provided herein can be formulated as an immediate-release dosage form or an improved release dosage form, including delayed-release, sustained-release, pulsatile-release, controlled-release, targeted-release, and programmed-release forms.

[0412] Dispersants and granules suitable for preparing aqueous suspensions by adding water provide active ingredients that can be mixed with dispersants or wetting agents, suspending agents, and one or more preservatives. Examples of suitable dispersants or wetting agents and suspending agents are provided herein.

[0413] The pharmaceutical composition can also include excipients to protect the composition from rapid degradation or discharge from the body, such as controlled release formulations, including implants, liposomes, hydrogels, prodrugs and microencapsulation delivery systems. For example, time delay materials, such as glyceryl monostearate or glyceryl stearate, can be used alone or in combination with wax. The extended absorption of the injectable pharmaceutical composition can be achieved by including an agent (such as aluminum monostearate or gelatin) that delays absorption. The prevention of microbial action can be achieved by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc.

[0414] The pharmaceutical compositions provided herein can be stored at -80°C, 4°C, 25°C, or 37°C.

[0415] Lyophilized compositions can be prepared by freeze-drying the liquid pharmaceutical compositions provided herein. In one specific embodiment, the pharmaceutical compositions provided herein are lyophilized pharmaceutical compositions. In some embodiments, the pharmaceutical preparations are lyophilized powders that can be reconstituted for application in the form of solutions, emulsions, and other mixtures. They can also be reconstituted and formulated into solids or gels.

[0416] In some embodiments, the preparation of the lyophilized formulations provided herein involves batch filling of a bulk solution for lyophilization and aseptic filtration into vials, freezing the vials in a freeze dryer chamber, followed by lyophilization, stoppering, and capping.

[0417] A lyophilizer can be used to prepare lyophilized formulations. For example, the VirTis Genesis Model EL test unit can be used. This unit has a chamber with three working shelves (up to approximately 0.4 square meters of total usable shelf area), an external condenser, and a mechanical vacuum pump system. Cascaded mechanical refrigeration allows the shelves to be cooled to -70°C or lower, and the external condenser to -90°C or lower. The shelf temperature and chamber pressure are automatically controlled to + / -0.5°C and + / -2 micrometers (millitors), respectively. The unit is equipped with a vacuum capacitive pressure gauge, a Pirani vacuum gauge, a pressure transducer (measuring range: 0 to 1 atmosphere), and a relative humidity sensor.

[0418] The lyophilized powder can be prepared by dissolving the antibody-drug conjugate or its pharmaceutically acceptable derivative provided herein in a suitable solvent. In some embodiments, the lyophilized powder is sterile. The solution is then sterilely filtered and subsequently lyophilized under standard conditions known to those skilled in the art to obtain the desired formulation. In one embodiment, the resulting solution is dispensed into vials for lyophilization. Each vial will contain a single or multiple doses of the antibody-drug conjugate. The lyophilized powder can be stored under suitable conditions, such as from about 4°C to room temperature.

[0419] Reconstitute this lyophilized powder with water for injection to obtain a formulation for parenteral administration. For reconstitution, add the lyophilized powder to sterile water or other suitable excipients. This amount can be determined empirically and adjusted according to specific needs.

[0420] The exemplary reconstitution procedure is described below: (1) Fit an 18 or 20 gauge needle into a 5 mL or 3 mL syringe and fill the syringe with water for injection (WFI) grade water; (2) Measure an appropriate amount of WFI using the syringe scale to ensure the syringe is free of air bubbles; (3) Insert the needle through the rubber stopper; (4) Dispense the entire contents of the syringe down the vial wall into the container, remove the syringe and needle and place them in the tip container; (5) Continuously vortex the vial to carefully dissolve the entire contents of the vial until complete reconstitution (e.g., about 20-40 seconds) and minimize excessive agitation of the protein solution that may cause foaming.

[0421] In some embodiments, the pharmaceutical compositions provided herein are supplied in the form of a dry, sterile lyophilized powder or anhydrous concentrate in a hermetically sealed container and can be reconstituted with, for example, water or saline to an appropriate concentration for administration to a subject. In some embodiments, the antibody-drug conjugate is supplied in the form of a dry, sterile lyophilized powder in a hermetically sealed container at unit doses of at least 0.1 mg, at least 0.5 mg, at least 1 mg, at least 2 mg, at least 3 mg, at least 5 mg, at least 10 mg, at least 15 mg, at least 25 mg, at least 30 mg, at least 35 mg, at least 45 mg, at least 50 mg, at least 60 mg, at least 75 mg, at least 80 mg, at least 85 mg, at least 90 mg, at least 95 mg, or at least 100 mg. The lyophilized antibody-drug conjugate can be stored in its original container between 2 and 8°C, and the antibody-drug conjugate can be administered within 12 hours, for example, within 6 hours, 5 hours, 3 hours, or 1 hour after reconstitution. In an alternative embodiment, the pharmaceutical composition comprising the antibody-drug conjugate provided herein is supplied in liquid form in a hermetically sealed container, the container indicating the quantity and concentration of the antibody-drug conjugate. In some embodiments, the liquid form of the antibody-drug conjugate is supplied in a hermetically sealed container at doses of at least 0.1 mg / ml, at least 0.5 mg / ml, at least 1 mg / ml, at least 5 mg / ml, at least 10 mg / ml, at least 15 mg / ml, at least 25 mg / ml, at least 30 mg / ml, at least 40 mg / ml, at least 50 mg / ml, at least 60 mg / ml, at least 70 mg / ml, at least 80 mg / ml, at least 90 mg / ml, or at least 100 mg / ml.

[0422] Additional embodiments of pharmaceutical compositions have been described in U.S. Patent No. 8,637,642 and International Application No. PCT / US2019 / 056214 (Publication No. WO2020 / 117373), both of which are hereby incorporated by reference in their entirety.

[0423] 5.5 Combination Therapy

[0424] The method for suppressing tumor cell growth using pharmaceutical composition provided herein and chemotherapy or radiation or a combination thereof, including before, during or after starting chemotherapy or radiotherapy and any combination thereof (that is, before and during starting chemotherapy and / or radiotherapy, before and after, during and after, or before, during and after), administering pharmaceutical composition of the present invention.Depending on the treatment regimen and specific patient needs, the method is performed in a manner that will provide the most effective treatment and ultimately extend the patient's life.Additional embodiments of such combination therapies have been described in U.S. Patent No. 8,637,642 and International Application No. PCT / US2019 / 056214 (disclosure No. WO2020 / 117373), both of which are incorporated herein by reference in their entirety.

[0425] 5.6 ADC dose used in the method described

[0426] In some embodiments, the amount of the effective preventive or therapeutic agent (for example, antibody drug conjugates provided herein) or pharmaceutical composition provided herein in the prevention and / or treatment of cancer can be determined by standard clinical techniques. In some embodiments, the effective dose can be extrapolated according to the dose-response curve derived from in vitro or animal model test systems. It should be understood that the precise dosage to be used in the preparation will also depend on the severity of the cancer of the route of administration and the experimenter, and should be determined according to the judgment of the practitioner and the situation of each patient.

[0427] In some embodiments, the ADC of the methods described in this section (Section 5.6) for various dosages is enrotumumab vedotin (EV).

[0428] In some embodiments, the route of administration for administering the dosage of the antibody drug conjugate formulated in the pharmaceutical composition provided herein to the patient is intranasal, intramuscular, intravenous, intravesical, or a combination thereof, but other approaches described herein are also acceptable. Each dose may or may not be administered by the same route of administration. In some embodiments, the antibody drug conjugate formulated in the pharmaceutical composition provided herein can be administered simultaneously or thereafter with one or more additional therapeutic agents of other dosages via a variety of routes of administration. In some embodiments, the pharmaceutical composition comprising the antibody drug conjugate provided herein is administered intravesically.

[0429] For pharmaceutical compositions comprising antibody drug conjugates provided herein, the effective amount of ADC is a dosage between about 10 mg to about 1000 mg, wherein the drip volume is between about 10 mL to about 100 mL. In some embodiments, the effective amount of ADC is a dosage between about 125 mg to about 950 mg, wherein the drip volume is between about 10 mL to about 100 mL. In some embodiments, the effective amount of ADC is a dosage between about 125 mg to about 900 mg, wherein the drip volume is between about 10 mL to about 100 mL. In some embodiments, the effective amount of ADC is a dosage between about 125 mg to about 850 mg, wherein the drip volume is between about 10 mL to about 100 mL. In some embodiments, the effective amount of ADC is a dosage between about 125 mg to about 800 mg, wherein the drip volume is between about 10 mL to about 100 mL. In some embodiments, the effective amount of ADC is a dosage between about 125 mg to about 750 mg, wherein the drip volume is between about 10 mL to about 100 mL. In some implementations, the effective amount of the ADC is a dose between about 125 mg and about 750 mg, wherein the infusion volume is about 25 mL.

[0430] In some embodiments, the effective amount of ADC is a dose between about 10 mg and about 1000 mg. In some embodiments, the effective amount of ADC is a dose between about 50 mg and about 1000 mg. In some embodiments, the effective amount of ADC is a dose between about 100 mg and about 900 mg. In some embodiments, the effective amount of ADC is a dose between about 125 mg and about 900 mg. In some embodiments, the effective amount of ADC is a dose between about 125 mg and about 850 mg. In some embodiments, the effective amount of ADC is a dose between about 125 mg and about 800 mg. In some embodiments, the effective amount of ADC is a dose between about 125 mg and about 750 mg.

[0431] In some embodiments, the effective amount of ADC is a dose of about 100 mg. In some embodiments, the effective amount of ADC is a dose of about 125 mg. In some embodiments, the effective amount of ADC is a dose of about 150 mg. In some embodiments, the effective amount of ADC is a dose of about 200 mg. In some embodiments, the effective amount of ADC is a dose of about 250 mg. In some embodiments, the effective amount of ADC is a dose of about 300 mg. In some embodiments, the effective amount of ADC is a dose of about 350 mg. In some embodiments, the effective amount of ADC is a dose of about 400 mg. In some embodiments, the effective amount of ADC is a dose of about 450 mg. In some embodiments, the effective amount of ADC is a dose of about 500 mg. In some embodiments, the effective amount of ADC is a dose of about 550 mg. In some embodiments, the effective amount of ADC is a dose of about 600 mg. In some embodiments, the effective amount of ADC is a dose of about 650 mg. In some embodiments, the effective amount of ADC is a dose of about 700 mg. In some embodiments, the effective amount of ADC is a dose of about 750 mg. In some embodiments, the effective amount of ADC is a dose of about 800 mg. In some embodiments, the effective amount of ADC is a dose of about 850 mg. In some embodiments, the effective amount of ADC is a dose of about 900 mg.

[0432] In some embodiments, the effective amount of ADC is a dose of 100 mg. In some embodiments, the effective amount of ADC is a dose of 125 mg. In some embodiments, the effective amount of ADC is a dose of 150 mg. In some embodiments, the effective amount of ADC is a dose of 200 mg. In some embodiments, the effective amount of ADC is a dose of 250 mg. In some embodiments, the effective amount of ADC is a dose of 300 mg. In some embodiments, the effective amount of ADC is a dose of 350 mg. In some embodiments, the effective amount of ADC is a dose of 400 mg. In some embodiments, the effective amount of ADC is a dose of 450 mg. In some embodiments, the effective amount of ADC is a dose of 500 mg. In some embodiments, the effective amount of ADC is a dose of 550 mg. In some embodiments, the effective amount of ADC is a dose of 600 mg. In some embodiments, the effective amount of ADC is a dose of 650 mg. In some embodiments, the effective amount of ADC is a dose of 700 mg. In some embodiments, the effective amount of ADC is a dose of 750 mg. In some embodiments, the effective amount of ADC is a dose of 800 mg. In some embodiments, the effective amount of the ADC is a dose of 850 mg. In some embodiments, the effective amount of the ADC is a dose of 900 mg.

[0433] In some embodiments, the instillation volume is between about 10 mL and about 100 mL. In some embodiments, the instillation volume is between about 10 mL and about 50 mL. In some embodiments, the instillation volume is between about 15 mL and about 30 mL. In some embodiments, the instillation volume is about 10 mL. In some embodiments, the instillation volume is about 15 mL. In some embodiments, the instillation volume is about 20 mL. In some embodiments, the instillation volume is about 25 mL. In some embodiments, the instillation volume is about 30 mL. In some embodiments, the instillation volume is about 35 mL. In some embodiments, the instillation volume is about 40 mL. In some embodiments, the instillation volume is about 45 mL. In some embodiments, the instillation volume is about 50 mL. In some embodiments, the instillation volume is about 55 mL. In some embodiments, the instillation volume is about 60 mL. In some embodiments, the instillation volume is about 65 mL. In some embodiments, the instillation volume is about 70 mL. In some embodiments, the instillation volume is about 75 mL. In some embodiments, the infusion volume is approximately 80 mL. In some embodiments, the infusion volume is approximately 85 mL. In some embodiments, the infusion volume is approximately 90 mL. In some embodiments, the infusion volume is approximately 95 mL. In some embodiments, the infusion volume is approximately 100 mL.

[0434] In some embodiments, the instillation volume is 10 mL. In some embodiments, the instillation volume is 15 mL. In some embodiments, the instillation volume is 20 mL. In some embodiments, the instillation volume is 25 mL. In some embodiments, the instillation volume is 30 mL. In some embodiments, the instillation volume is 35 mL. In some embodiments, the instillation volume is 40 mL. In some embodiments, the instillation volume is 45 mL. In some embodiments, the instillation volume is 50 mL. In some embodiments, the instillation volume is 55 mL. In some embodiments, the instillation volume is 60 mL. In some embodiments, the instillation volume is 65 mL. In some embodiments, the instillation volume is 70 mL. In some embodiments, the instillation volume is 75 mL. In some embodiments, the instillation volume is 80 mL. In some embodiments, the instillation volume is 85 mL. In some embodiments, the instillation volume is 90 mL. In some embodiments, the instillation volume is 95 mL. In some embodiments, the instillation volume is 100 mL.

[0435] In some embodiments, the effective amount of ADC is a dose of about 100 mg, wherein the instillation volume is about 10 mL. In some embodiments, the effective amount of ADC is a dose of about 125 mg, wherein the instillation volume is about 10 mL. In some embodiments, the effective amount of ADC is a dose of about 150 mg, wherein the instillation volume is about 10 mL. In some embodiments, the effective amount of ADC is a dose of about 200 mg, wherein the instillation volume is about 10 mL. In some embodiments, the effective amount of ADC is a dose of about 250 mg, wherein the instillation volume is about 10 mL. In some embodiments, the effective amount of ADC is a dose of about 300 mg, wherein the instillation volume is about 10 mL. In some embodiments, the effective amount of ADC is a dose of about 350 mg, wherein the instillation volume is about 10 mL. In some embodiments, the effective amount of ADC is a dose of about 400 mg, wherein the instillation volume is about 10 mL. In some embodiments, the effective amount of ADC is a dose of about 450 mg, wherein the instillation volume is about 10 mL. In some embodiments, the effective amount of ADC is a dose of about 500 mg, wherein the instillation volume is about 10 mL. In some embodiments, the effective amount of ADC is a dose of about 550 mg, wherein the instillation volume is about 10 mL. In some embodiments, the effective amount of ADC is a dose of about 600 mg, wherein the instillation volume is about 10 mL. In some embodiments, the effective amount of ADC is a dose of about 650 mg, wherein the instillation volume is about 10 mL. In some embodiments, the effective amount of ADC is a dose of about 700 mg, wherein the instillation volume is about 10 mL. In some embodiments, the effective amount of ADC is a dose of about 750 mg, wherein the instillation volume is about 10 mL. In some embodiments, the effective amount of ADC is a dose of about 800 mg, wherein the instillation volume is about 10 mL. In some embodiments, the effective amount of ADC is a dose of about 850 mg, wherein the instillation volume is about 10 mL. In some embodiments, the effective amount of ADC is a dose of about 900 mg, wherein the instillation volume is about 10 mL.

[0436] In some embodiments, the effective amount of ADC is a dose of 100 mg, wherein the instillation volume is 10 mL. In some embodiments, the effective amount of ADC is a dose of 125 mg, wherein the instillation volume is 10 mL. In some embodiments, the effective amount of ADC is a dose of 150 mg, wherein the instillation volume is 10 mL. In some embodiments, the effective amount of ADC is a dose of 200 mg, wherein the instillation volume is 10 mL. In some embodiments, the effective amount of ADC is a dose of 250 mg, wherein the instillation volume is 10 mL. In some embodiments, the effective amount of ADC is a dose of 300 mg, wherein the instillation volume is 10 mL. In some embodiments, the effective amount of ADC is a dose of 350 mg, wherein the instillation volume is 10 mL. In some embodiments, the effective amount of ADC is a dose of 400 mg, wherein the instillation volume is 10 mL. In some embodiments, the effective amount of ADC is a dose of 450 mg, wherein the instillation volume is 10 mL. In some embodiments, the effective amount of ADC is a dose of 500 mg, wherein the instillation volume is 10 mL. In some embodiments, the effective amount of ADC is a dose of 550 mg, wherein the instillation volume is 10 mL. In some embodiments, the effective amount of ADC is a dose of 600 mg, wherein the instillation volume is 10 mL. In some embodiments, the effective amount of ADC is a dose of 650 mg, wherein the instillation volume is 10 mL. In some embodiments, the effective amount of ADC is a dose of 700 mg, wherein the instillation volume is 10 mL. In some embodiments, the effective amount of ADC is a dose of 750 mg, wherein the instillation volume is 10 mL. In some embodiments, the effective amount of ADC is a dose of 800 mg, wherein the instillation volume is 10 mL. In some embodiments, the effective amount of ADC is a dose of 850 mg, wherein the instillation volume is 10 mL. In some embodiments, the effective amount of ADC is a dose of 900 mg, wherein the instillation volume is 10 mL.

[0437] In some embodiments, the effective amount of ADC is a dose of about 100 mg, wherein the instillation volume is about 15 mL. In some embodiments, the effective amount of ADC is a dose of about 125 mg, wherein the instillation volume is about 15 mL. In some embodiments, the effective amount of ADC is a dose of about 150 mg, wherein the instillation volume is about 15 mL. In some embodiments, the effective amount of ADC is a dose of about 200 mg, wherein the instillation volume is about 15 mL. In some embodiments, the effective amount of ADC is a dose of about 250 mg, wherein the instillation volume is about 15 mL. In some embodiments, the effective amount of ADC is a dose of about 300 mg, wherein the instillation volume is about 15 mL. In some embodiments, the effective amount of ADC is a dose of about 350 mg, wherein the instillation volume is about 15 mL. In some embodiments, the effective amount of ADC is a dose of about 400 mg, wherein the instillation volume is about 15 mL. In some embodiments, the effective amount of ADC is a dose of about 450 mg, wherein the instillation volume is about 15 mL. In some embodiments, the effective amount of ADC is a dose of about 500 mg, wherein the instillation volume is about 15 mL. In some embodiments, the effective amount of ADC is a dose of about 550 mg, wherein the instillation volume is about 15 mL. In some embodiments, the effective amount of ADC is a dose of about 600 mg, wherein the instillation volume is about 15 mL. In some embodiments, the effective amount of ADC is a dose of about 650 mg, wherein the instillation volume is about 15 mL. In some embodiments, the effective amount of ADC is a dose of about 700 mg, wherein the instillation volume is about 15 mL. In some embodiments, the effective amount of ADC is a dose of about 750 mg, wherein the instillation volume is about 15 mL. In some embodiments, the effective amount of ADC is a dose of about 800 mg, wherein the instillation volume is about 15 mL. In some embodiments, the effective amount of ADC is a dose of about 850 mg, wherein the instillation volume is about 15 mL. In some embodiments, the effective amount of ADC is a dose of about 900 mg, wherein the instillation volume is about 15 mL.

[0438] In some embodiments, the effective amount of ADC is a dose of 100 mg, wherein the instillation volume is 15 mL. In some embodiments, the effective amount of ADC is a dose of 125 mg, wherein the instillation volume is 15 mL. In some embodiments, the effective amount of ADC is a dose of 150 mg, wherein the instillation volume is 15 mL. In some embodiments, the effective amount of ADC is a dose of 200 mg, wherein the instillation volume is 15 mL. In some embodiments, the effective amount of ADC is a dose of 250 mg, wherein the instillation volume is 15 mL. In some embodiments, the effective amount of ADC is a dose of 300 mg, wherein the instillation volume is 15 mL. In some embodiments, the effective amount of ADC is a dose of 350 mg, wherein the instillation volume is 15 mL. In some embodiments, the effective amount of ADC is a dose of 400 mg, wherein the instillation volume is 15 mL. In some embodiments, the effective amount of ADC is a dose of 450 mg, wherein the instillation volume is 15 mL. In some embodiments, the effective amount of ADC is a dose of 500 mg, wherein the instillation volume is 15 mL. In some embodiments, the effective amount of ADC is a dose of 550 mg, wherein the instillation volume is 15 mL. In some embodiments, the effective amount of ADC is a dose of 600 mg, wherein the instillation volume is 15 mL. In some embodiments, the effective amount of ADC is a dose of 650 mg, wherein the instillation volume is 15 mL. In some embodiments, the effective amount of ADC is a dose of 700 mg, wherein the instillation volume is 15 mL. In some embodiments, the effective amount of ADC is a dose of 750 mg, wherein the instillation volume is 15 mL. In some embodiments, the effective amount of ADC is a dose of 800 mg, wherein the instillation volume is 15 mL. In some embodiments, the effective amount of ADC is a dose of 850 mg, wherein the instillation volume is 15 mL. In some embodiments, the effective amount of ADC is a dose of 900 mg, wherein the instillation volume is 15 mL.

[0439] In some embodiments, the effective amount of ADC is a dose of about 100 mg, wherein the instillation volume is about 20 mL. In some embodiments, the effective amount of ADC is a dose of about 125 mg, wherein the instillation volume is about 20 mL. In some embodiments, the effective amount of ADC is a dose of about 150 mg, wherein the instillation volume is about 20 mL. In some embodiments, the effective amount of ADC is a dose of about 200 mg, wherein the instillation volume is about 20 mL. In some embodiments, the effective amount of ADC is a dose of about 250 mg, wherein the instillation volume is about 20 mL. In some embodiments, the effective amount of ADC is a dose of about 300 mg, wherein the instillation volume is about 20 mL. In some embodiments, the effective amount of ADC is a dose of about 350 mg, wherein the instillation volume is about 20 mL. In some embodiments, the effective amount of ADC is a dose of about 400 mg, wherein the instillation volume is about 20 mL. In some embodiments, the effective amount of ADC is a dose of about 450 mg, wherein the instillation volume is about 20 mL. In some embodiments, the effective amount of ADC is a dose of about 500 mg, wherein the instillation volume is about 20 mL. In some embodiments, the effective amount of ADC is a dose of about 550 mg, wherein the instillation volume is about 20 mL. In some embodiments, the effective amount of ADC is a dose of about 600 mg, wherein the instillation volume is about 20 mL. In some embodiments, the effective amount of ADC is a dose of about 650 mg, wherein the instillation volume is about 20 mL. In some embodiments, the effective amount of ADC is a dose of about 700 mg, wherein the instillation volume is about 20 mL. In some embodiments, the effective amount of ADC is a dose of about 750 mg, wherein the instillation volume is about 20 mL. In some embodiments, the effective amount of ADC is a dose of about 800 mg, wherein the instillation volume is about 20 mL. In some embodiments, the effective amount of ADC is a dose of about 850 mg, wherein the instillation volume is about 20 mL. In some embodiments, the effective amount of ADC is a dose of about 900 mg, wherein the instillation volume is about 20 mL.

[0440] In some embodiments, the effective amount of ADC is a dose of 100 mg, wherein the instillation volume is 20 mL. In some embodiments, the effective amount of ADC is a dose of 125 mg, wherein the instillation volume is 20 mL. In some embodiments, the effective amount of ADC is a dose of 150 mg, wherein the instillation volume is 20 mL. In some embodiments, the effective amount of ADC is a dose of 200 mg, wherein the instillation volume is 20 mL. In some embodiments, the effective amount of ADC is a dose of 250 mg, wherein the instillation volume is 20 mL. In some embodiments, the effective amount of ADC is a dose of 300 mg, wherein the instillation volume is 20 mL. In some embodiments, the effective amount of ADC is a dose of 350 mg, wherein the instillation volume is 20 mL. In some embodiments, the effective amount of ADC is a dose of 400 mg, wherein the instillation volume is 20 mL. In some embodiments, the effective amount of ADC is a dose of 450 mg, wherein the instillation volume is 20 mL. In some embodiments, the effective amount of ADC is a dose of 500 mg, wherein the instillation volume is 20 mL. In some embodiments, the effective amount of ADC is a dose of 550 mg, wherein the instillation volume is 20 mL. In some embodiments, the effective amount of ADC is a dose of 600 mg, wherein the instillation volume is 20 mL. In some embodiments, the effective amount of ADC is a dose of 650 mg, wherein the instillation volume is 20 mL. In some embodiments, the effective amount of ADC is a dose of 700 mg, wherein the instillation volume is 20 mL. In some embodiments, the effective amount of ADC is a dose of 750 mg, wherein the instillation volume is 20 mL. In some embodiments, the effective amount of ADC is a dose of 800 mg, wherein the instillation volume is 20 mL. In some embodiments, the effective amount of ADC is a dose of 850 mg, wherein the instillation volume is 20 mL. In some embodiments, the effective amount of ADC is a dose of 900 mg, wherein the instillation volume is 20 mL.

[0441] In some embodiments, the effective dose of the ADC is about 100 mg, with an infusion volume of about 25 mL. In some embodiments, the effective dose of the ADC is about 125 mg, with an infusion volume of about 25 mL. In some embodiments, the effective dose of the ADC is about 150 mg, with an infusion volume of about 25 mL. In some embodiments, the effective dose of the ADC is about 200 mg, with an infusion volume of about 25 mL. In some embodiments, the effective dose of the ADC is about 250 mg, with an infusion volume of about 25 mL. In some embodiments, the effective dose of the ADC is about 300 mg, with an infusion volume of about 25 mL. In some embodiments, the effective dose of the ADC is about 350 mg, with an infusion volume of about 25 mL. In some embodiments, the effective dose of the ADC is about 400 mg, with an infusion volume of about 25 mL. In some embodiments, the effective dose of the ADC is about 450 mg, with an infusion volume of about 25 mL. In some embodiments, the effective dose of the ADC is about 500 mg, with an infusion volume of about 25 mL. In some embodiments, the effective dose of the ADC is about 550 mg, with an infusion volume of about 25 mL. In some embodiments, the effective dose of the ADC is about 600 mg, with an infusion volume of about 25 mL. In some embodiments, the effective dose of the ADC is about 650 mg, with an infusion volume of about 25 mL. In some embodiments, the effective dose of the ADC is about 700 mg, with an infusion volume of about 25 mL. In some embodiments, the effective dose of the ADC is about 750 mg, with an infusion volume of about 25 mL. In some embodiments, the effective dose of the ADC is about 800 mg, with an infusion volume of about 25 mL. In some embodiments, the effective dose of the ADC is about 850 mg, with an infusion volume of about 25 mL. In some embodiments, the effective dose of the ADC is about 900 mg, with an infusion volume of about 25 mL.

[0442] In some embodiments, the effective amount of ADC is a dose of 100 mg, wherein the instillation volume is 25 mL. In some embodiments, the effective amount of ADC is a dose of 125 mg, wherein the instillation volume is 25 mL. In some embodiments, the effective amount of ADC is a dose of 150 mg, wherein the instillation volume is 25 mL. In some embodiments, the effective amount of ADC is a dose of 200 mg, wherein the instillation volume is 25 mL. In some embodiments, the effective amount of ADC is a dose of 250 mg, wherein the instillation volume is 25 mL. In some embodiments, the effective amount of ADC is a dose of 300 mg, wherein the instillation volume is 25 mL. In some embodiments, the effective amount of ADC is a dose of 350 mg, wherein the instillation volume is 25 mL. In some embodiments, the effective amount of ADC is a dose of 400 mg, wherein the instillation volume is 25 mL. In some embodiments, the effective amount of ADC is a dose of 450 mg, wherein the instillation volume is 25 mL. In some embodiments, the effective amount of ADC is a dose of 500 mg, wherein the instillation volume is 25 mL. In some embodiments, the effective amount of ADC is a dose of 550 mg, wherein the instillation volume is 25 mL. In some embodiments, the effective amount of ADC is a dose of 600 mg, wherein the instillation volume is 25 mL. In some embodiments, the effective amount of ADC is a dose of 650 mg, wherein the instillation volume is 25 mL. In some embodiments, the effective amount of ADC is a dose of 700 mg, wherein the instillation volume is 25 mL. In some embodiments, the effective amount of ADC is a dose of 750 mg, wherein the instillation volume is 25 mL. In some embodiments, the effective amount of ADC is a dose of 800 mg, wherein the instillation volume is 25 mL. In some embodiments, the effective amount of ADC is a dose of 850 mg, wherein the instillation volume is 25 mL. In some embodiments, the effective amount of ADC is a dose of 900 mg, wherein the instillation volume is 25 mL.

[0443] In some embodiments, the effective amount of ADC is a dose of about 100 mg, wherein the instillation volume is about 30 mL. In some embodiments, the effective amount of ADC is a dose of about 125 mg, wherein the instillation volume is about 30 mL. In some embodiments, the effective amount of ADC is a dose of about 150 mg, wherein the instillation volume is about 30 mL. In some embodiments, the effective amount of ADC is a dose of about 200 mg, wherein the instillation volume is about 30 mL. In some embodiments, the effective amount of ADC is a dose of about 250 mg, wherein the instillation volume is about 30 mL. In some embodiments, the effective amount of ADC is a dose of about 300 mg, wherein the instillation volume is about 30 mL. In some embodiments, the effective amount of ADC is a dose of about 350 mg, wherein the instillation volume is about 30 mL. In some embodiments, the effective amount of ADC is a dose of about 400 mg, wherein the instillation volume is about 30 mL. In some embodiments, the effective amount of ADC is a dose of about 450 mg, wherein the instillation volume is about 30 mL. In some embodiments, the effective amount of ADC is a dose of about 500 mg, wherein the instillation volume is about 30 mL. In some embodiments, the effective amount of ADC is a dose of about 550 mg, wherein the instillation volume is about 30 mL. In some embodiments, the effective amount of ADC is a dose of about 600 mg, wherein the instillation volume is about 30 mL. In some embodiments, the effective amount of ADC is a dose of about 650 mg, wherein the instillation volume is about 30 mL. In some embodiments, the effective amount of ADC is a dose of about 700 mg, wherein the instillation volume is about 30 mL. In some embodiments, the effective amount of ADC is a dose of about 750 mg, wherein the instillation volume is about 30 mL. In some embodiments, the effective amount of ADC is a dose of about 800 mg, wherein the instillation volume is about 30 mL. In some embodiments, the effective amount of ADC is a dose of about 850 mg, wherein the instillation volume is about 30 mL. In some embodiments, the effective amount of ADC is a dose of about 900 mg, wherein the instillation volume is about 30 mL.

[0444] In some embodiments, the effective amount of ADC is a dose of 100 mg, wherein the instillation volume is 30 mL. In some embodiments, the effective amount of ADC is a dose of 125 mg, wherein the instillation volume is 30 mL. In some embodiments, the effective amount of ADC is a dose of 150 mg, wherein the instillation volume is 30 mL. In some embodiments, the effective amount of ADC is a dose of 200 mg, wherein the instillation volume is 30 mL. In some embodiments, the effective amount of ADC is a dose of 250 mg, wherein the instillation volume is 30 mL. In some embodiments, the effective amount of ADC is a dose of 300 mg, wherein the instillation volume is 30 mL. In some embodiments, the effective amount of ADC is a dose of 350 mg, wherein the instillation volume is 30 mL. In some embodiments, the effective amount of ADC is a dose of 400 mg, wherein the instillation volume is 30 mL. In some embodiments, the effective amount of ADC is a dose of 450 mg, wherein the instillation volume is 30 mL. In some embodiments, the effective amount of ADC is a dose of 500 mg, wherein the instillation volume is 30 mL. In some embodiments, the effective amount of ADC is a dose of 550 mg, wherein the instillation volume is 30 mL. In some embodiments, the effective amount of ADC is a dose of 600 mg, wherein the instillation volume is 30 mL. In some embodiments, the effective amount of ADC is a dose of 650 mg, wherein the instillation volume is 30 mL. In some embodiments, the effective amount of ADC is a dose of 700 mg, wherein the instillation volume is 30 mL. In some embodiments, the effective amount of ADC is a dose of 750 mg, wherein the instillation volume is 30 mL. In some embodiments, the effective amount of ADC is a dose of 800 mg, wherein the instillation volume is 30 mL. In some embodiments, the effective amount of ADC is a dose of 850 mg, wherein the instillation volume is 30 mL. In some embodiments, the effective amount of ADC is a dose of 900 mg, wherein the instillation volume is 30 mL.

[0445] In some embodiments, the effective amount of ADC is a dose of about 100 mg, wherein the instillation volume is about 35 mL. In some embodiments, the effective amount of ADC is a dose of about 125 mg, wherein the instillation volume is about 35 mL. In some embodiments, the effective amount of ADC is a dose of about 150 mg, wherein the instillation volume is about 35 mL. In some embodiments, the effective amount of ADC is a dose of about 200 mg, wherein the instillation volume is about 35 mL. In some embodiments, the effective amount of ADC is a dose of about 250 mg, wherein the instillation volume is about 35 mL. In some embodiments, the effective amount of ADC is a dose of about 300 mg, wherein the instillation volume is about 35 mL. In some embodiments, the effective amount of ADC is a dose of about 350 mg, wherein the instillation volume is about 35 mL. In some embodiments, the effective amount of ADC is a dose of about 400 mg, wherein the instillation volume is about 35 mL. In some embodiments, the effective amount of ADC is a dose of about 450 mg, wherein the instillation volume is about 35 mL. In some embodiments, the effective amount of ADC is a dose of about 500 mg, wherein the instillation volume is about 35 mL. In some embodiments, the effective amount of ADC is a dose of about 550 mg, wherein the instillation volume is about 35 mL. In some embodiments, the effective amount of ADC is a dose of about 600 mg, wherein the instillation volume is about 35 mL. In some embodiments, the effective amount of ADC is a dose of about 650 mg, wherein the instillation volume is about 35 mL. In some embodiments, the effective amount of ADC is a dose of about 700 mg, wherein the instillation volume is about 35 mL. In some embodiments, the effective amount of ADC is a dose of about 750 mg, wherein the instillation volume is about 35 mL. In some embodiments, the effective amount of ADC is a dose of about 800 mg, wherein the instillation volume is about 35 mL. In some embodiments, the effective amount of ADC is a dose of about 850 mg, wherein the instillation volume is about 35 mL. In some embodiments, the effective amount of ADC is a dose of about 900 mg, wherein the instillation volume is about 35 mL.

[0446] In some embodiments, the effective amount of ADC is a dose of 100 mg, wherein the instillation volume is 35 mL. In some embodiments, the effective amount of ADC is a dose of 125 mg, wherein the instillation volume is 35 mL. In some embodiments, the effective amount of ADC is a dose of 150 mg, wherein the instillation volume is 35 mL. In some embodiments, the effective amount of ADC is a dose of 200 mg, wherein the instillation volume is 35 mL. In some embodiments, the effective amount of ADC is a dose of 250 mg, wherein the instillation volume is 35 mL. In some embodiments, the effective amount of ADC is a dose of 300 mg, wherein the instillation volume is 35 mL. In some embodiments, the effective amount of ADC is a dose of 350 mg, wherein the instillation volume is 35 mL. In some embodiments, the effective amount of ADC is a dose of 400 mg, wherein the instillation volume is 35 mL. In some embodiments, the effective amount of ADC is a dose of 450 mg, wherein the instillation volume is 35 mL. In some embodiments, the effective amount of ADC is a dose of 500 mg, wherein the instillation volume is 35 mL. In some embodiments, the effective amount of ADC is a dose of 550 mg, wherein the instillation volume is 35 mL. In some embodiments, the effective amount of ADC is a dose of 600 mg, wherein the instillation volume is 35 mL. In some embodiments, the effective amount of ADC is a dose of 650 mg, wherein the instillation volume is 35 mL. In some embodiments, the effective amount of ADC is a dose of 700 mg, wherein the instillation volume is 35 mL. In some embodiments, the effective amount of ADC is a dose of 750 mg, wherein the instillation volume is 35 mL. In some embodiments, the effective amount of ADC is a dose of 800 mg, wherein the instillation volume is 35 mL. In some embodiments, the effective amount of ADC is a dose of 850 mg, wherein the instillation volume is 35 mL. In some embodiments, the effective amount of ADC is a dose of 900 mg, wherein the instillation volume is 35 mL.

[0447] In some embodiments, the effective amount of ADC is a dose of about 100 mg, wherein the instillation volume is about 40 mL. In some embodiments, the effective amount of ADC is a dose of about 125 mg, wherein the instillation volume is about 40 mL. In some embodiments, the effective amount of ADC is a dose of about 150 mg, wherein the instillation volume is about 40 mL. In some embodiments, the effective amount of ADC is a dose of about 200 mg, wherein the instillation volume is about 40 mL. In some embodiments, the effective amount of ADC is a dose of about 250 mg, wherein the instillation volume is about 40 mL. In some embodiments, the effective amount of ADC is a dose of about 300 mg, wherein the instillation volume is about 40 mL. In some embodiments, the effective amount of ADC is a dose of about 350 mg, wherein the instillation volume is about 40 mL. In some embodiments, the effective amount of ADC is a dose of about 400 mg, wherein the instillation volume is about 40 mL. In some embodiments, the effective amount of ADC is a dose of about 450 mg, wherein the instillation volume is about 40 mL. In some embodiments, the effective amount of ADC is a dose of about 500 mg, wherein the instillation volume is about 40 mL. In some embodiments, the effective amount of ADC is a dose of about 550 mg, wherein the instillation volume is about 40 mL. In some embodiments, the effective amount of ADC is a dose of about 600 mg, wherein the instillation volume is about 40 mL. In some embodiments, the effective amount of ADC is a dose of about 650 mg, wherein the instillation volume is about 40 mL. In some embodiments, the effective amount of ADC is a dose of about 700 mg, wherein the instillation volume is about 40 mL. In some embodiments, the effective amount of ADC is a dose of about 750 mg, wherein the instillation volume is about 40 mL. In some embodiments, the effective amount of ADC is a dose of about 800 mg, wherein the instillation volume is about 40 mL. In some embodiments, the effective amount of ADC is a dose of about 850 mg, wherein the instillation volume is about 40 mL. In some embodiments, the effective amount of ADC is a dose of about 900 mg, wherein the instillation volume is about 40 mL.

[0448] In some embodiments, the effective amount of ADC is a dose of 100 mg, wherein the instillation volume is 40 mL. In some embodiments, the effective amount of ADC is a dose of 125 mg, wherein the instillation volume is 40 mL. In some embodiments, the effective amount of ADC is a dose of 150 mg, wherein the instillation volume is 40 mL. In some embodiments, the effective amount of ADC is a dose of 200 mg, wherein the instillation volume is 40 mL. In some embodiments, the effective amount of ADC is a dose of 250 mg, wherein the instillation volume is 40 mL. In some embodiments, the effective amount of ADC is a dose of 300 mg, wherein the instillation volume is 40 mL. In some embodiments, the effective amount of ADC is a dose of 350 mg, wherein the instillation volume is 40 mL. In some embodiments, the effective amount of ADC is a dose of 400 mg, wherein the instillation volume is 40 mL. In some embodiments, the effective amount of ADC is a dose of 450 mg, wherein the instillation volume is 40 mL. In some embodiments, the effective amount of ADC is a dose of 500 mg, wherein the instillation volume is 40 mL. In some embodiments, the effective amount of ADC is a dose of 550 mg, wherein the instillation volume is 40 mL. In some embodiments, the effective amount of ADC is a dose of 600 mg, wherein the instillation volume is 40 mL. In some embodiments, the effective amount of ADC is a dose of 650 mg, wherein the instillation volume is 40 mL. In some embodiments, the effective amount of ADC is a dose of 700 mg, wherein the instillation volume is 40 mL. In some embodiments, the effective amount of ADC is a dose of 750 mg, wherein the instillation volume is 40 mL. In some embodiments, the effective amount of ADC is a dose of 800 mg, wherein the instillation volume is 40 mL. In some embodiments, the effective amount of ADC is a dose of 850 mg, wherein the instillation volume is 40 mL. In some embodiments, the effective amount of ADC is a dose of 900 mg, wherein the instillation volume is 40 mL.

[0449] In some embodiments, the effective amount of ADC is a dose of about 100 mg, wherein the instillation volume is about 45 mL. In some embodiments, the effective amount of ADC is a dose of about 125 mg, wherein the instillation volume is about 45 mL. In some embodiments, the effective amount of ADC is a dose of about 150 mg, wherein the instillation volume is about 45 mL. In some embodiments, the effective amount of ADC is a dose of about 200 mg, wherein the instillation volume is about 45 mL. In some embodiments, the effective amount of ADC is a dose of about 250 mg, wherein the instillation volume is about 45 mL. In some embodiments, the effective amount of ADC is a dose of about 300 mg, wherein the instillation volume is about 45 mL. In some embodiments, the effective amount of ADC is a dose of about 350 mg, wherein the instillation volume is about 45 mL. In some embodiments, the effective amount of ADC is a dose of about 400 mg, wherein the instillation volume is about 45 mL. In some embodiments, the effective amount of ADC is a dose of about 450 mg, wherein the instillation volume is about 45 mL. In some embodiments, the effective amount of ADC is a dose of about 500 mg, wherein the instillation volume is about 45 mL. In some embodiments, the effective amount of ADC is a dose of about 550 mg, wherein the instillation volume is about 45 mL. In some embodiments, the effective amount of ADC is a dose of about 600 mg, wherein the instillation volume is about 45 mL. In some embodiments, the effective amount of ADC is a dose of about 650 mg, wherein the instillation volume is about 45 mL. In some embodiments, the effective amount of ADC is a dose of about 700 mg, wherein the instillation volume is about 45 mL. In some embodiments, the effective amount of ADC is a dose of about 750 mg, wherein the instillation volume is about 45 mL. In some embodiments, the effective amount of ADC is a dose of about 800 mg, wherein the instillation volume is about 45 mL. In some embodiments, the effective amount of ADC is a dose of about 850 mg, wherein the instillation volume is about 45 mL. In some embodiments, the effective amount of ADC is a dose of about 900 mg, wherein the instillation volume is about 45 mL.

[0450] In some embodiments, the effective amount of ADC is a dose of 100 mg, wherein the instillation volume is 45 mL. In some embodiments, the effective amount of ADC is a dose of 125 mg, wherein the instillation volume is 45 mL. In some embodiments, the effective amount of ADC is a dose of 150 mg, wherein the instillation volume is 45 mL. In some embodiments, the effective amount of ADC is a dose of 200 mg, wherein the instillation volume is 45 mL. In some embodiments, the effective amount of ADC is a dose of 250 mg, wherein the instillation volume is 45 mL. In some embodiments, the effective amount of ADC is a dose of 300 mg, wherein the instillation volume is 45 mL. In some embodiments, the effective amount of ADC is a dose of 350 mg, wherein the instillation volume is 45 mL. In some embodiments, the effective amount of ADC is a dose of 400 mg, wherein the instillation volume is 45 mL. In some embodiments, the effective amount of ADC is a dose of 450 mg, wherein the instillation volume is 45 mL. In some embodiments, the effective amount of ADC is a dose of 500 mg, wherein the instillation volume is 45 mL. In some embodiments, the effective amount of ADC is a dose of 550 mg, wherein the instillation volume is 45 mL. In some embodiments, the effective amount of ADC is a dose of 600 mg, wherein the instillation volume is 45 mL. In some embodiments, the effective amount of ADC is a dose of 650 mg, wherein the instillation volume is 45 mL. In some embodiments, the effective amount of ADC is a dose of 700 mg, wherein the instillation volume is 45 mL. In some embodiments, the effective amount of ADC is a dose of 750 mg, wherein the instillation volume is 45 mL. In some embodiments, the effective amount of ADC is a dose of 800 mg, wherein the instillation volume is 45 mL. In some embodiments, the effective amount of ADC is a dose of 850 mg, wherein the instillation volume is 45 mL. In some embodiments, the effective amount of ADC is a dose of 900 mg, wherein the instillation volume is 45 mL.

[0451] In some embodiments, the effective dose of the ADC is about 100 mg, with an infusion volume of about 50 mL. In some embodiments, the effective dose of the ADC is about 125 mg, with an infusion volume of about 50 mL. In some embodiments, the effective dose of the ADC is about 150 mg, with an infusion volume of about 50 mL. In some embodiments, the effective dose of the ADC is about 200 mg, with an infusion volume of about 50 mL. In some embodiments, the effective dose of the ADC is about 250 mg, with an infusion volume of about 50 mL. In some embodiments, the effective dose of the ADC is about 300 mg, with an infusion volume of about 50 mL. In some embodiments, the effective dose of the ADC is about 350 mg, with an infusion volume of about 50 mL. In some embodiments, the effective dose of the ADC is about 400 mg, with an infusion volume of about 50 mL. In some embodiments, the effective dose of the ADC is about 450 mg, with an infusion volume of about 50 mL. In some embodiments, the effective dose of the ADC is about 500 mg, with an infusion volume of about 50 mL. In some embodiments, the effective dose of the ADC is about 550 mg, with an infusion volume of about 50 mL. In some embodiments, the effective dose of the ADC is about 600 mg, with an infusion volume of about 50 mL. In some embodiments, the effective dose of the ADC is about 650 mg, with an infusion volume of about 50 mL. In some embodiments, the effective dose of the ADC is about 700 mg, with an infusion volume of about 50 mL. In some embodiments, the effective dose of the ADC is about 750 mg, with an infusion volume of about 50 mL. In some embodiments, the effective dose of the ADC is about 800 mg, with an infusion volume of about 50 mL. In some embodiments, the effective dose of the ADC is about 850 mg, with an infusion volume of about 50 mL. In some embodiments, the effective dose of the ADC is about 900 mg, with an infusion volume of about 50 mL.

[0452] In some embodiments, the effective dose of the ADC is 100 mg, with an infusion volume of 50 mL. In some embodiments, the effective dose of the ADC is 125 mg, with an infusion volume of 50 mL. In some embodiments, the effective dose of the ADC is 150 mg, with an infusion volume of 50 mL. In some embodiments, the effective dose of the ADC is 200 mg, with an infusion volume of 50 mL. In some embodiments, the effective dose of the ADC is 250 mg, with an infusion volume of 50 mL. In some embodiments, the effective dose of the ADC is 300 mg, with an infusion volume of 50 mL. In some embodiments, the effective dose of the ADC is 350 mg, with an infusion volume of 50 mL. In some embodiments, the effective dose of the ADC is 400 mg, with an infusion volume of 50 mL. In some embodiments, the effective dose of the ADC is 450 mg, with an infusion volume of 50 mL. In some embodiments, the effective dose of the ADC is 500 mg, with an infusion volume of 50 mL. In some embodiments, the effective dose of the ADC is 550 mg, with an infusion volume of 50 mL. In some embodiments, the effective dose of the ADC is 600 mg, with an infusion volume of 50 mL. In some embodiments, the effective dose of the ADC is 650 mg, with an infusion volume of 50 mL. In some embodiments, the effective dose of the ADC is 700 mg, with an infusion volume of 50 mL. In some embodiments, the effective dose of the ADC is 750 mg, with an infusion volume of 50 mL. In some embodiments, the effective dose of the ADC is 800 mg, with an infusion volume of 50 mL. In some embodiments, the effective dose of the ADC is 850 mg, with an infusion volume of 50 mL. In some embodiments, the effective dose of the ADC is 900 mg, with an infusion volume of 50 mL.

[0453] In some embodiments, the maximum dwell time for each intravesical administration is about 120 minutes. In some embodiments, the maximum dwell time for each intravesical administration is about 90 minutes. In some embodiments, the maximum dwell time for each intravesical administration is the dwell time tolerated by the subject. In some embodiments, the dwell time for each intravesical administration is between about 30 minutes and about 120 minutes. In some embodiments, the dwell time for each intravesical administration is between about 30 minutes and about 90 minutes. In some embodiments, the dwell time for each intravesical administration is about 30 minutes. In some embodiments, the dwell time for each intravesical administration is about 40 minutes. In some embodiments, the dwell time for each intravesical administration is about 50 minutes. In some embodiments, the dwell time for each intravesical administration is about 60 minutes. In some embodiments, the dwell time for each intravesical administration is about 70 minutes. In some embodiments, the dwell time for each intravesical administration is about 80 minutes. In some embodiments, the dwell time for each intravesical administration is about 90 minutes. In some embodiments, the dwell time for each intravesical administration is about 100 minutes. In some embodiments, the dwell time for each intravesical administration is about 110 minutes. In some embodiments, the dwell time for each intravesical administration is about 120 minutes. In some embodiments, the dwell time for each intravesical administration is 30 minutes. In some embodiments, the dwell time for each intravesical administration is 40 minutes. In some embodiments, the dwell time for each intravesical administration is 50 minutes. In some embodiments, the dwell time for each intravesical administration is 60 minutes. In some embodiments, the dwell time for each intravesical administration is 70 minutes. In some embodiments, the dwell time for each intravesical administration is 80 minutes. In some embodiments, the dwell time for each intravesical administration is 90 minutes. In some embodiments, the dwell time for each intravesical administration is 100 minutes. In some embodiments, the dwell time for each intravesical administration is 110 minutes. In some embodiments, the dwell time for each intravesical administration is 120 minutes.

[0454] In some embodiments, a pharmaceutical composition comprising an antibody drug conjugate as provided herein is administered intravesically during the induction phase. In some embodiments, a pharmaceutical composition comprising an antibody drug conjugate as provided herein is administered intravesically during the maintenance phase. In some embodiments, a pharmaceutical composition comprising an antibody drug conjugate as provided herein is administered intravesically during two phases, wherein the two phases are the induction phase and the maintenance phase. In some embodiments, the maintenance phase begins after the induction phase. In some embodiments, the maintenance phase begins between six and ten weeks, between six and nine weeks, or between six and eight weeks after the induction phase. In some embodiments, the maintenance phase begins ten weeks after the induction phase. In some embodiments, the maintenance phase begins nine weeks after the induction phase. In some embodiments, the maintenance phase begins eight weeks after the induction phase. In some embodiments, the maintenance phase begins seven weeks after the induction phase. In some embodiments, the maintenance phase begins six weeks after the induction phase.

[0455] In some embodiments, the pharmaceutical composition comprising the antibody drug conjugate provided herein is administered about 1 time to about 25 times, wherein the dosage can be administered as needed, for example, weekly, biweekly, monthly, every two months, every three months, etc., as determined by a physician. In some embodiments, the pharmaceutical composition comprising the antibody drug conjugate provided herein is administered weekly. In some embodiments, the pharmaceutical composition comprising the antibody drug conjugate provided herein is administered every two weeks. In some embodiments, the pharmaceutical composition comprising the antibody drug conjugate provided herein is administered monthly. In some embodiments, the pharmaceutical composition comprising the antibody drug conjugate provided herein is administered every two months. In some embodiments, the pharmaceutical composition comprising the antibody drug conjugate provided herein is administered every three months. In some embodiments, a pharmaceutical composition comprising an antibody drug conjugate provided herein is administered 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 time to treat NMIBC, wherein the dose is between about 10 mg to about 1000 mg, and wherein the instillation volume is between about 10 mL to about 100 mL.

[0456] In some embodiments, during the induction phase, a pharmaceutical composition comprising the antibody-drug conjugate described herein is administered intravesically once weekly for four weeks. In some embodiments, during the induction phase, a pharmaceutical composition comprising the antibody-drug conjugate described herein is administered intravesically once weekly for five weeks. In some embodiments, during the induction phase, a pharmaceutical composition comprising the antibody-drug conjugate described herein is administered intravesically once weekly for six weeks. In some embodiments, during the induction phase, a pharmaceutical composition comprising the antibody-drug conjugate described herein is administered intravesically once weekly for seven weeks. In some embodiments, during the induction phase, a pharmaceutical composition comprising the antibody-drug conjugate described herein is administered intravesically once weekly for eight weeks.

[0457] In some embodiments, during the maintenance phase, a pharmaceutical composition comprising the antibody-drug conjugate described herein is administered intravesically once a month for six months. In some embodiments, during the maintenance phase, a pharmaceutical composition comprising the antibody-drug conjugate described herein is administered intravesically once a month for seven months. In some embodiments, during the maintenance phase, a pharmaceutical composition comprising the antibody-drug conjugate described herein is administered intravesically once a month for eight months. In some embodiments, during the maintenance phase, a pharmaceutical composition comprising the antibody-drug conjugate described herein is administered intravesically once a month for nine months. In some embodiments, during the maintenance phase, a pharmaceutical composition comprising the antibody-drug conjugate described herein is administered intravesically once a month for ten months. In some embodiments, during the maintenance phase, a pharmaceutical composition comprising the antibody-drug conjugate described herein is administered intravesically once a month for eleven months.

[0458] In some embodiments, a pharmaceutical composition comprising an antibody drug conjugate provided herein is administered intravesically once weekly for six weeks in an induction phase and once monthly for nine months in a maintenance phase, wherein the maintenance phase begins between six and ten weeks, between six and nine weeks, or between six and eight weeks after the induction phase.

[0459] In some more specific embodiments of the methods provided herein, the ADC has the structure:

[0460]

[0461] wherein L- represents an antibody or antigen-binding fragment thereof, and p is from about 3 to about 4, the antibody comprising a heavy chain comprising an amino acid sequence ranging from amino acid 20 (glutamic acid) to amino acid 466 (lysine) of SEQ ID NO:7; and a light chain comprising an amino acid sequence ranging from amino acid 23 (aspartic acid) to amino acid 236 (cysteine) of SEQ ID NO:8, wherein the ADC is administered intravesically at a dose of about 125 mg with an instillation volume of about 25 mL and a maximum residence time of 90 minutes, wherein the dose is administered intravesically once weekly for six weeks in an induction phase and once monthly for nine months in a maintenance phase, and wherein the maintenance phase begins between six and ten weeks after the induction phase.

[0462] In some more specific embodiments of the methods provided herein, the ADC has the structure:

[0463]

[0464] wherein L- represents an antibody or antigen-binding fragment thereof, and p is from about 3 to about 4, the antibody comprising a heavy chain comprising an amino acid sequence ranging from amino acid 20 (glutamic acid) to amino acid 466 (lysine) of SEQ ID NO:7; and a light chain comprising an amino acid sequence ranging from amino acid 23 (aspartic acid) to amino acid 236 (cysteine) of SEQ ID NO:8, wherein the ADC is administered intravesically at a dose of about 250 mg with an instillation volume of about 25 mL and a maximum residence time of 90 minutes, wherein the dose is administered intravesically once weekly for six weeks in an induction phase and once monthly for nine months in a maintenance phase, and wherein the maintenance phase begins between six and ten weeks after the induction phase.

[0465] In some more specific implementations of the methods presented herein, the ADC has the following structure:

[0466]

[0467] Wherein L- represents an antibody or an antigen-binding fragment thereof, and p is about 3 to about 4, the antibody comprises a heavy chain comprising an amino acid sequence ranging from amino acid 20 (glutamic acid) to amino acid 466 (lysine) of SEQ ID NO: 7; and a light chain comprising an amino acid sequence ranging from amino acid 23 (aspartic acid) to amino acid 236 (cysteine) of SEQ ID NO: 8, wherein the ADC is administered intravesically at a dose of about 500 mg, wherein the infusion volume is about 25 mL and the maximum residence time is 90 minutes, wherein the dose is administered intravesically once a week for six weeks during the induction phase and once a month for nine months during the maintenance phase, and wherein the maintenance phase begins between six and ten weeks after the induction phase.

[0468] In some more specific embodiments of the methods provided herein, the ADC has the structure:

[0469]

[0470] Wherein L- represents an antibody or an antigen-binding fragment thereof, and p is about 3 to about 4, the antibody comprises a heavy chain comprising an amino acid sequence ranging from amino acid 20 (glutamic acid) to amino acid 466 (lysine) of SEQ ID NO: 7; and a light chain comprising an amino acid sequence ranging from amino acid 23 (aspartic acid) to amino acid 236 (cysteine) of SEQ ID NO: 8, wherein the ADC is administered intravesically at a dose of about 750 mg, wherein the infusion volume is about 25 mL and the maximum residence time is 90 minutes, wherein the dose is administered intravesically once a week for six weeks during the induction phase and once a month for nine months during the maintenance phase, and wherein the maintenance phase begins between six and ten weeks after the induction phase.

[0471] 5.7 Methods for Determining Biomarkers

[0472] This disclosure provides that the expression of any of the biomarkers provided herein can be determined by various methods known in the art. In some embodiments, biomarker expression can be determined based on the amount or relative amount of mRNA transcribed from the biomarker gene. In one embodiment, biomarker gene expression can be determined based on the amount or relative amount of the protein product encoded by the biomarker gene. In another embodiment, biomarker gene expression can be determined based on the level of biological or chemical response induced by the protein product encoded by the biomarker gene. Additionally, in some embodiments, biomarker gene expression can be determined based on the expression of one or more genes associated with biomarker gene expression.

[0473] As described above, the level or amount of the gene transcript (e.g., mRNA) of the marker gene can be used as an indication of the expression level of the marker gene. A variety of different PCR or qPCR protocols are known in the art, including those illustrated herein. In some embodiments, a variety of PCR or qPCR methods are applied to or adapted for measuring the mRNA levels of various marker genes. Quantitative PCR (qPCR) (also referred to as real-time PCR) is applied to and adapted for use in some embodiments because it not only provides quantitative measurement results, but also reduces time and contamination. As used herein, "quantitative PCR (or "qPCR")" refers to direct monitoring of the PCR amplification process as it occurs, without the need for repeated sampling of the reaction products. In quantitative PCR, the reaction products can be monitored via a signal transduction mechanism (e.g., fluorescence) when they are produced and tracked as the signal rises above the background level, but before the reaction reaches a plateau. The number of cycles required to reach a detectable or "threshold" fluorescence level varies directly with the concentration of the amplifiable target at the beginning of the PCR process, thereby allowing measurement of signal intensity to measure the target nucleic acid content in the sample in real time. When qPCR is applied to determine mRNA expression levels, an additional step of reverse transcription of the mRNA into DNA is performed prior to qPCR analysis. Examples of PCR methods can be found in the literature (Wong et al., BioTechniques 39: 75-85 (2005); D'haene et al., Methods 50: 262-270 (2010)), which are incorporated herein by reference in their entirety. Examples of PCR assays can also be found in U.S. Patent No. 6,927,024, which is incorporated herein by reference in its entirety. Examples of RT-PCR methods can be found in U.S. Patent No. 7,122,799, which is incorporated herein by reference in its entirety. Fluorescent in situ PCR methods are described in U.S. Patent No. 7,186,507, which is incorporated herein by reference in its entirety.

[0474] In a specific embodiment, qPCR can be performed as follows to determine or measure the mRNA level of a marker gene. Briefly, the average Ct (cycle threshold) value (or interchangeably referred to herein as Cq (quantification cycle)) of replicate qPCR reactions of a marker gene and one or more housekeeping genes is determined. The average Ct value of the marker gene can then be normalized to the Ct value of the housekeeping gene using the following example formula: marker gene ΔCt=(average Ct of marker gene-average Ct of housekeeping gene A). The relative level of the marker gene mRNA can then be determined using the relative marker gene ΔCt, for example, by using the mRNA expression formula = 2 -ΔCtFor an overview of Ct and Cq values, see the MIQE guidelines (Bustin et al., The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments, Clinical Chemistry 55:4 (2009)).

[0475] To quantify the RNA transcripts of marker genes in a sample as an indicator of marker gene expression, other common methods known in the art can also be used, including northern blotting and in situ hybridization (Parker and Barnes, Methods in Molecular Biology 106:247-283 (1999)); RNase protection assay (Hod, Biotechniques 13:852-854 (1992)); microarray method (Hoheisel et al., Nature Reviews Genetics 7:200-210 (2006); Jaluria et al., Microbial Cell Factories 6:4 (2007)); and polymerase chain reaction (PCR) (Weis et al., Trends in Genetics 8:263-264 (1992)). RNA in situ hybridization (ISH) is a molecular biology technique that is widely used to measure and locate specific RNA sequences, such as messenger RNA (mRNA), long non-coding RNA (lncRNA), and microRNA (miRNA), within cells (e.g., circulating tumor cells (CTCs)) or tissue sections, while preserving the cell and tissue environment. ISH is a type of hybridization that uses directly or indirectly labeled complementary DNA or RNA chains (e.g., probes) to bind to and locate specific nucleic acids, such as DNA or RNA, in a sample (particularly a portion or section of a tissue or cell (in situ)). The probe type can be double-stranded DNA (dsDNA), single-stranded DNA (ssDNA), single-stranded complementary RNA (sscRNA), messenger RNA (mRNA), microRNA (miRNA), ribosomal RNA, mitochondrial RNA, and / or synthetic oligonucleotides. The term "fluorescence in situ hybridization" or "FISH" refers to a type of ISH that uses fluorescent labels. The term "chromogenic in situ hybridization" or "CISH" refers to a type of ISH that uses chromogenic labels. ISH, FISH and CISH methods are well known to those skilled in the art (see, for example, Stoler, Clinics in Laboratory Medicine 10(1): 215-236 (1990); In situ hybridization. A practical approach, Wilkinson ed., IRL Press, Oxford (1992); Schwarzacher and Heslop-Harrison, Practical in situ hybridization, BIOS Scientific Publishers Ltd, Oxford (2000)).RNA ISH thus provides spatial-temporal visualization and quantification of gene expression in cells and tissues. It has wide applications in research and diagnosis (Hu et al., Biomark.Res.2(1):1-13, doi:10.1186 / 2050-7771-2-3(2014); Ratan et al., Cureus 9(6):e1325.doi:10.7759 / cureus.1325(2017); Weier et al., Expert Rev.Mol.Diagn.2(2):109-119(2002)). Fluorescent RNA ISH uses fluorescent dyes and fluorescence microscopy for RNA labeling and detection. Fluorescent RNA ISH can provide multi-tasking processing of four to five target sequences.

[0476] Alternatively, RNA transcripts of marker genes in a sample can serve as indicators of marker gene expression and can be determined using sequencing technology. Representative methods for sequencing-based gene expression analysis include Serial Analysis of Gene Expression (SAGE) and gene expression analysis via massively parallel signature sequencing (MPSS).

[0477] In some implementations, the expression of a marker gene can be determined based on the relative abundance of the marker gene's RNA transcripts (including, for example, mRNA) in the total transcribed RNA pool. Such relative abundance of the marker gene's RNA transcripts can be determined by next-generation sequencing called RNA-seq. In one example of an RNA-seq procedure, RNA from various sources (blood, tissue, cells) is purified, optionally enriched (e.g., using oligonucleotide (dT) primers), converted to cDNA, and fragmented. Millions or even billions of short reads are generated using a randomly fragmented cDNA library. See Zhao et al., BMCgenomics 16:97 (2015); Zhao et al., Scie...

Claims

1. A method for treating bladder cancer in a human subject, the method comprising administering an effective amount of an antibody drug conjugate (ADC) to the subject's bladder, wherein the ADC comprises an antibody or antigen-binding fragment thereof that binds to 191P4D12, which is coupled to one or more units of monomethyl auristatin E (MMAE).

2. The method of claim 1, wherein the bladder cancer is non-muscle invasive bladder cancer (NMIBC).

3. The method of claim 2, wherein the NMIBC has been histologically confirmed and is carcinoma in situ (CIS).

4. The method of claim 3, wherein the subject suffers from a papillary disease.

5. The method of claim 3, wherein the subject does not suffer from papillary disease.

6. The method of any one of claims 2 to 5, wherein the NMIBC has been confirmed histologically and wherein the major histological component (>50%) is urothelial (transitional cell) carcinoma.

7. The method of any one of claims 1 to 6, wherein the subject has high-risk Bacillus Calmette-Guérin (BCG) non-responsive disease.

8. The method of any one of claims 1 to 7, wherein the subject is not suitable for or refuses radical cystectomy.

9. The method of any one of claims 1 to 8, wherein all visible papillary Ta / T1 tumors of the subject have been completely resected within 60 days prior to the treatment.

10. The method of claim 9, wherein the subject has residual pure CIS.

11. The method of claim 9, wherein the subject does not have residual pure CIS.

12. The method of any one of claims 1 to 11, wherein the subject has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0.

13. The method of any one of claims 1 to 11, wherein the subject has an Eastern Cooperative Oncology Group (ECOG) performance status score of 1.

14. The method of any one of claims 1 to 11, wherein the subject has an Eastern Cooperative Oncology Group (ECOG) performance status score of 2.

15. The method of claim 14, wherein the subject has a glomerular filtration rate (GFR) of no less than 50 mL / min and the subject does not suffer from New York Heart Association (NYHA) Class III heart failure.

16. The method of any one of claims 1 to 15, wherein the subject has one or more conditions selected from the group consisting of: a. Absolute neutrophil count (ANC)>1500 / μL; b. Hemoglobin (Hgb) ≥ 10 g / dL; c. Platelet count ≥100,000 / μL: d. Serum bilirubin ≤1.5× upper limit of normal (ULN) or ≤3×ULN for subjects with Gilbert's disease; e. Calculated creatinine clearance (CrCl) ≥ 30 mL / min (GFR can also be used instead of creatinine or CrCl). CrCl should be calculated using the Cockcroft-Gault method or the Modification of Diet in Renal Disease (MDRD) equation. Subjects with an ECOG performance status of 2 must have a GFR ≥ 50 mL / min; f. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN; or g. International normalized ratio (INR) or prothrombin time (PT), activated partial thromboplastin time (aPTT), or partial thromboplastin time (PTT) ≤ 1.5 ULN, unless the subject is receiving anticoagulant therapy, as long as the PT or aPTT is within the therapeutic range for the intended use of the anticoagulant.

17. The method of claim 16, wherein the subject has all of conditions (a) to (g) of claim 16.

18. The method of any one of claims 1 to 17, wherein the subject has an estimated life expectancy of more than 2 years.

19. The method of any one of claims 1 to 18, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising a complementarity determining region (CDR) comprising the amino acid sequence of the heavy chain variable region shown in SEQ ID NO: 22; and a light chain variable region comprising a CDR comprising the amino acid sequence of the CDR of the light chain variable region shown in SEQ ID NO:

23.

20. The method according to any one of claims 1 to 19, wherein the antibody or antigen-binding fragment thereof comprises: a CDR-H1 comprising an amino acid sequence of SEQ ID NO: 9, a CDR-H2 comprising an amino acid sequence of SEQ ID NO: 10, a CDR-H3 comprising an amino acid sequence of SEQ ID NO: 11; a CDR-L1 comprising an amino acid sequence of SEQ ID NO: 12, a CDR-L2 comprising an amino acid sequence of SEQ ID NO: 13, and a CDR-L3 comprising an amino acid sequence of SEQ ID NO: 14, or The antibody or its antigen-binding fragment comprises: CDR-H1 comprising the amino acid sequence of SEQ ID NO: 16, CDR-H2 comprising the amino acid sequence of SEQ ID NO: 17, CDR-H3 comprising the amino acid sequence of SEQ ID NO: 18; CDR-L1 comprising the amino acid sequence of SEQ ID NO: 19, CDR-L2 comprising the amino acid sequence of SEQ ID NO: 20, and CDR-L3 comprising the amino acid sequence of SEQ ID NO:

21.

21. The method according to any one of claims 1 to 19, wherein the antibody or antigen-binding fragment thereof comprises: a CDR-H1 consisting of the amino acid sequence of SEQ ID NO: 9, a CDR-H2 consisting of the amino acid sequence of SEQ ID NO: 10, a CDR-H3 consisting of the amino acid sequence of SEQ ID NO: 11; a CDR-L1 consisting of the amino acid sequence of SEQ ID NO: 12, a CDR-L2 consisting of the amino acid sequence of SEQ ID NO: 13, and a CDR-L3 consisting of the amino acid sequence of SEQ ID NO: 14, or The antibody or its antigen-binding fragment comprises: CDR-H1 composed of the amino acid sequence SEQ ID NO: 16, CDR-H2 composed of the amino acid sequence SEQ ID NO: 17, CDR-H3 composed of the amino acid sequence SEQ ID NO: 18; CDR-L1 composed of the amino acid sequence SEQ ID NO: 19, CDR-L2 composed of the amino acid sequence SEQ ID NO: 20, and CDR-L3 composed of the amino acid sequence SEQ ID NO:

21.

22. The method of any one of claims 1 to 21, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 22 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:

23.

23. The method of any one of claims 1 to 22, wherein the antibody comprises a heavy chain comprising an amino acid sequence ranging from amino acid 20 (glutamic acid) to amino acid 466 (lysine) of SEQ ID NO: 7; and a light chain comprising an amino acid sequence ranging from amino acid 23 (aspartic acid) to amino acid 236 (cysteine) of SEQ ID NO:

8.

24. The method of any one of claims 1 to 23, wherein the antigen binding fragment is Fab, F(ab')2, Fv or scFv.

25. The method of any one of claims 1 to 24, wherein the antibody is a fully human antibody.

26. The method of any one of claims 1 to 25, wherein the antibody is an IgG1 and the light chain is a kappa light chain.

27. The method of any one of claims 1 to 26, wherein the antibody or antigen-binding fragment thereof is recombinantly produced.

28. The method of any one of claims 1 to 27, wherein the antibody or antigen-binding fragment is coupled to each unit of MMAE via a linker.

29. The method of claim 28, wherein the linker is an enzyme-cleavable linker, and wherein the linker forms a bond with a sulfur atom of the antibody or antigen-binding fragment thereof.

30. The method of claim 28 or 29, wherein the linker has the formula: -Aa-Ww-Yy-; wherein -A- is a stretcher unit, a is 0 or 1; -W- is an amino acid unit, w is an integer in the range of 0 to 12; and -Y- is a spacer unit, y is 0, 1 or 2.

31. The method of claim 30, wherein the stretcher unit has the structure of formula (1); the amino acid unit is valine-citrulline; and the spacer unit is a PAB group comprising the structure of formula (2):

32. The method of claim 30 or 31, wherein the Stretcher unit forms a bond with a sulfur atom of the antibody or antigen-binding fragment thereof; and wherein the Spacer unit is linked to MMAE via a carbamate group.

33. The method of any one of claims 1 to 32, wherein the ADC comprises 1 to 20 MMAE units per antibody or antigen-binding fragment thereof.

34. The method of any one of claims 1 to 33, wherein the ADC comprises 1 to 10 MMAE units per antibody or antigen-binding fragment thereof.

35. The method of any one of claims 1 to 34, wherein the ADC comprises 2 to 8 MMAE units per antibody or antigen-binding fragment thereof.

36. The method of any one of claims 1 to 35, wherein the ADC comprises 3 to 5 MMAE units per antibody or antigen-binding fragment thereof.

37. The method of any one of claims 1 to 36, wherein the ADC has the following structure: wherein L- represents the antibody or antigen-binding fragment thereof, and p is 1 to 10.

38. The method of claim 37, wherein p is 2 to 8.

39. The method of claim 37 or 38, wherein p is 3 to 5.

40. The method of any one of claims 37 to 39, wherein p is 3 to 4.

41. The method of any one of claims 37 to 40, wherein p is about 4.

42. The method of any one of claims 37 to 40, wherein the effective amount of the antibody drug conjugate has a mean p-value of about 3.

8.

43. The method of any one of claims 1 to 42, wherein the ADC is formulated as a pharmaceutical composition comprising L-histidine, polysorbate-20 (TWEEN-20), and trehalose dihydrate.

44. The method of any one of claims 1 to 43, wherein the ADC is formulated as a pharmaceutical composition comprising about 20 mM L-histidine, about 0.02% (w / v) TWEEN-20, about 5.5% (w / v) trehalose dihydrate, and hydrochloride, and wherein the pharmaceutical composition has a pH of about 6.0 at 25°C.

45. The method of any one of claims 1 to 43, wherein the ADC is formulated as a pharmaceutical composition comprising about 9 mM histidine, about 11 mM histidine hydrochloride monohydrate, about 0.02% (w / v) TWEEN-20, and about 5.5% (w / v) trehalose dihydrate, and wherein the pharmaceutical composition has a pH of about 6.0 at 25°C.

46. ​​The method of any one of claims 1 to 45, wherein the effective amount of the ADC is a dose of between about 100 mg to about 1000 mg, between about 125 mg to about 950 mg, between about 125 mg to about 900 mg, between about 125 mg to about 850 mg, between about 125 mg to about 800 mg, or between about 125 mg to about 750 mg, wherein the instillation volume is between about 10 mL to about 100 mL.

47. The method of any one of claims 1 to 46, wherein the effective amount of the ADC is a dose between about 125 mg to about 750 mg, with an instillation volume of about 25 mL.

48. The method of any one of claims 1 to 47, wherein the effective amount of the ADC is a dose of about 125 mg with an instillation volume of about 25 mL.

49. The method of any one of claims 1 to 47, wherein the effective amount of the ADC is a dose of about 250 mg with an instillation volume of about 25 mL.

50. The method of any one of claims 1 to 47, wherein the effective amount of the ADC is a dose of about 500 mg, wherein the instillation volume is about 25 mL.

51. The method of any one of claims 1 to 47, wherein the effective amount of the ADC is a dose of about 750 mg with an instillation volume of about 25 mL.

52. The method of any one of claims 1 to 51, wherein the maximum residence time for each intravesical administration is about 90 minutes.

53. The method of any one of claims 1 to 51, wherein the maximum residence time for each intravesical administration is about 120 minutes.

54. The method of any one of claims 1 to 51, wherein the residence time for each intravesical administration is about 30, 40, 50, 60, 70, 80, 90, or 120 minutes.

55. The method of any one of claims 1 to 54, wherein the ADC is administered intravesically in two phases, wherein the two phases are an induction phase and a maintenance phase.

56. The method of claim 55, wherein the maintenance phase begins between six and ten weeks, between six and nine weeks, or between six and eight weeks after the induction phase.

57. The method of claim 55 or 56, wherein the ADC is administered intravesically once a week for six weeks during the induction phase.

58. The method of any one of claims 55 to 57, wherein the ADC is administered intravesically once a month for nine months during the maintenance phase.

59. The method of any one of claims 1 to 58, wherein the ADC has the following structure: wherein L- represents the antibody or antigen-binding fragment thereof, and p is from about 3 to about 4, the antibody comprises a heavy chain comprising an amino acid sequence ranging from amino acid 20 (glutamic acid) to amino acid 466 (lysine) of SEQ ID NO:7; and a light chain comprising an amino acid sequence ranging from amino acid 23 (aspartic acid) to amino acid 236 (cysteine) of SEQ ID NO:8, wherein the ADC is administered intravesically at a dose of about 125 mg, with an instillation volume of about 25 mL and a maximum residence time of 90 minutes, wherein the dose is administered intravesically once a week for six weeks in the induction phase and once a month for nine months in the maintenance phase, and wherein the maintenance phase begins between six and ten weeks after the induction phase.

60. The method of any one of claims 1 to 58, wherein the ADC has the following structure: wherein L- represents the antibody or antigen-binding fragment thereof, and p is from about 3 to about 4, the antibody comprising a heavy chain comprising an amino acid sequence ranging from amino acid 20 (glutamic acid) to amino acid 466 (lysine) of SEQ ID NO:7; and a light chain comprising an amino acid sequence ranging from amino acid 23 (aspartic acid) to amino acid 236 (cysteine) of SEQ ID NO:8, wherein the ADC is administered intravesically at a dose of about 250 mg, with an instillation volume of about 25 mL and a maximum residence time of 90 minutes, wherein the dose is administered intravesically once a week for six weeks in the induction phase and once a month for nine months in the maintenance phase, and wherein the maintenance phase begins between six and ten weeks after the induction phase.

61. The method of any one of claims 1 to 58, wherein the ADC has the following structure: wherein L- represents the antibody or antigen-binding fragment thereof, and p is from about 3 to about 4, the antibody comprises a heavy chain comprising an amino acid sequence ranging from amino acid 20 (glutamic acid) to amino acid 466 (lysine) of SEQ ID NO:7; and a light chain comprising an amino acid sequence ranging from amino acid 23 (aspartic acid) to amino acid 236 (cysteine) of SEQ ID NO:8, wherein the ADC is administered intravesically at a dose of about 500 mg, with an instillation volume of about 25 mL and a maximum residence time of 90 minutes, wherein the dose is administered intravesically once a week for six weeks in the induction phase and once a month for nine months in the maintenance phase, and wherein the maintenance phase begins between six and ten weeks after the induction phase.

62. The method of any one of claims 1 to 58, wherein the ADC has the following structure: wherein L- represents the antibody or antigen-binding fragment thereof, and p is from about 3 to about 4, the antibody comprising a heavy chain comprising an amino acid sequence ranging from amino acid 20 (glutamic acid) to amino acid 466 (lysine) of SEQ ID NO:7; and a light chain comprising an amino acid sequence ranging from amino acid 23 (aspartic acid) to amino acid 236 (cysteine) of SEQ ID NO:8, wherein the ADC is administered intravesically at a dose of about 750 mg, with an instillation volume of about 25 mL and a maximum residence time of 90 minutes, wherein the dose is administered intravesically once a week for six weeks in the induction phase and once a month for nine months in the maintenance phase, and wherein the maintenance phase begins between six and ten weeks after the induction phase.

Citation Information

Patent Citations

  • Gas turbine two-phase internal combustion engine and method

    EP0065000A1

  • Method for the production of non-immunogenic proteins

    US20030153043A1

  • Ultra sensitive method for in SITU detection of nucleic acids

    US20120100540A1

  • Systems and methods for improved oct measurements

    US20190056214A1

  • Enzymatic immunological method for the determination of antigens and antibodies

    US4016043A